<?xml version='1.0' encoding='utf-8'?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd"><key id="d9" for="edge" attr.name="context" attr.type="string"/>
<key id="d8" for="edge" attr.name="type" attr.type="string"/>
<key id="d7" for="node" attr.name="canonical_name" attr.type="string"/>
<key id="d6" for="node" attr.name="name" attr.type="string"/>
<key id="d5" for="node" attr.name="entity_type" attr.type="string"/>
<key id="d4" for="node" attr.name="paper_id" attr.type="string"/>
<key id="d3" for="node" attr.name="statement" attr.type="string"/>
<key id="d2" for="node" attr.name="year" attr.type="long"/>
<key id="d1" for="node" attr.name="content" attr.type="string"/>
<key id="d0" for="node" attr.name="type" attr.type="string"/>
<graph edgedefault="directed"><node id="PDF_15">
  <data key="d0">Paper</data>
  <data key="d1">ORIGINAL ARTICLE
Journal of Human Hypertension (2000) 14, 321-325
© 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00
www.nature.com/jhh
Antihypertensive efficacy of the ACE-
inhibitor perindopril in the elderly
FHH Leenen¹, J Tanner² and CF McNally³
1University of Ottawa Heart Institute, Ottawa, Ontario, Canada; 2General Practice Research Group,
Toronto, Ontario, Canada; ³Clinical Research Partners, Mount Laurel, NJ, USA
To assess the antihypertensive efficacy of the angiote</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_15_Method_-578211472894560442">
  <data key="d0">Method</data>
  <data key="d1">The study used a multicentre, randomised, placebo-controlled, parallel group design, and was conducted in 15 centres in Ontario, Canada, in 1995/1996.</data>
  <data key="d3">The study used a multicentre, randomised, placebo-controlled, parallel group design, and was conducted in 15 centres in Ontario, Canada, in 1995/1996.</data>
  <data key="d4">PDF_15</data>
</node>
<node id="PDF_15_Result_5014316397909361333">
  <data key="d0">Result</data>
  <data key="d1">Perindopril was significantly more effective than placebo in decreasing supine BP, both diastolic and systolic at all visits on double-blind treatment.</data>
  <data key="d3">Perindopril was significantly more effective than placebo in decreasing supine BP, both diastolic and systolic at all visits on double-blind treatment.</data>
  <data key="d4">PDF_15</data>
</node>
<node id="Compound_PERINDOPRIL">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">PERINDOPRIL</data>
  <data key="d7">Perindopril</data>
</node>
<node id="PDF_15_Result_3256342382947594458">
  <data key="d0">Result</data>
  <data key="d1">Successful treatment, defined as supine diastolic BP &lt;90 mm Hg or &gt;10 mm Hg decrease from baseline at end of treatment was significantly (P = 0.014) higher on perindopril (58/96 = 60%) compared to placebo (42/95 = 44%).</data>
  <data key="d3">Successful treatment, defined as supine diastolic BP &lt;90 mm Hg or &gt;10 mm Hg decrease from baseline at end of treatment was significantly (P = 0.014) higher on perindopril (58/96 = 60%) compared to placebo (42/95 = 44%).</data>
  <data key="d4">PDF_15</data>
</node>
<node id="PDF_15_Result_-973644626587201168">
  <data key="d0">Result</data>
  <data key="d1">Relative to baseline, perindopril as monotherapy lowered diastolic BP by about 6 mm Hg, and systolic BP by about 10–11 mm Hg</data>
  <data key="d3">Relative to baseline, perindopril as monotherapy lowered diastolic BP by about 6 mm Hg, and systolic BP by about 10–11 mm Hg</data>
  <data key="d4">PDF_15</data>
</node>
<node id="PDF_15_Conclusion_-6193526426296019953">
  <data key="d0">Conclusion</data>
  <data key="d1">In summary, the present double-blind, placebo-controlled study shows a significant antihypertensive effect of placebo, and additional effect of perindopril in an elderly population.</data>
  <data key="d3">In summary, the present double-blind, placebo-controlled study shows a significant antihypertensive effect of placebo, and additional effect of perindopril in an elderly population.</data>
  <data key="d4">PDF_15</data>
</node>
<node id="PDF_13">
  <data key="d0">Paper</data>
  <data key="d1">Efficacy and Safety of Perindopril in Patients with Essential Hypertension

DOI: 10.5455/msm.2020.32.4-9
Received: JAN 09 2020; Accepted: MAR 02, 2020
2020 Enisa Hodzic, Ehlimana Pecar, Alen Dzubur, Elnur Smajic, Zorica Hondo, Daniela Delic, Edhem Rustempasic
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/4.0/) which permits unrestricted non-commercial use, distribution, and reprodu</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_13_Result_-2118415563075348230">
  <data key="d0">Result</data>
  <data key="d1">Perindopril was effective as monotherapy in the great majority of the study patients, achieving a significant reduction in both systolic and diastolic blood pressure.</data>
  <data key="d3">Perindopril was effective as monotherapy in the great majority of the study patients, achieving a significant reduction in both systolic and diastolic blood pressure.</data>
  <data key="d4">PDF_13</data>
</node>
<node id="PDF_13_Result_-9132323818105741274">
  <data key="d0">Result</data>
  <data key="d1">In three-quarters of the study patients, perindopril normalized both systolic and diastolic blood pressure.</data>
  <data key="d3">In three-quarters of the study patients, perindopril normalized both systolic and diastolic blood pressure.</data>
  <data key="d4">PDF_13</data>
</node>
<node id="PDF_13_Result_6225785780675340033">
  <data key="d0">Result</data>
  <data key="d1">The effectiveness of perindopril was shown in both patients with previously and newly diagnosed hypertension.</data>
  <data key="d3">The effectiveness of perindopril was shown in both patients with previously and newly diagnosed hypertension.</data>
  <data key="d4">PDF_13</data>
</node>
<node id="Disease_HYPERTENSION">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">HYPERTENSION</data>
  <data key="d7">Hypertension</data>
</node>
<node id="PDF_13_Result_-6788833057832102103">
  <data key="d0">Result</data>
  <data key="d1">Adverse events were mild and rare, even hyperkalemia was encountered less often than before the onset of the therapy with perindopril.</data>
  <data key="d3">Adverse events were mild and rare, even hyperkalemia was encountered less often than before the onset of the therapy with perindopril.</data>
  <data key="d4">PDF_13</data>
</node>
<node id="PDF_13_Conclusion_-42029183976039292">
  <data key="d0">Conclusion</data>
  <data key="d1">Our study confirmed excellent effectiveness of perindopril in the treatment of essential hypertension and its remarkable safety.</data>
  <data key="d3">Our study confirmed excellent effectiveness of perindopril in the treatment of essential hypertension and its remarkable safety.</data>
  <data key="d4">PDF_13</data>
</node>
<node id="PDF_13_Conclusion_-1048253378150093435">
  <data key="d0">Conclusion</data>
  <data key="d1">When used as monotherapy of hypertension, perindopril's doses should be carefully titrated until the achievement of full effect, which in some patients should be awaited for at least 6 months from onset of the therapy.</data>
  <data key="d3">When used as monotherapy of hypertension, perindopril's doses should be carefully titrated until the achievement of full effect, which in some patients should be awaited for at least 6 months from onset of the therapy.</data>
  <data key="d4">PDF_13</data>
</node>
<node id="PDF_1">
  <data key="d0">Paper</data>
  <data key="d1">nature metabolism
Letter
a
https://doi.org/10.1038/s42255-023-00943-3
Randomized open-label trial of semaglutide
and dapagliflozin in patients with type 2
diabetes of different pathophysiology
Received: 9 May 2023
A list of authors and their affiliations appears at the end of the paper
Accepted: 8 November 2023
Published online: 4 January 2024
Check for updates
The limited understanding of the heterogeneity in the treatment response
to antidiabetic drugs contributes to metabolic deterioration an</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_1_Result_-5167562052163967682">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
  <data key="d3">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
  <data key="d4">PDF_1</data>
</node>
<node id="Protein_HBA1C">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">HBA1C</data>
  <data key="d7">HbA1c</data>
</node>
<node id="Compound_SEMAGLUTIDE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">SEMAGLUTIDE</data>
  <data key="d7">Semaglutide</data>
</node>
<node id="Compound_DAPAGLIFLOZIN">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">DAPAGLIFLOZIN</data>
  <data key="d7">dapagliflozin</data>
</node>
<node id="Disease_SIDD">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">SIDD</data>
  <data key="d7">SIDD</data>
</node>
<node id="PDF_1_Result_7495475486352378264">
  <data key="d0">Result</data>
  <data key="d1">No significant interaction was found between drug assignment and the SIDD or SIRD subgroup.</data>
  <data key="d3">No significant interaction was found between drug assignment and the SIDD or SIRD subgroup.</data>
  <data key="d4">PDF_1</data>
</node>
<node id="Disease_SIRD">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">SIRD</data>
  <data key="d7">SIRD</data>
</node>
<node id="PDF_1_Result_2527217168376533811">
  <data key="d0">Result</data>
  <data key="d1">continuous measures of body mass index, blood pressure, insulin secretion and insulin resistance were useful in identifying those likely to have the largest improvements in glycaemic control and cardiovascular risk factors by adding semaglutide or dapagliflozin.</data>
  <data key="d3">continuous measures of body mass index, blood pressure, insulin secretion and insulin resistance were useful in identifying those likely to have the largest improvements in glycaemic control and cardiovascular risk factors by adding semaglutide or dapagliflozin.</data>
  <data key="d4">PDF_1</data>
</node>
<node id="Protein_INSULIN">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">INSULIN</data>
  <data key="d7">Insulin</data>
</node>
<node id="PDF_1_Conclusion_-889991433722731225">
  <data key="d0">Conclusion</data>
  <data key="d1">systematic evaluation of continuous pathophysiological variables can guide the prediction of the treatment response to these drugs and provide more information than stratified subgroups</data>
  <data key="d3">systematic evaluation of continuous pathophysiological variables can guide the prediction of the treatment response to these drugs and provide more information than stratified subgroups</data>
  <data key="d4">PDF_1</data>
</node>
<node id="PDF_16">
  <data key="d0">Paper</data>
  <data key="d1">RESEARCH
Effect of perindopril on physical function in elderly people
with functional impairment: a randomized controlled trial
Deepa Sumukadas MBBS MD, Miles D. Witham MBChB PhD, Allan D. Struthers MBChB MD,
Marion E.T. McMurdo MBChB MD
8
See related article page 891
ABSTRACT
Background: Physical function and exercise capacity decline
with age and are a major source of disability in older people.
Recent evidence suggests a potential role for the renin-
angiotensin system in modulating muscle fu</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_16_Method_234051311002480332">
  <data key="d0">Method</data>
  <data key="d1">double-blind randomized controlled trial</data>
  <data key="d3">double-blind randomized controlled trial</data>
  <data key="d4">PDF_16</data>
</node>
<node id="PDF_16_Method_3080411910226675941">
  <data key="d0">Method</data>
  <data key="d1">Participants were randomly assigned to receive either perindopril or placebo for 20 weeks.</data>
  <data key="d3">Participants were randomly assigned to receive either perindopril or placebo for 20 weeks.</data>
  <data key="d4">PDF_16</data>
</node>
<node id="PDF_16_Method_-7430451657682466480">
  <data key="d0">Method</data>
  <data key="d1">The primary outcome was the change in the 6-minute walking distance over the 20 weeks.</data>
  <data key="d3">The primary outcome was the change in the 6-minute walking distance over the 20 weeks.</data>
  <data key="d4">PDF_16</data>
</node>
<node id="PDF_16_Method_-6242020639914613255">
  <data key="d0">Method</data>
  <data key="d1">Secondary outcomes were changes in muscle function, daily activity levels, self-reported function and health-related quality of life.</data>
  <data key="d3">Secondary outcomes were changes in muscle function, daily activity levels, self-reported function and health-related quality of life.</data>
  <data key="d4">PDF_16</data>
</node>
<node id="PDF_16_Result_-8253323808069576894">
  <data key="d0">Result</data>
  <data key="d1">At 20 weeks, the mean 6-minute walking distance was significantly improved in the perindopril group relative to the placebo group</data>
  <data key="d3">At 20 weeks, the mean 6-minute walking distance was significantly improved in the perindopril group relative to the placebo group</data>
  <data key="d4">PDF_16</data>
</node>
<node id="PDF_16_Result_3574267891343578640">
  <data key="d0">Result</data>
  <data key="d1">There was a significant impact on health-related quality of life: although the mean score for part 1 of the EQ-5D questionnaire deteriorated over time in the placebo group, quality of life was maintained in the perindopril group</data>
  <data key="d3">There was a significant impact on health-related quality of life: although the mean score for part 1 of the EQ-5D questionnaire deteriorated over time in the placebo group, quality of life was maintained in the perindopril group</data>
  <data key="d4">PDF_16</data>
</node>
<node id="PDF_16_Conclusion_6335179029935553904">
  <data key="d0">Conclusion</data>
  <data key="d1">Use of the ACE inhibitor perindopril improved exercise capacity in functionally impaired elderly people who had no heart failure and maintained health-related quality of life.</data>
  <data key="d3">Use of the ACE inhibitor perindopril improved exercise capacity in functionally impaired elderly people who had no heart failure and maintained health-related quality of life.</data>
  <data key="d4">PDF_16</data>
</node>
<node id="PDF_18">
  <data key="d0">Paper</data>
  <data key="d1">communications biology
Article
a
https://doi.org/10.1038/s42003-024-07387-9
Resveratrol does not mimic the positive
effects of calorie restriction on lifespan in
Microcebus murinus
Fabien Pifferi¹
Jérémy Terrien¹, Julia Marchal¹, Alexandre Dal-Pan¹, Fathia Djelti 1,2,
Martine Perret¹, Jacques Epelbaum¹, Stéphane Blanc³, Jean-Luc Picq¹, Marc Dhenain5,6 &amp;
Fabienne Aujard¹
Check for updates
Resveratrol (RSV), a polyphenol with anti-aging properties affecting metabolism and energy balance,
is consid</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_18_Hypothesis_-6782162243753243341">
  <data key="d0">Hypothesis</data>
  <data key="d1">We hypothesize that long-term supplementation with intermediate dose of RSV (i.e. 200 mg/kg.day¯¹) affects the health and lifespan of the grey mouse lemur (Microcebus murinus).</data>
  <data key="d3">We hypothesize that long-term supplementation with intermediate dose of RSV (i.e. 200 mg/kg.day¯¹) affects the health and lifespan of the grey mouse lemur (Microcebus murinus).</data>
  <data key="d4">PDF_18</data>
</node>
<node id="Gene_MICROCEBUS MURINUS">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">MICROCEBUS MURINUS</data>
  <data key="d7">Microcebus murinus</data>
</node>
<node id="Compound_RESVERATROL">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">RESVERATROL</data>
  <data key="d7">Resveratrol</data>
</node>
<node id="PDF_18_Method_-5430719080444498488">
  <data key="d0">Method</data>
  <data key="d1">Longitudinal monitoring of cognitive and motor performances, occurrence of age-related pathologies, age-related brain atrophy and mortality was performed from adulthood to death in a cohort of male grey mouse lemurs (Microcebus murinus, N = 33), all receiving 105 kJ/day of food but with a subset of 18 animals receiving RSV (200 mg.kg¯¹ body weight.day¯¹).</data>
  <data key="d3">Longitudinal monitoring of cognitive and motor performances, occurrence of age-related pathologies, age-related brain atrophy and mortality was performed from adulthood to death in a cohort of male grey mouse lemurs (Microcebus murinus, N = 33), all receiving 105 kJ/day of food but with a subset of 18 animals receiving RSV (200 mg.kg¯¹ body weight.day¯¹).</data>
  <data key="d4">PDF_18</data>
</node>
<node id="PDF_18_Result_6797652856178707722">
  <data key="d0">Result</data>
  <data key="d1">RSV supplementation improved cognitive and motor performance at middle age as compared to control (CTL) animals.</data>
  <data key="d3">RSV supplementation improved cognitive and motor performance at middle age as compared to control (CTL) animals.</data>
  <data key="d4">PDF_18</data>
</node>
<node id="PDF_18_Result_-4624684354295206998">
  <data key="d0">Result</data>
  <data key="d1">Median-lifespan was greater in RSV-fed animals (7.9 years compared to 6.4 years for CTL) but long-term RSV supplementation did not significantly affect all-cause nor age-related mortality.</data>
  <data key="d3">Median-lifespan was greater in RSV-fed animals (7.9 years compared to 6.4 years for CTL) but long-term RSV supplementation did not significantly affect all-cause nor age-related mortality.</data>
  <data key="d4">PDF_18</data>
</node>
<node id="PDF_18_Result_-5494509411713272209">
  <data key="d0">Result</data>
  <data key="d1">Brain grey matter atrophy accelerated in the RSV group at old age as compared to the CTL group.</data>
  <data key="d3">Brain grey matter atrophy accelerated in the RSV group at old age as compared to the CTL group.</data>
  <data key="d4">PDF_18</data>
</node>
<node id="PDF_18_Conclusion_-8075648162043344478">
  <data key="d0">Conclusion</data>
  <data key="d1">Long-term RSV supplementation procures health benefits at middle-age in male mouse lemurs but has limited long-term effects on health and longevity and might even impair brain integrity at older ages.</data>
  <data key="d3">Long-term RSV supplementation procures health benefits at middle-age in male mouse lemurs but has limited long-term effects on health and longevity and might even impair brain integrity at older ages.</data>
  <data key="d4">PDF_18</data>
</node>
<node id="PDF_17">
  <data key="d0">Paper</data>
  <data key="d1">Here is the complete text extracted from the provided PDF.

**CARDIOVASCULAR MEDICINE**

**Perindopril improves six minute walking distance in older
patients with left ventricular systolic dysfunction:
a randomised double blind placebo controlled trial**

*SD Hutcheon, N D Gillespie, I K Crombie, A D Struthers, MET McMurdo*

Objective: To evaluate the effects of the angiotensin converting enzyme inhibitor perindopril on six
minute walking distance and quality of life in very old patients with le</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_17_Result_9194818847878280887">
  <data key="d0">Result</data>
  <data key="d1">Six minute walking distance was significantly increased in the treatment group (37.1 m) compared with the placebo group (-0.3 m, p &lt; 0.001) in patients with left ventricular systolic dysfunction.</data>
  <data key="d3">Six minute walking distance was significantly increased in the treatment group (37.1 m) compared with the placebo group (-0.3 m, p &lt; 0.001) in patients with left ventricular systolic dysfunction.</data>
  <data key="d4">PDF_17</data>
</node>
<node id="PDF_17_Result_-8106803482728420531">
  <data key="d0">Result</data>
  <data key="d1">Six minute walking distance is improved considerably by treatment with perindopril in older patients with heart failure caused by left ventricular systolic dysfunction.</data>
  <data key="d3">Six minute walking distance is improved considerably by treatment with perindopril in older patients with heart failure caused by left ventricular systolic dysfunction.</data>
  <data key="d4">PDF_17</data>
</node>
<node id="PDF_17_Method_3672532031162465124">
  <data key="d0">Method</data>
  <data key="d1">Prospective, double blind placebo controlled trial to determine the effects of perindopril on exercise capacity, quality of life, and cognitive function in elderly patients with congestive heart failure caused by left ventricular systolic dysfunction.</data>
  <data key="d3">Prospective, double blind placebo controlled trial to determine the effects of perindopril on exercise capacity, quality of life, and cognitive function in elderly patients with congestive heart failure caused by left ventricular systolic dysfunction.</data>
  <data key="d4">PDF_17</data>
</node>
<node id="PDF_17_Result_-2199568380892004508">
  <data key="d0">Result</data>
  <data key="d1">Patients randomly assigned to perindopril significantly improved their mean walking distance compared with those in the placebo group (p &lt; 0.001) with a mean increase of 37 m in the mean walking distance at 10 weeks.</data>
  <data key="d3">Patients randomly assigned to perindopril significantly improved their mean walking distance compared with those in the placebo group (p &lt; 0.001) with a mean increase of 37 m in the mean walking distance at 10 weeks.</data>
  <data key="d4">PDF_17</data>
</node>
<node id="PDF_17_Result_-2134582742111352736">
  <data key="d0">Result</data>
  <data key="d1">Patients who were in NYHA functional class I or II (n = 29) improved significantly with perindopril (36.1 m v 2.0 m, p &lt; 0.05) as did those who were in NYHA III or IV (n = 37) (38.2 m v -1.7 m, p = 0.003).</data>
  <data key="d3">Patients who were in NYHA functional class I or II (n = 29) improved significantly with perindopril (36.1 m v 2.0 m, p &lt; 0.05) as did those who were in NYHA III or IV (n = 37) (38.2 m v -1.7 m, p = 0.003).</data>
  <data key="d4">PDF_17</data>
</node>
<node id="PDF_17_Conclusion_-6127952188890531347">
  <data key="d0">Conclusion</data>
  <data key="d1">Perindopril significantly improved the six minute walking distance compared with placebo but had no effect on quality of life measures.</data>
  <data key="d3">Perindopril significantly improved the six minute walking distance compared with placebo but had no effect on quality of life measures.</data>
  <data key="d4">PDF_17</data>
</node>
<node id="PDF_17_Conclusion_4444072132154960485">
  <data key="d0">Conclusion</data>
  <data key="d1">This study provides a powerful evidence base to justify the widespread use of ACE inhibitors even in very old patients with left ventricular systolic dysfunction.</data>
  <data key="d3">This study provides a powerful evidence base to justify the widespread use of ACE inhibitors even in very old patients with left ventricular systolic dysfunction.</data>
  <data key="d4">PDF_17</data>
</node>
<node id="PDF_7">
  <data key="d0">Paper</data>
  <data key="d1">nature medicine
Article
a
https://doi.org/10.1038/s41591-024-03355-2
Proteomic changes upon treatment with
semaglutide in individuals with obesity
Received: 22 March 2024
Accepted: 14 October 2024
Published online: 3 January 2025
Check for updates
Lasse Maretty1,11, Dipender Gill 2,3, Lotte Simonsen, Keng Soh',
Loukas Zagkos2, Michael Galanakis¹5, Jonas Sibbesen¹,
Miquel Triana Iglesias¹, Anna Secher, Dirk Valkenborg,
Jonathan Q. Purnell, Lotte Bjerre Knudsen, Abd A. Tahrani 9,10,13 &amp;
Milan Geyb</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_7_Result_3611453984888046248">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment downregulates proteins involved in xenobiotic metabolism, fatty acid metabolism, and MTORC1 signaling.</data>
  <data key="d3">Semaglutide treatment downregulates proteins involved in xenobiotic metabolism, fatty acid metabolism, and MTORC1 signaling.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="Protein_MTORC1">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">MTORC1</data>
  <data key="d7">mTORC1</data>
</node>
<node id="Process_FATTY ACID METABOLISM">
  <data key="d0">Entity</data>
  <data key="d5">Process</data>
  <data key="d6">FATTY ACID METABOLISM</data>
  <data key="d7">fatty acid metabolism</data>
</node>
<node id="PDF_7_Result_-5317477738240816202">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment reduces a 27-protein CVD risk score compared to placebo.</data>
  <data key="d3">Semaglutide treatment reduces a 27-protein CVD risk score compared to placebo.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="Disease_CVD">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">CVD</data>
  <data key="d7">CVD</data>
</node>
<node id="PDF_7_Result_-9131761359181572749">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment favorably reduces the cardiovascular disease 2 (CVD2) risk score.</data>
  <data key="d3">Semaglutide treatment favorably reduces the cardiovascular disease 2 (CVD2) risk score.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="PDF_7_Hypothesis_-5185562836786652076">
  <data key="d0">Hypothesis</data>
  <data key="d1">TNC may act as a mediator, with downregulation contributing to the cardiovascular-protective effects of GLP-1RAs. This hypothesis will be tested using proteomic data from the SELECT trial for the six cardiovascular proteins listed above that were downregulated by semaglutide in STEP 1.</data>
  <data key="d3">TNC may act as a mediator, with downregulation contributing to the cardiovascular-protective effects of GLP-1RAs. This hypothesis will be tested using proteomic data from the SELECT trial for the six cardiovascular proteins listed above that were downregulated by semaglutide in STEP 1.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="Protein_TNC">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">TNC</data>
  <data key="d7">TNC</data>
</node>
<node id="Compound_GLP-1RAS">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">GLP-1RAS</data>
  <data key="d7">GLP-1RAs</data>
</node>
<node id="PDF_7_Result_-1578089971508452148">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment reduced this CVD risk score compared with placebo.</data>
  <data key="d3">Semaglutide treatment reduced this CVD risk score compared with placebo.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="PDF_7_Result_-4157133644117106142">
  <data key="d0">Result</data>
  <data key="d1">Several proteins were regulated with semaglutide, after accounting for changes in body weight and HbA1c at end of trial, suggesting effects of semaglutide on the proteome beyond weight loss and glucose lowering.</data>
  <data key="d3">Several proteins were regulated with semaglutide, after accounting for changes in body weight and HbA1c at end of trial, suggesting effects of semaglutide on the proteome beyond weight loss and glucose lowering.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="PDF_7_Result_7590995980995773769">
  <data key="d0">Result</data>
  <data key="d1">After 68 weeks of treatment, 495 protein targets (438 unique proteins) were identified to be significantly affected by semaglutide treatment.</data>
  <data key="d3">After 68 weeks of treatment, 495 protein targets (438 unique proteins) were identified to be significantly affected by semaglutide treatment.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="PDF_7_Result_-4774825531143330166">
  <data key="d0">Result</data>
  <data key="d1">levels of digestive enzymes secreted from the exocrine pancreas were increased by semaglutide</data>
  <data key="d3">levels of digestive enzymes secreted from the exocrine pancreas were increased by semaglutide</data>
  <data key="d4">PDF_7</data>
</node>
<node id="PDF_12">
  <data key="d0">Paper</data>
  <data key="d1">Drugs 1996; 52 Suppl. 3: 39-47
0012-6667/96/0003-0039/$04.50/0
Adis International Limited. All rights reserved.

Pharmacology and Clinical Experience
with Tramadol in Osteoarthritis
Warren A. Katz
University of Pennsylvania Health System, Presbyterian Medical Center, Philadelphia,
Pennsylvania, USA

Summary
Tramadol is a centrally acting analgesic that has been shown to be effective
in a variety of acute and chronic pain states. Unlike other centrally acting anal-
gesics, it exerts a dual action</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_12_Result_-9187083338672855303">
  <data key="d0">Result</data>
  <data key="d1">Tramadol is effective in acute and chronic pain states due to its dual action: binding to opioid receptors and weakly inhibiting reuptake of biogenic amines.</data>
  <data key="d3">Tramadol is effective in acute and chronic pain states due to its dual action: binding to opioid receptors and weakly inhibiting reuptake of biogenic amines.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_TRAMADOL">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">TRAMADOL</data>
  <data key="d7">Tramadol</data>
</node>
<node id="PDF_12_Result_-5733080962139891931">
  <data key="d0">Result</data>
  <data key="d1">Tramadol does not aggravate hypertension or congestive heart failure, nor does it cause peptic ulcer disease, unlike NSAIDs.</data>
  <data key="d3">Tramadol does not aggravate hypertension or congestive heart failure, nor does it cause peptic ulcer disease, unlike NSAIDs.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_NSAIDS">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">NSAIDS</data>
  <data key="d7">NSAIDs</data>
</node>
<node id="PDF_12_Result_4120594458912425293">
  <data key="d0">Result</data>
  <data key="d1">Tramadol binds to the u opioid receptor site in the central nervous system, with a binding affinity 6000 times less than that of morphine.</data>
  <data key="d3">Tramadol binds to the u opioid receptor site in the central nervous system, with a binding affinity 6000 times less than that of morphine.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_MORPHINE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">MORPHINE</data>
  <data key="d7">morphine</data>
</node>
<node id="PDF_12_Result_674491331230390053">
  <data key="d0">Result</data>
  <data key="d1">Tramadol-mediated analgesia is only partially reduced by naloxone, suggesting a nonopioid mechanism of action.</data>
  <data key="d3">Tramadol-mediated analgesia is only partially reduced by naloxone, suggesting a nonopioid mechanism of action.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_NALOXONE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">NALOXONE</data>
  <data key="d7">naloxone</data>
</node>
<node id="PDF_12_Result_1905569409571579676">
  <data key="d0">Result</data>
  <data key="d1">Reuptake inhibitory effects on noradrenaline and serotonin contribute to the analgesic effects of tramadol by inhibiting pain transmission in the spinal cord.</data>
  <data key="d3">Reuptake inhibitory effects on noradrenaline and serotonin contribute to the analgesic effects of tramadol by inhibiting pain transmission in the spinal cord.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_NOREPINEPHRINE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">NOREPINEPHRINE</data>
  <data key="d7">Norepinephrine</data>
</node>
<node id="Compound_SEROTONIN">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">SEROTONIN</data>
  <data key="d7">serotonin</data>
</node>
<node id="PDF_12_Result_-8756349941327744436">
  <data key="d0">Result</data>
  <data key="d1">The (+) enantiomer of tramadol inhibits the reuptake of serotonin, whereas the (-) enantiomer preferentially inhibits the reuptake of noradrenaline.</data>
  <data key="d3">The (+) enantiomer of tramadol inhibits the reuptake of serotonin, whereas the (-) enantiomer preferentially inhibits the reuptake of noradrenaline.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_7292076278537665474">
  <data key="d0">Result</data>
  <data key="d1">Tramadol showed comparable efficacy to diclofenac after 4 weeks in patients with osteoarthritis of the hip and/or knee.</data>
  <data key="d3">Tramadol showed comparable efficacy to diclofenac after 4 weeks in patients with osteoarthritis of the hip and/or knee.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_DICLOFENAC">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">DICLOFENAC</data>
  <data key="d7">diclofenac</data>
</node>
<node id="Disease_OSTEOARTHRITIS">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">OSTEOARTHRITIS</data>
  <data key="d7">osteoarthritis</data>
</node>
<node id="PDF_12_Result_4012132410910561633">
  <data key="d0">Result</data>
  <data key="d1">Tramadol can be effectively substituted for NSAIDs in some patients with osteoarthritis.</data>
  <data key="d3">Tramadol can be effectively substituted for NSAIDs in some patients with osteoarthritis.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_-7520773854883127398">
  <data key="d0">Result</data>
  <data key="d1">Tramadol was significantly more effective than placebo in reducing the severity of pain at rest in patients with osteoarthritis.</data>
  <data key="d3">Tramadol was significantly more effective than placebo in reducing the severity of pain at rest in patients with osteoarthritis.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_6">
  <data key="d0">Paper</data>
  <data key="d1">nature medicine
a
Article
https://doi.org/10.1038/s41591-024-03463-z
Subcutaneous weekly semaglutide with
automated insulin delivery in type 1 diabetes:
a double-blind, randomized, crossover trial
Received: 12 August 2024
Accepted: 11 December 2024
Published online: 10 January 2025
Check for updates
Melissa-Rosina Pasqua 1,2,3 Michael A. Tsoukas 1,2,3, Alessandra Kobayati 2,3,
Wedyan Aboznadah¹4, Adnan Jafar &amp; Ahmad Haidar 1,2,3,5
Efforts to improve glycemic control in type 1 diabetes are ongoin</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_6_Result_8306978191084530718">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide increased time in the target range by a mean 4.8 (s.d. = 7.6) percentage points (P = 0.006), without increasing the time spent below 3.9 mmol 1¯¹ (P = 0.19) or below 3.0 mmol l¯¹ (P = 0.65).</data>
  <data key="d3">Semaglutide increased time in the target range by a mean 4.8 (s.d. = 7.6) percentage points (P = 0.006), without increasing the time spent below 3.9 mmol 1¯¹ (P = 0.19) or below 3.0 mmol l¯¹ (P = 0.65).</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Result_2173756238646118882">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide improves glycemic control with automated insulin delivery compared to placebo.</data>
  <data key="d3">Semaglutide improves glycemic control with automated insulin delivery compared to placebo.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Result_2090660425365293038">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide led to a higher time in range by 4.3 percentage points (5.5, P = 0.02), lower insulin usage by 12.2 U [-16.2, -5.4] (P = 0.008) and lower carbohydrate intake by 50 g (35; P = 0.0004) compared to placebo, without increasing time spent in hypoglycemia</data>
  <data key="d3">Semaglutide led to a higher time in range by 4.3 percentage points (5.5, P = 0.02), lower insulin usage by 12.2 U [-16.2, -5.4] (P = 0.008) and lower carbohydrate intake by 50 g (35; P = 0.0004) compared to placebo, without increasing time spent in hypoglycemia</data>
  <data key="d4">PDF_6</data>
</node>
<node id="Compound_INSULIN">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">INSULIN</data>
  <data key="d7">Insulin</data>
</node>
<node id="Disease_HYPOGLYCEMIA">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">HYPOGLYCEMIA</data>
  <data key="d7">Hypoglycemia</data>
</node>
<node id="PDF_6_Result_-8070704830058289503">
  <data key="d0">Result</data>
  <data key="d1">Weight was reduced by 5.3 (2.9) kg with semaglutide compared to placebo (P&lt;0.001; Table 3), constituting a -5.1% (3.0) relative change from baseline.</data>
  <data key="d3">Weight was reduced by 5.3 (2.9) kg with semaglutide compared to placebo (P&lt;0.001; Table 3), constituting a -5.1% (3.0) relative change from baseline.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Result_8851808403034214315">
  <data key="d0">Result</data>
  <data key="d1">Daily insulin use was reduced by 11.3 units [-23.6, -4.9] with semaglutide compared to placebo (P&lt;0.001; Table 2).</data>
  <data key="d3">Daily insulin use was reduced by 11.3 units [-23.6, -4.9] with semaglutide compared to placebo (P&lt;0.001; Table 2).</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Result_-8257117801097698704">
  <data key="d0">Result</data>
  <data key="d1">Daily carbohydrate intake (as entered into the participants' bolus calculator) was also reduced by 36 g [-55, -15] with semaglutide compared to placebo (P&lt;0.001).</data>
  <data key="d3">Daily carbohydrate intake (as entered into the participants' bolus calculator) was also reduced by 36 g [-55, -15] with semaglutide compared to placebo (P&lt;0.001).</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Conclusion_4473825811740049547">
  <data key="d0">Conclusion</data>
  <data key="d1">Semaglutide improved glycemic control, with lower insulin requirements, in adults with T1D when used with AID.</data>
  <data key="d3">Semaglutide improved glycemic control, with lower insulin requirements, in adults with T1D when used with AID.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="Disease_TYPE 1 DIABETES">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">TYPE 1 DIABETES</data>
  <data key="d7">Type 1 Diabetes</data>
</node>
<node id="PDF_6_Conclusion_2000144748216711248">
  <data key="d0">Conclusion</data>
  <data key="d1">Semaglutide also reduced carbohydrate intake, body weight, BMI and waist and hip circumferences compared to placebo.</data>
  <data key="d3">Semaglutide also reduced carbohydrate intake, body weight, BMI and waist and hip circumferences compared to placebo.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Conclusion_3344410280758824495">
  <data key="d0">Conclusion</data>
  <data key="d1">Those who had the highest weight reduction had the most glycemic benefits.</data>
  <data key="d3">Those who had the highest weight reduction had the most glycemic benefits.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Method_-1812287868508375680">
  <data key="d0">Method</data>
  <data key="d1">We performed a randomized, double-blind, crossover trial to assess semaglutide as adjunct to automated insulin delivery therapy in adults with type 1 diabetes.</data>
  <data key="d3">We performed a randomized, double-blind, crossover trial to assess semaglutide as adjunct to automated insulin delivery therapy in adults with type 1 diabetes.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Method_5467834125242263946">
  <data key="d0">Method</data>
  <data key="d1">participants were titrated up to 1 mg or the maximum tolerated dose of semaglutide or placebo over 11 weeks, followed by the use of an automated insulin delivery system for 4 weeks.</data>
  <data key="d3">participants were titrated up to 1 mg or the maximum tolerated dose of semaglutide or placebo over 11 weeks, followed by the use of an automated insulin delivery system for 4 weeks.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Result_-7969519358875206180">
  <data key="d0">Result</data>
  <data key="d1">HbAlc reductions in those with detectable C-peptide levels tended to be higher than those with undetectable levels</data>
  <data key="d3">HbAlc reductions in those with detectable C-peptide levels tended to be higher than those with undetectable levels</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_20">
  <data key="d0">Paper</data>
  <data key="d1">Here is the extracted text from the scientific PDF, as requested:

**SCIENTIFIC REPORTS**

**OPEN**

**SUBJECT AREAS:**
DRUG DEVELOPMENT
NATURAL PRODUCTS

Received
2 September 2014

Accepted
5 January 2015

Published
28 January 2015

Correspondence and
requests for materials
should be addressed to
A.K.S. (Shetty@
medicine.tamhsc.edu)

* These authors
contributed equally to
this work.

† Current address:
Department of
Radiation Oncology,
Univ California Irvine.

Resveratrol Prevents Age-Related
M</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_20_Hypothesis_7815950929145965661">
  <data key="d0">Hypothesis</data>
  <data key="d1">Resveratrol is efficacious for counteracting age-related memory and mood impairments and the associated detrimental changes in the hippocampus.</data>
  <data key="d3">Resveratrol is efficacious for counteracting age-related memory and mood impairments and the associated detrimental changes in the hippocampus.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Method_-3192592762685504414">
  <data key="d0">Method</data>
  <data key="d1">Two groups of male F344 rats in late middle-age having similar learning and memory abilities were chosen and treated with resveratrol or vehicle for four weeks.</data>
  <data key="d3">Two groups of male F344 rats in late middle-age having similar learning and memory abilities were chosen and treated with resveratrol or vehicle for four weeks.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_7880338680616154425">
  <data key="d0">Result</data>
  <data key="d1">Analyses at ~25 months of age uncovered improved learning, memory and mood function in resveratrol-treated animals but impairments in vehicle-treated animals.</data>
  <data key="d3">Analyses at ~25 months of age uncovered improved learning, memory and mood function in resveratrol-treated animals but impairments in vehicle-treated animals.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_-2454235102931694743">
  <data key="d0">Result</data>
  <data key="d1">Resveratrol-treated animals also displayed increased net neurogenesis and microvasculature, and diminished astrocyte hypertrophy and microglial activation in the hippocampus.</data>
  <data key="d3">Resveratrol-treated animals also displayed increased net neurogenesis and microvasculature, and diminished astrocyte hypertrophy and microglial activation in the hippocampus.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Conclusion_332732362293398497">
  <data key="d0">Conclusion</data>
  <data key="d1">Resveratrol treatment in late middle age is efficacious for improving memory and mood function in old age. Modulation of the hippocampus plasticity and suppression of chronic low-level inflammation appear to underlie the functional benefits mediated by resveratrol.</data>
  <data key="d3">Resveratrol treatment in late middle age is efficacious for improving memory and mood function in old age. Modulation of the hippocampus plasticity and suppression of chronic low-level inflammation appear to underlie the functional benefits mediated by resveratrol.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Method_-2759039647837489812">
  <data key="d0">Method</data>
  <data key="d1">Administration of resveratrol (RESV), a naturally occurring polyphenol found in high concentrations in the skin of red grapes, appears suitable for counteracting age-related detrimental changes in the hippocampus because of its pro-angiogenic and antiinflammatory properties with no adverse side effects</data>
  <data key="d3">Administration of resveratrol (RESV), a naturally occurring polyphenol found in high concentrations in the skin of red grapes, appears suitable for counteracting age-related detrimental changes in the hippocampus because of its pro-angiogenic and antiinflammatory properties with no adverse side effects</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_-1958938736660902508">
  <data key="d0">Result</data>
  <data key="d1">RESV treatment enhanced net neurogenesis in the hippocampus of aged rats.</data>
  <data key="d3">RESV treatment enhanced net neurogenesis in the hippocampus of aged rats.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_8971111134504406777">
  <data key="d0">Result</data>
  <data key="d1">RESV treatment promoted increased neurogenesis in aged rats for prolonged periods.</data>
  <data key="d3">RESV treatment promoted increased neurogenesis in aged rats for prolonged periods.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_8833305366754644014">
  <data key="d0">Result</data>
  <data key="d1">RESV treatment enhanced microvasculature in the hippocampus of aged rats.</data>
  <data key="d3">RESV treatment enhanced microvasculature in the hippocampus of aged rats.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_-7934427894631955237">
  <data key="d0">Result</data>
  <data key="d1">RESV treatment reduced the hypertrophy of astrocytes in aged rats.</data>
  <data key="d3">RESV treatment reduced the hypertrophy of astrocytes in aged rats.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_-3313445731501826354">
  <data key="d0">Result</data>
  <data key="d1">RESV treatment reduced activation of microglia in aged rats.</data>
  <data key="d3">RESV treatment reduced activation of microglia in aged rats.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_5">
  <data key="d0">Paper</data>
  <data key="d1">Here's the extracted text from the scientific PDF you provided:

**scientific reports**

**OPEN A GLP1 receptor agonist diabetes drug ameliorates neurodegeneration in a mouse model of infantile neurometabolic disease**

L. Poupon-Bejuit1,2, M. P. Hughes1,2, W. Liu¹, A. Geard¹, N. Faour-Slika¹, S. Whaler¹, G. Massaro1 &amp; A. A. Rahim1

Infantile neuroaxonal dystrophy (INAD) is a rare paediatric neurodegenerative condition caused by mutations in the PLA2G6 gene, which is also the causative gene for </data>
  <data key="d2">2024</data>
</node>
<node id="PDF_5_Result_7755476335848891001">
  <data key="d0">Result</data>
  <data key="d1">Systemically administered high-dose semaglutide delivered weekly to juvenile INAD mice improved locomotor function and extended the lifespan.</data>
  <data key="d3">Systemically administered high-dose semaglutide delivered weekly to juvenile INAD mice improved locomotor function and extended the lifespan.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="Disease_INAD">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">INAD</data>
  <data key="d7">INAD</data>
</node>
<node id="PDF_5_Result_-334082166859481260">
  <data key="d0">Result</data>
  <data key="d1">semaglutide significantly increased levels of key neuroprotective molecules while decreasing those involved in pro-neurodegenerative pathways.</data>
  <data key="d3">semaglutide significantly increased levels of key neuroprotective molecules while decreasing those involved in pro-neurodegenerative pathways.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_1284800464766322825">
  <data key="d0">Result</data>
  <data key="d1">The expression of mediators in both the apoptotic and necroptotic pathways were also significantly reduced in semaglutide treated mice.</data>
  <data key="d3">The expression of mediators in both the apoptotic and necroptotic pathways were also significantly reduced in semaglutide treated mice.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_-5160257447693917409">
  <data key="d0">Result</data>
  <data key="d1">A reduction of neuronal loss and neuroinflammation was observed.</data>
  <data key="d3">A reduction of neuronal loss and neuroinflammation was observed.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_6540219734818116931">
  <data key="d0">Result</data>
  <data key="d1">There was no obvious inflammatory response in wild-type mice associated with the repeated high doses of semaglutide used in this study.</data>
  <data key="d3">There was no obvious inflammatory response in wild-type mice associated with the repeated high doses of semaglutide used in this study.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_-4969595479476564550">
  <data key="d0">Result</data>
  <data key="d1">A significant increase in survival was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide, with median survival at 129 days vs 99 days for untreated Pla2g6¯¹- mice</data>
  <data key="d3">A significant increase in survival was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide, with median survival at 129 days vs 99 days for untreated Pla2g6¯¹- mice</data>
  <data key="d4">PDF_5</data>
</node>
<node id="Gene_PLA2G6">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">PLA2G6</data>
  <data key="d7">Pla2g6</data>
</node>
<node id="PDF_5_Result_-5592462067182580329">
  <data key="d0">Result</data>
  <data key="d1">Pla2g6-/- mice treated with 0.5 µg/g semaglutide did not show a significant deficit in rotarod performance compared to wild-type controls at any time point measured.</data>
  <data key="d3">Pla2g6-/- mice treated with 0.5 µg/g semaglutide did not show a significant deficit in rotarod performance compared to wild-type controls at any time point measured.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_3558410145889663672">
  <data key="d0">Result</data>
  <data key="d1">Treatment of Pla2g6-¹- mice with 0.5 µg/g semaglutide resulted in a significant improvement in performance of the vertical pole test compared to untreated mice from week 9 to week 13</data>
  <data key="d3">Treatment of Pla2g6-¹- mice with 0.5 µg/g semaglutide resulted in a significant improvement in performance of the vertical pole test compared to untreated mice from week 9 to week 13</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_-3112029605417809537">
  <data key="d0">Result</data>
  <data key="d1">Data analyses showed a significant reduction in the total distance travelled, average speed, total mobility time, total immobility time and freezing time measurements in 12-week-old Pla2g6- mice when compared to wild-type counterparts.</data>
  <data key="d3">Data analyses showed a significant reduction in the total distance travelled, average speed, total mobility time, total immobility time and freezing time measurements in 12-week-old Pla2g6- mice when compared to wild-type counterparts.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_8672654303686994003">
  <data key="d0">Result</data>
  <data key="d1">Data analyses didn't reveal a significant difference when comparing the untreated Pla2g6¯/¯ mice to the Pla2g6-¹- group treated with high-dose semaglutide, except for a significant decrease in the freezing time at 12 weeks.</data>
  <data key="d3">Data analyses didn't reveal a significant difference when comparing the untreated Pla2g6¯/¯ mice to the Pla2g6-¹- group treated with high-dose semaglutide, except for a significant decrease in the freezing time at 12 weeks.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_-1203627661883813793">
  <data key="d0">Result</data>
  <data key="d1">The Pla2g6-/- group treated with high-dose semaglutide were comparable to age-matched wild type controls for all measured parameters, excluding the total mobility and immobility time.</data>
  <data key="d3">The Pla2g6-/- group treated with high-dose semaglutide were comparable to age-matched wild type controls for all measured parameters, excluding the total mobility and immobility time.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_7122110065846937519">
  <data key="d0">Result</data>
  <data key="d1">A significant increase in GLP-1R expression was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide at 14 weeks when compared to age-matched wild-type and untreated Pla2g6¯¹- controls</data>
  <data key="d3">A significant increase in GLP-1R expression was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide at 14 weeks when compared to age-matched wild-type and untreated Pla2g6¯¹- controls</data>
  <data key="d4">PDF_5</data>
</node>
<node id="Protein_GLP-1R">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">GLP-1R</data>
  <data key="d7">GLP-1R</data>
</node>
<node id="PDF_5_Result_-5164405377201281036">
  <data key="d0">Result</data>
  <data key="d1">A significant increase of ATF-3 was detected by qPCR at 14 weeks in untreated Pla2g6-- mice compared to age-matched wild-type controls.</data>
  <data key="d3">A significant increase of ATF-3 was detected by qPCR at 14 weeks in untreated Pla2g6-- mice compared to age-matched wild-type controls.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="Protein_ATF-3">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">ATF-3</data>
  <data key="d7">ATF-3</data>
</node>
<node id="PDF_5_Method_-8999913684500077984">
  <data key="d0">Method</data>
  <data key="d1">The Pla2g6-inad knock-in mouse model (Pla2g6-/-) was administered with semaglutide at three doses; 0.5 µg/g, 0.25 µg/g or 0.15 µg/g, via intraperitoneal injection once a week.</data>
  <data key="d3">The Pla2g6-inad knock-in mouse model (Pla2g6-/-) was administered with semaglutide at three doses; 0.5 µg/g, 0.25 µg/g or 0.15 µg/g, via intraperitoneal injection once a week.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_3">
  <data key="d0">Paper</data>
  <data key="d1">LTH &amp; HUMAN SERVICES-US,
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
HHS Public Access
Author manuscript
Nat Metab. Author manuscript; available in PMC 2021 August 15.
Published in final edited form as:
Nat Metab. 2021 February ; 3(2): 258–273. doi:10.1038/s42255-021-00344-4.
Central and peripheral GLP-1 systems independently suppress
eating
Daniel I. Brierley¹, Marie K. Holt2, Arashdeep Singh3,7, Alan de Araujo 3,7, Molly
McDougle 3,7, Macarena Vergara3,7, Majd H. Af</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_3_Hypothesis_5937887320383361804">
  <data key="d0">Hypothesis</data>
  <data key="d1">peripheral GLP-1 signals to the brain to suppress eating via vagal and/or endocrine activation of central GLP-1-producing preproglucagon (PPG) neurons, i.e. that peripheral and central GLP-1 systems comprise a unified, directly connected gut-brain satiation circuit.</data>
  <data key="d3">peripheral GLP-1 signals to the brain to suppress eating via vagal and/or endocrine activation of central GLP-1-producing preproglucagon (PPG) neurons, i.e. that peripheral and central GLP-1 systems comprise a unified, directly connected gut-brain satiation circuit.</data>
  <data key="d4">PDF_3</data>
</node>
<node id="Protein_GLP-1">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">GLP-1</data>
  <data key="d7">GLP-1</data>
</node>
<node id="Gene_PPG">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">PPG</data>
  <data key="d7">PPG</data>
</node>
<node id="PDF_3_Method_4983325178299917240">
  <data key="d0">Method</data>
  <data key="d1">viral ablation of PPGNTS neurons, using AAV-mediated selective expression of diptheria toxin subunit A (DTA)</data>
  <data key="d3">viral ablation of PPGNTS neurons, using AAV-mediated selective expression of diptheria toxin subunit A (DTA)</data>
  <data key="d4">PDF_3</data>
</node>
<node id="Gene_PPGNTS">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">PPGNTS</data>
  <data key="d7">PPGNTS</data>
</node>
<node id="PDF_3_Result_-8926515749602198478">
  <data key="d0">Result</data>
  <data key="d1">Food intake over the circadian cycle was unaffected by neuronal ablation in either sex</data>
  <data key="d3">Food intake over the circadian cycle was unaffected by neuronal ablation in either sex</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_-8889060088529917024">
  <data key="d0">Result</data>
  <data key="d1">PPGNTS neuron inhibition increased fasting-induced pellet refeeding during hour 1 in a sex-independent manner, and this effect was driven by increased meal size, rather than frequency</data>
  <data key="d3">PPGNTS neuron inhibition increased fasting-induced pellet refeeding during hour 1 in a sex-independent manner, and this effect was driven by increased meal size, rather than frequency</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_7738172035843986321">
  <data key="d0">Result</data>
  <data key="d1">Ensure intake was increased by PPGNTS neuron inhibition, and, consistent with effects on pellet intake in the FED system, this increase was driven by increased duration of Ensure eating</data>
  <data key="d3">Ensure intake was increased by PPGNTS neuron inhibition, and, consistent with effects on pellet intake in the FED system, this increase was driven by increased duration of Ensure eating</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_-6606204955788834190">
  <data key="d0">Result</data>
  <data key="d1">PPGNTS activation reduced intake by ~40% in the first 24 hours</data>
  <data key="d3">PPGNTS activation reduced intake by ~40% in the first 24 hours</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_-2337145280325494230">
  <data key="d0">Result</data>
  <data key="d1">PPGNTS neuron activation advanced the point of satiation by ~15 minutes</data>
  <data key="d3">PPGNTS neuron activation advanced the point of satiation by ~15 minutes</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_5019986530835264392">
  <data key="d0">Result</data>
  <data key="d1">chemogenetic activation of Glp1rVANs using the excitatory hM3Dq DREADD in ad libitum eating mice suppressed eating during the dark but not subsequent light phase</data>
  <data key="d3">chemogenetic activation of Glp1rVANs using the excitatory hM3Dq DREADD in ad libitum eating mice suppressed eating during the dark but not subsequent light phase</data>
  <data key="d4">PDF_3</data>
</node>
<node id="Gene_GLP-1R">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">GLP-1R</data>
  <data key="d7">GLP-1R</data>
</node>
<node id="PDF_3_Result_-6432978783889930376">
  <data key="d0">Result</data>
  <data key="d1">Optogenetic activation of Glp1r terminals within the NTS conditioned avoidance of the paired flavour</data>
  <data key="d3">Optogenetic activation of Glp1r terminals within the NTS conditioned avoidance of the paired flavour</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_3176674364245536181">
  <data key="d0">Result</data>
  <data key="d1">superfusion of oxytocin activated 84% of glutamate-responsive PPGNTS neurons</data>
  <data key="d3">superfusion of oxytocin activated 84% of glutamate-responsive PPGNTS neurons</data>
  <data key="d4">PDF_3</data>
</node>
<node id="Compound_OXYTOCIN">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">OXYTOCIN</data>
  <data key="d7">oxytocin</data>
</node>
<node id="PDF_3_Result_-6444487890488775633">
  <data key="d0">Result</data>
  <data key="d1">oxytocin acutely suppressed eating in ad libitum eating control mice, this effect was completely abolished in mice in which PPGNTS neurons had been virally ablated by DTA expression</data>
  <data key="d3">oxytocin acutely suppressed eating in ad libitum eating control mice, this effect was completely abolished in mice in which PPGNTS neurons had been virally ablated by DTA expression</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_6663617786060617154">
  <data key="d0">Result</data>
  <data key="d1">Liraglutide robustly suppressed intake and bodyweight over 24 hours in ad libitum eating eGFP-transduced control mice, however DTA ablation of PPGNTS neurons had no effect on the magnitude of eating suppression at any timepoint</data>
  <data key="d3">Liraglutide robustly suppressed intake and bodyweight over 24 hours in ad libitum eating eGFP-transduced control mice, however DTA ablation of PPGNTS neurons had no effect on the magnitude of eating suppression at any timepoint</data>
  <data key="d4">PDF_3</data>
</node>
<node id="Compound_LIRAGLUTIDE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">LIRAGLUTIDE</data>
  <data key="d7">Liraglutide</data>
</node>
<node id="PDF_3_Result_3284929924712106620">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide induced robust cFos expression within the AP and throughout the rostro-caudal extent of the NTS</data>
  <data key="d3">Semaglutide induced robust cFos expression within the AP and throughout the rostro-caudal extent of the NTS</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_1069820669888993396">
  <data key="d0">Result</data>
  <data key="d1">PPGNTS neuron activation augments semaglutide-induced eating suppression</data>
  <data key="d3">PPGNTS neuron activation augments semaglutide-induced eating suppression</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Conclusion_8825786606699857213">
  <data key="d0">Conclusion</data>
  <data key="d1">central and peripheral GLP-1 systems suppress eating via independent gut-brain circuits, providing a rationale for pharmacological activation of PPGNTS neurons in combination with GLP-1 receptor agonists as an obesity treatment strategy.</data>
  <data key="d3">central and peripheral GLP-1 systems suppress eating via independent gut-brain circuits, providing a rationale for pharmacological activation of PPGNTS neurons in combination with GLP-1 receptor agonists as an obesity treatment strategy.</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Conclusion_8475083258189845961">
  <data key="d0">Conclusion</data>
  <data key="d1">PPGNTS neurons are not necessary for GLP-1RA-induced suppression of eating.</data>
  <data key="d3">PPGNTS neurons are not necessary for GLP-1RA-induced suppression of eating.</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Conclusion_-8971442004466911014">
  <data key="d0">Conclusion</data>
  <data key="d1">Oxtr- rather than Glp1r-expressing VANs are the primary source of gastrointestinal distension signals driving PPGNTS neuron-mediated satiation.</data>
  <data key="d3">Oxtr- rather than Glp1r-expressing VANs are the primary source of gastrointestinal distension signals driving PPGNTS neuron-mediated satiation.</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_2">
  <data key="d0">Paper</data>
  <data key="d1">JCI INSIGHT
RESEARCH ARTICLE
Semaglutide lowers body weight in
rodents via distributed neural pathways
Sanaz Gabery,¹ Casper G. Salinas,¹ Sarah J. Paulsen, ¹ Jonas Ahnfelt-Rønne,¹ Tomas Alanentalo,¹ Arian
F. Baquero, Stephen T. Buckley,² Erzsébet Farkas, Csaba Fekete,³ Klaus S. Frederiksen,¹ Wouter
Frederik Johan Hogendorf, Hans Christian C. Helms,² Jacob F. Jeppesen,¹ Linu M. John,¹ Charles
Pyke,¹ Jane Nøhr,¹ Tess T. Lu,¹ Joseph Polex-Wolf,¹ Vincent Prevot, 4 Kirsten Raun,¹ Lotte Simonsen,¹
Gao</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_2_Hypothesis_1815441347359116181">
  <data key="d0">Hypothesis</data>
  <data key="d1">GLP-1RAs may reduce food intake and BW through distributed effects in the CNS, rather than through a specific localized population of GLP-1Rs.</data>
  <data key="d3">GLP-1RAs may reduce food intake and BW through distributed effects in the CNS, rather than through a specific localized population of GLP-1Rs.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="Process_BW">
  <data key="d0">Entity</data>
  <data key="d5">Process</data>
  <data key="d6">BW</data>
  <data key="d7">BW</data>
</node>
<node id="PDF_2_Result_4611493572516884927">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide dose-dependently reduced BW and suppressed food intake in DIO mice.</data>
  <data key="d3">Semaglutide dose-dependently reduced BW and suppressed food intake in DIO mice.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="PDF_2_Result_-2273015844379847364">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide suppressed food intake and induced a 17%-18% reduction in BW.</data>
  <data key="d3">Semaglutide suppressed food intake and induced a 17%-18% reduction in BW.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="PDF_2_Result_-6346404022377378758">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide transiently reduced dark phase EE until day 6 of treatment, after which levels were not significantly lower than those of the vehicle-treated controls.</data>
  <data key="d3">Semaglutide transiently reduced dark phase EE until day 6 of treatment, after which levels were not significantly lower than those of the vehicle-treated controls.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="Process_EE">
  <data key="d0">Entity</data>
  <data key="d5">Process</data>
  <data key="d6">EE</data>
  <data key="d7">EE</data>
</node>
<node id="PDF_2_Result_-6241028819256066407">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide VT750 was observed in the choroid plexus.</data>
  <data key="d3">Semaglutide VT750 was observed in the choroid plexus.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="PDF_2_Result_9092086921935191153">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide increased prolactin-releasing peptide (PrRP) and tyrosine hydroxylase (TH) in the hindbrain.</data>
  <data key="d3">Semaglutide increased prolactin-releasing peptide (PrRP) and tyrosine hydroxylase (TH) in the hindbrain.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="Protein_PRRP">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">PRRP</data>
  <data key="d7">PrRP</data>
</node>
<node id="Protein_TH">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">TH</data>
  <data key="d7">TH</data>
</node>
<node id="PDF_2_Result_-5072708663807857775">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
  <data key="d3">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="Protein_CART">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">CART</data>
  <data key="d7">CART</data>
</node>
<node id="Protein_SST">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">SST</data>
  <data key="d7">SST</data>
</node>
<node id="Process_ARH">
  <data key="d0">Entity</data>
  <data key="d5">Process</data>
  <data key="d6">ARH</data>
  <data key="d7">ARH</data>
</node>
<node id="PDF_2_Result_8364534849777428125">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide stimulates neuronal activity in brain areas involved in appetite regulation.</data>
  <data key="d3">Semaglutide stimulates neuronal activity in brain areas involved in appetite regulation.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="PDF_2_Result_-4903554970747745773">
  <data key="d0">Result</data>
  <data key="d1">POMC/CART neurons were depolarized in response to semaglutide, whereas NPY/AgRP neurons elicited membrane hyperpolarization and became inactivated</data>
  <data key="d3">POMC/CART neurons were depolarized in response to semaglutide, whereas NPY/AgRP neurons elicited membrane hyperpolarization and became inactivated</data>
  <data key="d4">PDF_2</data>
</node>
<node id="Gene_POMC">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">POMC</data>
  <data key="d7">POMC</data>
</node>
<node id="Gene_NPY">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">NPY</data>
  <data key="d7">NPY</data>
</node>
<node id="Protein_AGRP">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">AGRP</data>
  <data key="d7">AgRP</data>
</node>
<node id="PDF_2_Result_-5696175074845712873">
  <data key="d0">Result</data>
  <data key="d1">CART mRNA levels were increased in semaglutide-treated mice compared with the vehicle-fed mice and weight-matched mice, whereas POMC expression was unaffected</data>
  <data key="d3">CART mRNA levels were increased in semaglutide-treated mice compared with the vehicle-fed mice and weight-matched mice, whereas POMC expression was unaffected</data>
  <data key="d4">PDF_2</data>
</node>
<node id="Gene_CART">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">CART</data>
  <data key="d7">CART</data>
</node>
<node id="PDF_2_Result_3465555475323324561">
  <data key="d0">Result</data>
  <data key="d1">Increased c-Fos activity was observed in the bed nuclei of the stria terminalis (BST), central amygdala nucleus (CeA), OV, parasubthalamic nucleus (PSTN), SFO, midline group of the dorsal thalamus (MTN), PB, AP, DMX, and NTS after acute s.c. semaglutide (4 hours)</data>
  <data key="d3">Increased c-Fos activity was observed in the bed nuclei of the stria terminalis (BST), central amygdala nucleus (CeA), OV, parasubthalamic nucleus (PSTN), SFO, midline group of the dorsal thalamus (MTN), PB, AP, DMX, and NTS after acute s.c. semaglutide (4 hours)</data>
  <data key="d4">PDF_2</data>
</node>
<node id="Protein_C-FOS">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">C-FOS</data>
  <data key="d7">c-Fos</data>
</node>
<node id="PDF_14">
  <data key="d0">Paper</data>
  <data key="d1">Here is the full text from the scientific PDF, with all text included in English only:

JAFRICA CARDIOVASCULAR JOURNAL OF AFRICA • Vol 20, No 2, March/April 2009
127
Review Article
Perindopril: do randomised, controlled trials support an
ACE inhibitor class effect? A meta-analysis of clinical
trials
JACQUES R SNYMAN, FRANCOIS WESSELS
Summary
Background: Due to the lack of face-to-face trials between
ACE inhibitors, clinicians and third-party funders may
assume they provide similar outcomes. As a</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_14_Result_3338617942436835057">
  <data key="d0">Result</data>
  <data key="d1">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality.</data>
  <data key="d3">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality.</data>
  <data key="d4">PDF_14</data>
</node>
<node id="Compound_ACEIS">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">ACEIS</data>
  <data key="d7">ACEIs</data>
</node>
<node id="Disease_MYOCARDIAL INFARCTION">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">MYOCARDIAL INFARCTION</data>
  <data key="d7">myocardial infarction</data>
</node>
<node id="Disease_STROKE">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">STROKE</data>
  <data key="d7">stroke</data>
</node>
<node id="Process_MORTALITY">
  <data key="d0">Entity</data>
  <data key="d5">Process</data>
  <data key="d6">MORTALITY</data>
  <data key="d7">mortality</data>
</node>
<node id="PDF_14_Conclusion_-950585630135367454">
  <data key="d0">Conclusion</data>
  <data key="d1">In the presence of positive outcomes from robust randomised, controlled trials for perindopril, one cannot assume a class effect for all ACEIs.</data>
  <data key="d3">In the presence of positive outcomes from robust randomised, controlled trials for perindopril, one cannot assume a class effect for all ACEIs.</data>
  <data key="d4">PDF_14</data>
</node>
<node id="PDF_14_Method_1698245611462071840">
  <data key="d0">Method</data>
  <data key="d1">Published randomised, controlled trials were selected using an applicable literature search for all ACEIs, irrespective of drug combination, for any cardiovascular outcome (both composite and individual outcomes were included).</data>
  <data key="d3">Published randomised, controlled trials were selected using an applicable literature search for all ACEIs, irrespective of drug combination, for any cardiovascular outcome (both composite and individual outcomes were included).</data>
  <data key="d4">PDF_14</data>
</node>
<node id="PDF_14_Result_-2440080024292915146">
  <data key="d0">Result</data>
  <data key="d1">The ACEIs as a class had a lower likelihood of an event occurring, compared to any of the comparator drugs or placebo.</data>
  <data key="d3">The ACEIs as a class had a lower likelihood of an event occurring, compared to any of the comparator drugs or placebo.</data>
  <data key="d4">PDF_14</data>
</node>
<node id="PDF_14_Result_-3056562445746325210">
  <data key="d0">Result</data>
  <data key="d1">Perindopril showed a significant risk reduction of 18% (OR 0.82; 95% CI: 0.77-0.88; p &lt; 0.0001) when compared to the overall ACEI effect.</data>
  <data key="d3">Perindopril showed a significant risk reduction of 18% (OR 0.82; 95% CI: 0.77-0.88; p &lt; 0.0001) when compared to the overall ACEI effect.</data>
  <data key="d4">PDF_14</data>
</node>
<node id="PDF_14_Result_4601801854187065423">
  <data key="d0">Result</data>
  <data key="d1">When this analysis was repeated, excluding the perindopril studies, the ACEI effect was reduced to 5% (OR 0.95; 95% CI: 0.91-0.98; p = 0.0039).</data>
  <data key="d3">When this analysis was repeated, excluding the perindopril studies, the ACEI effect was reduced to 5% (OR 0.95; 95% CI: 0.91-0.98; p = 0.0039).</data>
  <data key="d4">PDF_14</data>
</node>
<node id="PDF_14_Result_2377162177953663172">
  <data key="d0">Result</data>
  <data key="d1">The perindopril trials demonstrated a highly significant event reduction (OR 0.78; 95% CI: 0.72-0.85; p &lt; 0.0001). This was better than the event reduction with all other ACEIs combined (OR 0.86; 95% CI: 0.80-0.91; p &lt; 0.0001).</data>
  <data key="d3">The perindopril trials demonstrated a highly significant event reduction (OR 0.78; 95% CI: 0.72-0.85; p &lt; 0.0001). This was better than the event reduction with all other ACEIs combined (OR 0.86; 95% CI: 0.80-0.91; p &lt; 0.0001).</data>
  <data key="d4">PDF_14</data>
</node>
<node id="PDF_14_Result_617687932927020519">
  <data key="d0">Result</data>
  <data key="d1">The only other ACEI that has demonstrated a benefit in reduction of MI is ramipril, as used in the HOPE trial.</data>
  <data key="d3">The only other ACEI that has demonstrated a benefit in reduction of MI is ramipril, as used in the HOPE trial.</data>
  <data key="d4">PDF_14</data>
</node>
<node id="Compound_RAMIPRIL">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">RAMIPRIL</data>
  <data key="d7">Ramipril</data>
</node>
<node id="PDF_14_Result_5930299763765613412">
  <data key="d0">Result</data>
  <data key="d1">However, the exclusion of perindopril trials from the other ACEI trials reproduced a non-significant reduction in stroke events (OR 1.05; p = 0.1287).</data>
  <data key="d3">However, the exclusion of perindopril trials from the other ACEI trials reproduced a non-significant reduction in stroke events (OR 1.05; p = 0.1287).</data>
  <data key="d4">PDF_14</data>
</node>
<node id="PDF_14_Result_-7620526291293552557">
  <data key="d0">Result</data>
  <data key="d1">Perindopril, in the six outcome trials, showed a reduction in death compared to other drugs and or placebo (OR = 0.89; 95% CI: 0.84-0.95; p = 0.0008). This represents a significant 11% reduction in mortality, which is both a clinically and statistically significant benefit for all cardiovascular patients.</data>
  <data key="d3">Perindopril, in the six outcome trials, showed a reduction in death compared to other drugs and or placebo (OR = 0.89; 95% CI: 0.84-0.95; p = 0.0008). This represents a significant 11% reduction in mortality, which is both a clinically and statistically significant benefit for all cardiovascular patients.</data>
  <data key="d4">PDF_14</data>
</node>
<node id="PDF_14_Result_-5779278007953804647">
  <data key="d0">Result</data>
  <data key="d1">The ACEI benefit, demonstrated in 23 different ACEI trials, excluding perindopril, was only 5% (OR 0.95; 95% CI: 0.92- 0.98; p = 0.0033).</data>
  <data key="d3">The ACEI benefit, demonstrated in 23 different ACEI trials, excluding perindopril, was only 5% (OR 0.95; 95% CI: 0.92- 0.98; p = 0.0033).</data>
  <data key="d4">PDF_14</data>
</node>
<node id="PDF_8">
  <data key="d0">Paper</data>
  <data key="d1">ELSEVIER
DIABETES RESEARCH AND CLINICAL PRACTICE 93 (2011) 410-420
Contents lists available at ScienceDirect
Diabetes Research
and Clinical Practice
journal homepage: www.elsevier.com/locate/diabres
International
Diabetes
Federation
DIABETES
RESEARCH AND
CLINICAL PRACTICE
Peptide complex containing GLP-1 exhibited long-acting
properties in the treatment of type 2 diabetes
Xuemin Zheng a,1, Ying Lib,1, Xin Li, Lida Tanga, Weiren Xud, Min Gong b,d,*
a Department of Pharmaceutical Analysis, Tianjin</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_8_Hypothesis_-3933246017705166058">
  <data key="d0">Hypothesis</data>
  <data key="d1">Peptides known as GLP-1 protectors are predicted to increase the half-life of GLP-1 in vivo.</data>
  <data key="d3">Peptides known as GLP-1 protectors are predicted to increase the half-life of GLP-1 in vivo.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Method_6226713440386006436">
  <data key="d0">Method</data>
  <data key="d1">GLP-1 and protecting peptides (peptide 1 or peptide 2) were mixed at various ratios and then incubated at 25 °C for 5 min.</data>
  <data key="d3">GLP-1 and protecting peptides (peptide 1 or peptide 2) were mixed at various ratios and then incubated at 25 °C for 5 min.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Method_6125393978213197111">
  <data key="d0">Method</data>
  <data key="d1">GLP-1/peptide complexes were prepared at the proportions of 1:10 for peptide 1 or peptide 2 and then incubated with human serum (final sample volume of 1 ml; final GLP-1 mass of 750 µg) for 5 min to 250 h.</data>
  <data key="d3">GLP-1/peptide complexes were prepared at the proportions of 1:10 for peptide 1 or peptide 2 and then incubated with human serum (final sample volume of 1 ml; final GLP-1 mass of 750 µg) for 5 min to 250 h.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Method_-5646899149902963081">
  <data key="d0">Method</data>
  <data key="d1">Sprague Dawley rats (n = 5 per group, male) were subcutaneously injected with GLP-1/peptide 1 (1:10, containing of 750 µg GLP-1/kg body weight) and GLP-1/peptide 2 (1:10, containing of 750 µg GLP-1/kg body weight), respectively.</data>
  <data key="d3">Sprague Dawley rats (n = 5 per group, male) were subcutaneously injected with GLP-1/peptide 1 (1:10, containing of 750 µg GLP-1/kg body weight) and GLP-1/peptide 2 (1:10, containing of 750 µg GLP-1/kg body weight), respectively.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Method_-7183003868579564070">
  <data key="d0">Method</data>
  <data key="d1">Two complexes of GLP-1/peptide 1 and GLP-1/peptide 2 were subcutaneously injected into the rats so that each animal received 100 µg f GLP-1.</data>
  <data key="d3">Two complexes of GLP-1/peptide 1 and GLP-1/peptide 2 were subcutaneously injected into the rats so that each animal received 100 µg f GLP-1.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Method_548604743354006323">
  <data key="d0">Method</data>
  <data key="d1">Sprague Dawley rats (n = 5 per group) were subcutaneously injected with GLP-1/peptide 1 (1:10, containing of 100 µg GLP-1) or GLP-1/peptide 2 (1:10, containing of 100 µg GLP-1).</data>
  <data key="d3">Sprague Dawley rats (n = 5 per group) were subcutaneously injected with GLP-1/peptide 1 (1:10, containing of 100 µg GLP-1) or GLP-1/peptide 2 (1:10, containing of 100 µg GLP-1).</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Method_971662152183731818">
  <data key="d0">Method</data>
  <data key="d1">Fasting Sprague Dawley rats (n = 6 per group) were given a single dose of GLP-1/peptide complexes (GLP-1 ~300 µg/kg body weight) intraperitoneally 30 min prior to glucose administration.</data>
  <data key="d3">Fasting Sprague Dawley rats (n = 6 per group) were given a single dose of GLP-1/peptide complexes (GLP-1 ~300 µg/kg body weight) intraperitoneally 30 min prior to glucose administration.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Method_6440631248198029520">
  <data key="d0">Method</data>
  <data key="d1">Male Zucker Diabetic Fatty (ZDF) rats (n = 6 per group) were treated with GLP-1/peptide 1 complex (GLP-1 ~300 µg/kg/4 days), exenatide (100 µg/kg/12 h) and liraglutide (300 µg/kg/ daily) for 28 days.</data>
  <data key="d3">Male Zucker Diabetic Fatty (ZDF) rats (n = 6 per group) were treated with GLP-1/peptide 1 complex (GLP-1 ~300 µg/kg/4 days), exenatide (100 µg/kg/12 h) and liraglutide (300 µg/kg/ daily) for 28 days.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Result_-7071181622369019283">
  <data key="d0">Result</data>
  <data key="d1">The HPLC results predicted that the visible peak with a retention time of 18.8 min might be the GLP-1/ peptide 1 complex.</data>
  <data key="d3">The HPLC results predicted that the visible peak with a retention time of 18.8 min might be the GLP-1/ peptide 1 complex.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Result_7769921366646390716">
  <data key="d0">Result</data>
  <data key="d1">HPLC results demonstrated that either peptide 1 or peptide 2 were able to form a complex with GLP-1.</data>
  <data key="d3">HPLC results demonstrated that either peptide 1 or peptide 2 were able to form a complex with GLP-1.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Result_-4779896913638441684">
  <data key="d0">Result</data>
  <data key="d1">The half-life of GLP-1 inside the GLP-1/peptide 1 complex was 90 h and inside the GLP-1/peptide 2 complex was 75 h in human serum.</data>
  <data key="d3">The half-life of GLP-1 inside the GLP-1/peptide 1 complex was 90 h and inside the GLP-1/peptide 2 complex was 75 h in human serum.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Result_310004542361536949">
  <data key="d0">Result</data>
  <data key="d1">The concentration of GLP-1 reached a plateau at 10 h and gradually decreased but remained detectable until 150 h.</data>
  <data key="d3">The concentration of GLP-1 reached a plateau at 10 h and gradually decreased but remained detectable until 150 h.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Result_6003812801984434083">
  <data key="d0">Result</data>
  <data key="d1">The secreted insulin level was dramatically raised to 956.7 ± 37.84 pmol/l (GLP-1/peptide 1) and 827.9 ± 31.40 pmol/l (GLP-1/peptide 2).</data>
  <data key="d3">The secreted insulin level was dramatically raised to 956.7 ± 37.84 pmol/l (GLP-1/peptide 1) and 827.9 ± 31.40 pmol/l (GLP-1/peptide 2).</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Result_-9097538114006369516">
  <data key="d0">Result</data>
  <data key="d1">Blood glucose reached the maximum level 1 min after the administration of glucose and then declined to 6.66 ± 0.51 mmol/l (GLP-1/peptide 1) and 6.55 ± 0.61 mmol/l (GLP-1/peptide 2) after 10 min, P &lt; 0.01.</data>
  <data key="d3">Blood glucose reached the maximum level 1 min after the administration of glucose and then declined to 6.66 ± 0.51 mmol/l (GLP-1/peptide 1) and 6.55 ± 0.61 mmol/l (GLP-1/peptide 2) after 10 min, P &lt; 0.01.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Conclusion_8913866471670379834">
  <data key="d0">Conclusion</data>
  <data key="d1">Based upon these results, it is suggested that the GLP-1/peptide 1 complex might be utilized as a possible potent anti-diabetic drug in the treatment of type 2 diabetes mellitus.</data>
  <data key="d3">Based upon these results, it is suggested that the GLP-1/peptide 1 complex might be utilized as a possible potent anti-diabetic drug in the treatment of type 2 diabetes mellitus.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="Disease_TYPE 2 DIABETES MELLITUS">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">TYPE 2 DIABETES MELLITUS</data>
  <data key="d7">type 2 diabetes mellitus</data>
</node>
<node id="PDF_8_Conclusion_8328011558311435958">
  <data key="d0">Conclusion</data>
  <data key="d1">GLP-1 inside of a protecting peptide preserves the insulin secretion response and glucose regulatory effects of GLP-1.</data>
  <data key="d3">GLP-1 inside of a protecting peptide preserves the insulin secretion response and glucose regulatory effects of GLP-1.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_19">
  <data key="d0">Paper</data>
  <data key="d1">www.nature.com/scientificreports
scientific reports
OPEN A pro-oxidant combination
of resveratrol and copper
down-regulates multiple
biological hallmarks of ageing
and neurodegeneration in mice
Kavita Pal1,2,3, Gorantla V. Raghuram1,2,3, Jenevieve Dsouza¹,2, Sushma Shinde1,2,
Vishalkumar Jadhav¹,2, Alfina Shaikh¹,2, Bhagyeshri Rane¹,2, Harshali Tandel 1,2,
Dipali Kondhalkar¹,2, Shahid Chaudhary¹,2 &amp; Indraneel Mittra (1,2
Check for updates
Billions of cells die in the body every day, and cell-fre</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_19_Hypothesis_-2541411817281426873">
  <data key="d0">Hypothesis</data>
  <data key="d1">lifelong assault on healthy cells by cfChPs is the underlying cause of ageing, and that ageing could be retarded by deactivating extra-cellular cfChPs</data>
  <data key="d3">lifelong assault on healthy cells by cfChPs is the underlying cause of ageing, and that ageing could be retarded by deactivating extra-cellular cfChPs</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Compound_CFCHPS">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">CFCHPS</data>
  <data key="d7">cfChPs</data>
</node>
<node id="PDF_19_Method_2216283705138359622">
  <data key="d0">Method</data>
  <data key="d1">C57BL/6 mice were divided into 3 equal groups; one group was sacrificed at age 3 months, and which acted as young controls. The remaining mice were allowed to age, and at age 10 months the experimental ageing group was given R-Cu by oral gavage twice daily for further 12 months at a dose of 1 mg/kg of R and 0.1 µg/kg of Cu. The control ageing group was given water by oral gavage twice daily for 12 months. Animals of both groups were sacrificed at age 22 months</data>
  <data key="d3">C57BL/6 mice were divided into 3 equal groups; one group was sacrificed at age 3 months, and which acted as young controls. The remaining mice were allowed to age, and at age 10 months the experimental ageing group was given R-Cu by oral gavage twice daily for further 12 months at a dose of 1 mg/kg of R and 0.1 µg/kg of Cu. The control ageing group was given water by oral gavage twice daily for 12 months. Animals of both groups were sacrificed at age 22 months</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Gene_C57BL/6">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">C57BL/6</data>
  <data key="d7">C57BL/6</data>
</node>
<node id="Compound_R-CU">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">R-CU</data>
  <data key="d7">R-Cu</data>
</node>
<node id="Compound_R">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">R</data>
  <data key="d7">R</data>
</node>
<node id="Compound_CU">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">CU</data>
  <data key="d7">Cu</data>
</node>
<node id="PDF_19_Result_6198469308610633828">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction</data>
  <data key="d3">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Gene_TELOMERE">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">TELOMERE</data>
  <data key="d7">telomere</data>
</node>
<node id="Protein_AMYLOID">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">AMYLOID</data>
  <data key="d7">amyloid</data>
</node>
<node id="Gene_DNA">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">DNA</data>
  <data key="d7">DNA</data>
</node>
<node id="Process_APOPTOSIS">
  <data key="d0">Entity</data>
  <data key="d5">Process</data>
  <data key="d6">APOPTOSIS</data>
  <data key="d7">apoptosis</data>
</node>
<node id="Process_INFLAMMATION">
  <data key="d0">Entity</data>
  <data key="d5">Process</data>
  <data key="d6">INFLAMMATION</data>
  <data key="d7">inflammation</data>
</node>
<node id="Process_SENESCENCE">
  <data key="d0">Entity</data>
  <data key="d5">Process</data>
  <data key="d6">SENESCENCE</data>
  <data key="d7">senescence</data>
</node>
<node id="Process_ANEUPLOIDY">
  <data key="d0">Entity</data>
  <data key="d5">Process</data>
  <data key="d6">ANEUPLOIDY</data>
  <data key="d7">aneuploidy</data>
</node>
<node id="Disease_MITOCHONDRIAL DYSFUNCTION">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">MITOCHONDRIAL DYSFUNCTION</data>
  <data key="d7">mitochondrial dysfunction</data>
</node>
<node id="PDF_19_Result_8452349021456247325">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment also led to significant reduction in blood levels of glucose, cholesterol and C-reactive protein</data>
  <data key="d3">R-Cu treatment also led to significant reduction in blood levels of glucose, cholesterol and C-reactive protein</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Compound_GLUCOSE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">GLUCOSE</data>
  <data key="d7">glucose</data>
</node>
<node id="Compound_CHOLESTEROL">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">CHOLESTEROL</data>
  <data key="d7">cholesterol</data>
</node>
<node id="Protein_C-REACTIVE PROTEIN">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">C-REACTIVE PROTEIN</data>
  <data key="d7">C-reactive protein</data>
</node>
<node id="PDF_19_Conclusion_7581213139545090984">
  <data key="d0">Conclusion</data>
  <data key="d1">cfChPs may act as global instigators of ageing and neurodegeneration, and that therapeutic use of R-Cu may help to make healthy ageing an attainable goal</data>
  <data key="d3">cfChPs may act as global instigators of ageing and neurodegeneration, and that therapeutic use of R-Cu may help to make healthy ageing an attainable goal</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_19_Result_8488066197028720261">
  <data key="d0">Result</data>
  <data key="d1">ageing mice showed significant reduction in SOD levels in brain cells</data>
  <data key="d3">ageing mice showed significant reduction in SOD levels in brain cells</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Protein_SOD">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">SOD</data>
  <data key="d7">SOD</data>
</node>
<node id="PDF_19_Result_-2309636312143478063">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment led to marked increase in SOD levels that were similar to that detected in young control mice</data>
  <data key="d3">R-Cu treatment led to marked increase in SOD levels that were similar to that detected in young control mice</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_19_Result_3456673883778613236">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment did lead to an increase in SOD activity in serum of ageing mice, restoring them to levels similar to those seen in young control mice</data>
  <data key="d3">R-Cu treatment did lead to an increase in SOD activity in serum of ageing mice, restoring them to levels similar to those seen in young control mice</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_19_Result_7247821932593457490">
  <data key="d0">Result</data>
  <data key="d1">cfChPs were virtually eliminated following R-Cu treatment for one-year</data>
  <data key="d3">cfChPs were virtually eliminated following R-Cu treatment for one-year</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_19_Result_-1252050076845395299">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment restored telomere length to a significant degree in female mice</data>
  <data key="d3">R-Cu treatment restored telomere length to a significant degree in female mice</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_19_Result_-7676852047247529818">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment resulted in significant reduction in extra-cellular amyloid in mice of both sexes</data>
  <data key="d3">R-Cu treatment resulted in significant reduction in extra-cellular amyloid in mice of both sexes</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_19_Result_-413335566894609786">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment for one year resorted serum BDNF levels nearly to those seen in young mice in both sexes</data>
  <data key="d3">R-Cu treatment for one year resorted serum BDNF levels nearly to those seen in young mice in both sexes</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Protein_BDNF">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">BDNF</data>
  <data key="d7">BDNF</data>
</node>
<node id="PDF_19_Result_-8170279167056199065">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment reduced y-H2AX levels</data>
  <data key="d3">R-Cu treatment reduced y-H2AX levels</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Protein_H2AX">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">H2AX</data>
  <data key="d7">H2AX</data>
</node>
<node id="PDF_19_Result_-7097707872932512269">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment significantly reduced the degree of apoptosis in mice of both sexes</data>
  <data key="d3">R-Cu treatment significantly reduced the degree of apoptosis in mice of both sexes</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_19_Result_-4897362903626893323">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment significantly reduced NF-kB levels in both sexes</data>
  <data key="d3">R-Cu treatment significantly reduced NF-kB levels in both sexes</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Protein_NF-KB">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">NF-KB</data>
  <data key="d7">NF-kB</data>
</node>
<node id="PDF_19_Result_1114005357832605077">
  <data key="d0">Result</data>
  <data key="d1">Quantification of co-localising signals revealed a marked reduction following R-Cu treatment</data>
  <data key="d3">Quantification of co-localising signals revealed a marked reduction following R-Cu treatment</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_9">
  <data key="d0">Paper</data>
  <data key="d1">Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1
(IDO1) Inhibitors

Ute F. Röhrig,*,† Somi Reddy Majjigapu, *,* u,*,* Pierre Vogel,*$ Vincent Zoete,*,† and Olivier Michielin*,†,||,$

*Molecular Modeling Group, SIB Swiss Institute of Bioinformatics, CH-1015 Lausanne, Switzerland
*Laboratory of Glycochemistry and Asymmetric Synthesis, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne,
Switzerland
Ludwig Center for Cancer Research of the University of Lausanne, CH-1015 L</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_9_Hypothesis_-885440017935968242">
  <data key="d0">Hypothesis</data>
  <data key="d1">IDO1 inhibitors can be used in combination with other therapies to overcome tumor-induced immunosuppression.</data>
  <data key="d3">IDO1 inhibitors can be used in combination with other therapies to overcome tumor-induced immunosuppression.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="Gene_IDO1">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">IDO1</data>
  <data key="d7">IDO1</data>
</node>
<node id="PDF_9_Method_-8127754855858081363">
  <data key="d0">Method</data>
  <data key="d1">IDO1 inhibitory activity of small organic molecules was determined using an enzymatic assay with a specific incubation medium.</data>
  <data key="d3">IDO1 inhibitory activity of small organic molecules was determined using an enzymatic assay with a specific incubation medium.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_7635724024809655906">
  <data key="d0">Method</data>
  <data key="d1">The 2,2-diphenyl-1-picrylhydrazyl (DPPH) antioxidant assay was used to investigate redox-cycling properties of IDO1 inhibitors.</data>
  <data key="d3">The 2,2-diphenyl-1-picrylhydrazyl (DPPH) antioxidant assay was used to investigate redox-cycling properties of IDO1 inhibitors.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_2338569799055427341">
  <data key="d0">Method</data>
  <data key="d1">HPLC was used to monitor the amount of L-Trp breakdown.</data>
  <data key="d3">HPLC was used to monitor the amount of L-Trp breakdown.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_-234233171614585128">
  <data key="d0">Method</data>
  <data key="d1">UV absorption spectra of the characteristic heme peaks were used to argue for a direct binding of compounds to the iron ion in the IDO1 active site.</data>
  <data key="d3">UV absorption spectra of the characteristic heme peaks were used to argue for a direct binding of compounds to the iron ion in the IDO1 active site.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_-5141226431183046693">
  <data key="d0">Method</data>
  <data key="d1">Cellular assays were used to assess IDO1 inhibition, considering off-target effects, cell viability, and quantification of enzymatic reaction products.</data>
  <data key="d3">Cellular assays were used to assess IDO1 inhibition, considering off-target effects, cell viability, and quantification of enzymatic reaction products.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_-5258731870650769391">
  <data key="d0">Method</data>
  <data key="d1">Structure-based drug design, including docking studies, was used to identify and optimize IDO1 inhibitors.</data>
  <data key="d3">Structure-based drug design, including docking studies, was used to identify and optimize IDO1 inhibitors.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_410832292106273441">
  <data key="d0">Method</data>
  <data key="d1">High throughput screening (HTS) was used to discover new IDO1 inhibitor scaffolds.</data>
  <data key="d3">High throughput screening (HTS) was used to discover new IDO1 inhibitor scaffolds.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Result_7104102420254390310">
  <data key="d0">Result</data>
  <data key="d1">Selenic compound ebselen inhibits IDO1 by binding to several of its cysteine residues.</data>
  <data key="d3">Selenic compound ebselen inhibits IDO1 by binding to several of its cysteine residues.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="Compound_EBSELEN">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">EBSELEN</data>
  <data key="d7">ebselen</data>
</node>
<node id="PDF_9_Result_-3164336535847763056">
  <data key="d0">Result</data>
  <data key="d1">Isothiazolinone derivatives probably inhibit IDO1 through covalent modification of nucleophilic amino acid side chains.</data>
  <data key="d3">Isothiazolinone derivatives probably inhibit IDO1 through covalent modification of nucleophilic amino acid side chains.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Result_-1188211078373338751">
  <data key="d0">Result</data>
  <data key="d1">Menadione does not inhibit IDO1 when cytochrome P450 reductase/NADPH and cytochrome b5 are used as reductants.</data>
  <data key="d3">Menadione does not inhibit IDO1 when cytochrome P450 reductase/NADPH and cytochrome b5 are used as reductants.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="Protein_CYTOCHROME P450">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">CYTOCHROME P450</data>
  <data key="d7">cytochrome P450</data>
</node>
<node id="Protein_CYTOCHROME B5">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">CYTOCHROME B5</data>
  <data key="d7">cytochrome b5</data>
</node>
<node id="Compound_MENADIONE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">MENADIONE</data>
  <data key="d7">menadione</data>
</node>
<node id="PDF_9_Result_7785137958524726452">
  <data key="d0">Result</data>
  <data key="d1">Substrate inhibition of IDO1 by L-Trp has been described and attributed to sequential ordered binding.</data>
  <data key="d3">Substrate inhibition of IDO1 by L-Trp has been described and attributed to sequential ordered binding.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Result_2640077629412363245">
  <data key="d0">Result</data>
  <data key="d1">4-phenylimidazole (4PI) has a higher affinity for ferric rabbit small intestine IDO1 than for its ferrous form.</data>
  <data key="d3">4-phenylimidazole (4PI) has a higher affinity for ferric rabbit small intestine IDO1 than for its ferrous form.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="Compound_4-PHENYLIMIDAZOLE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">4-PHENYLIMIDAZOLE</data>
  <data key="d7">4-phenylimidazole</data>
</node>
<node id="PDF_9_Result_-7511363274713565443">
  <data key="d0">Result</data>
  <data key="d1">Binding of ebselen to cysteine residues of IDO1 shifts the Soret band of ferric IDO1 from 404 to 411 nm.</data>
  <data key="d3">Binding of ebselen to cysteine residues of IDO1 shifts the Soret band of ferric IDO1 from 404 to 411 nm.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Result_-2017196263807489895">
  <data key="d0">Result</data>
  <data key="d1">Miconazole and econazole are active against IDO1, while fluconazole is completely inactive.</data>
  <data key="d3">Miconazole and econazole are active against IDO1, while fluconazole is completely inactive.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="Compound_MICONAZOLE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">MICONAZOLE</data>
  <data key="d7">miconazole</data>
</node>
<node id="Compound_ECONAZOLE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">ECONAZOLE</data>
  <data key="d7">econazole</data>
</node>
<node id="Compound_FLUCONAZOLE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">FLUCONAZOLE</data>
  <data key="d7">fluconazole</data>
</node>
<node id="PDF_9_Result_4096444738177291706">
  <data key="d0">Result</data>
  <data key="d1">The rationally designed triazole 3 (MMG-0358) showed nanomolar activities in both enzymatic and cellular assays, low cellular toxicity, and high selectivity for IDO1 over TDO.</data>
  <data key="d3">The rationally designed triazole 3 (MMG-0358) showed nanomolar activities in both enzymatic and cellular assays, low cellular toxicity, and high selectivity for IDO1 over TDO.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="Gene_TDO">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">TDO</data>
  <data key="d7">TDO</data>
</node>
<node id="PDF_9_Conclusion_-8591738306725305241">
  <data key="d0">Conclusion</data>
  <data key="d1">Redox-cycling compounds will not only affect the kynurenine pathway of Trp degradation but also interfere with many other cellular pathways, so their use for IDO1 inhibition should be avoided.</data>
  <data key="d3">Redox-cycling compounds will not only affect the kynurenine pathway of Trp degradation but also interfere with many other cellular pathways, so their use for IDO1 inhibition should be avoided.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Conclusion_5764108499565985668">
  <data key="d0">Conclusion</data>
  <data key="d1">Kinetic measurements with variable L-Trp concentrations do not yield direct information if a compound binds to the IDO1 active site or not.</data>
  <data key="d3">Kinetic measurements with variable L-Trp concentrations do not yield direct information if a compound binds to the IDO1 active site or not.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Conclusion_-7020933065676688447">
  <data key="d0">Conclusion</data>
  <data key="d1">Caution should be used when interpreting docking results, taking into account that protein flexibility and heme interactions could be ill-described within the chosen approach.</data>
  <data key="d3">Caution should be used when interpreting docking results, taking into account that protein flexibility and heme interactions could be ill-described within the chosen approach.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_4">
  <data key="d0">Paper</data>
  <data key="d1">nature medicine
Article
a
https://doi.org/10.1038/s41591-024-02996-7
Long-term weight loss effects of semaglutide
in obesity without diabetes in the SELECT trial
Received: 1 March 2024
Accepted: 12 April 2024
Published online: 13 May 2024
Check for updates
Donna H. Ryan', Ildiko Lingvay 2, John Deanfield³, Steven E. Kahn,
Eric Barros, Bartolome Burguera, Helen M. Colhoun, Cintia Cercato 8,
Dror Dicker, Deborah B. Horn¹º, G. Kees Hovingh, Ole Kleist Jeppesen,
Alexander Kokkinos", A. Michael Linco</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_4_Result_-2683875459945412904">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide was associated with mean reduction in weight (-10.2%), waist circumference (-7.7 cm) and waist-to-height ratio (-6.9%) versus placebo (-1.5%, -1.3 cm and -1.0%, respectively; P &lt; 0.0001 for all comparisons versus placebo) at 208 weeks.</data>
  <data key="d3">Semaglutide was associated with mean reduction in weight (-10.2%), waist circumference (-7.7 cm) and waist-to-height ratio (-6.9%) versus placebo (-1.5%, -1.3 cm and -1.0%, respectively; P &lt; 0.0001 for all comparisons versus placebo) at 208 weeks.</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Result_-7469028941740501493">
  <data key="d0">Result</data>
  <data key="d1">Weight loss continued over 65 weeks and was sustained for up to 4 years in patients treated with semaglutide.</data>
  <data key="d3">Weight loss continued over 65 weeks and was sustained for up to 4 years in patients treated with semaglutide.</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Result_3068870194127367817">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide was associated with fewer serious adverse events.</data>
  <data key="d3">Semaglutide was associated with fewer serious adverse events.</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Result_3883041000718020292">
  <data key="d0">Result</data>
  <data key="d1">At week 208, mean weight loss in the semaglutide group analyzed as first on-treatment was -11.7% compared with -1.5% for the placebo group (P&lt;0.0001).</data>
  <data key="d3">At week 208, mean weight loss in the semaglutide group analyzed as first on-treatment was -11.7% compared with -1.5% for the placebo group (P&lt;0.0001).</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Result_7260200767491106545">
  <data key="d0">Result</data>
  <data key="d1">Weight loss of ≥5%, ≥10%, ≥15%, ≥20% and ≥25% was achieved by 67.8%, 44.2%, 22.9%, 11.0% and 4.9%, respectively, of those treated with semaglutide compared with 21.3%, 6.9%, 1.7%, 0.6% and 0.1% of those receiving placebo at week 104.</data>
  <data key="d3">Weight loss of ≥5%, ≥10%, ≥15%, ≥20% and ≥25% was achieved by 67.8%, 44.2%, 22.9%, 11.0% and 4.9%, respectively, of those treated with semaglutide compared with 21.3%, 6.9%, 1.7%, 0.6% and 0.1% of those receiving placebo at week 104.</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Result_-5668495360853338388">
  <data key="d0">Result</data>
  <data key="d1">At week 208, average reduction in WC was -7.7 cm with semaglutide versus -1.3 cm with placebo (P&lt;0.0001).</data>
  <data key="d3">At week 208, average reduction in WC was -7.7 cm with semaglutide versus -1.3 cm with placebo (P&lt;0.0001).</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Result_5041084921487977895">
  <data key="d0">Result</data>
  <data key="d1">At week 208, in the group randomized to semaglutide, there was a relative reduction of 6.9% in WHtR compared with 1.0% in placebo (P&lt;0.0001).</data>
  <data key="d3">At week 208, in the group randomized to semaglutide, there was a relative reduction of 6.9% in WHtR compared with 1.0% in placebo (P&lt;0.0001).</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Result_-4924147953508963545">
  <data key="d0">Result</data>
  <data key="d1">At week 104, 52.4% of patients treated with semaglutide achieved improvement in BMI category compared with 15.7% of those receiving placebo.</data>
  <data key="d3">At week 104, 52.4% of patients treated with semaglutide achieved improvement in BMI category compared with 15.7% of those receiving placebo.</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Result_3170910469353222436">
  <data key="d0">Result</data>
  <data key="d1">In the semaglutide group, 12.0% of patients achieved a BMI&lt;25 kg m², compared with 1.2% for placebo.</data>
  <data key="d3">In the semaglutide group, 12.0% of patients achieved a BMI&lt;25 kg m², compared with 1.2% for placebo.</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Result_-274728614665499438">
  <data key="d0">Result</data>
  <data key="d1">The proportion of patients with obesity (BMI ≥30 kg m²) fell from 71.0% to 43.3% in the semaglutide group versus 71.9% to 67.9% in the placebo group.</data>
  <data key="d3">The proportion of patients with obesity (BMI ≥30 kg m²) fell from 71.0% to 43.3% in the semaglutide group versus 71.9% to 67.9% in the placebo group.</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Result_-3067587265170287859">
  <data key="d0">Result</data>
  <data key="d1">Women had a greater difference in mean weight loss with semaglutide versus placebo (-11.1% versus -7.5% in men; P &lt; 0.0001).</data>
  <data key="d3">Women had a greater difference in mean weight loss with semaglutide versus placebo (-11.1% versus -7.5% in men; P &lt; 0.0001).</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Result_2835513584163089734">
  <data key="d0">Result</data>
  <data key="d1">Asian patients experienced slightly lower mean weight loss (estimated treatment difference with semaglutide for Asian race -7.27% (P = 0.0147) and for Asia -7.30 (P = 0.0016)).</data>
  <data key="d3">Asian patients experienced slightly lower mean weight loss (estimated treatment difference with semaglutide for Asian race -7.27% (P = 0.0147) and for Asia -7.30 (P = 0.0016)).</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Result_-6654836911274506089">
  <data key="d0">Result</data>
  <data key="d1">Lower BMI classes, discontinuation rates are higher in the semaglutide group but not the placebo group.</data>
  <data key="d3">Lower BMI classes, discontinuation rates are higher in the semaglutide group but not the placebo group.</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Result_3844259810186391888">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide was associated with lower SAEs, primarily driven by CV event and infections.</data>
  <data key="d3">Semaglutide was associated with lower SAEs, primarily driven by CV event and infections.</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Conclusion_-7705113909564477352">
  <data key="d0">Conclusion</data>
  <data key="d1">The weight-loss trajectory with semaglutide occurred over 65 weeks and was sustained up to 4 years.</data>
  <data key="d3">The weight-loss trajectory with semaglutide occurred over 65 weeks and was sustained up to 4 years.</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Conclusion_-9037046781256448444">
  <data key="d0">Conclusion</data>
  <data key="d1">The weight loss was associated with a greater proportion of patients receiving semaglutide achieving improvement in BMI category, healthy BMI (&lt;25 kg m²) and falling below the WC cutoff point above which increased cardiometabolic risk for the sex and race is greater.</data>
  <data key="d3">The weight loss was associated with a greater proportion of patients receiving semaglutide achieving improvement in BMI category, healthy BMI (&lt;25 kg m²) and falling below the WC cutoff point above which increased cardiometabolic risk for the sex and race is greater.</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Conclusion_-4318393518980955366">
  <data key="d0">Conclusion</data>
  <data key="d1">There was no evidence of increased SAEs based on BMI categories, although lower BMI category was associated with increased rates of trial product discontinuation, probably reflecting exposure to a higher level of drug in lower BMI categories.</data>
  <data key="d3">There was no evidence of increased SAEs based on BMI categories, although lower BMI category was associated with increased rates of trial product discontinuation, probably reflecting exposure to a higher level of drug in lower BMI categories.</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_4_Conclusion_-4078007186907932872">
  <data key="d0">Conclusion</data>
  <data key="d1">These data, representing the longest clinical trial of the effects of semaglutide versus placebo on weight, establish the safety and durability of semaglutide effects on weight loss and maintenance in a geographically and racially diverse population of adult men and women with overweight and obesity but not diabetes.</data>
  <data key="d3">These data, representing the longest clinical trial of the effects of semaglutide versus placebo on weight, establish the safety and durability of semaglutide effects on weight loss and maintenance in a geographically and racially diverse population of adult men and women with overweight and obesity but not diabetes.</data>
  <data key="d4">PDF_4</data>
</node>
<node id="PDF_11">
  <data key="d0">Paper</data>
  <data key="d1">DRUG EVALUATION
Drugs 42 (1): 90-114, 1991
0012-6667/91/0007-0090/$12.50/0
Adis International Limited. All rights reserved.
DRE1 15
Perindopril
A Review of its Pharmacological Properties and Therapeutic Use in
Cardiovascular Disorders
Peter A. Todd and Andrew Fitton
Adis International Limited, Auckland, New Zealand
Various sections of the manuscript reviewed by: A. Breckenridge, Department of Pharmacology and Therapeutics,
University of Liverpool, Liverpool, England; K. Dickstein, Department of </data>
  <data key="d2">2024</data>
</node>
<node id="PDF_11_Result_-5252757803203019223">
  <data key="d0">Result</data>
  <data key="d1">Perindopril 4 to 8mg once daily significantly reduces supine and standing blood pressure in patients with essential hypertension.</data>
  <data key="d3">Perindopril 4 to 8mg once daily significantly reduces supine and standing blood pressure in patients with essential hypertension.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-8330347455423032070">
  <data key="d0">Result</data>
  <data key="d1">Perindopril also improves arterial structure and reduces left ventricular hypertrophy in hypertensive patients.</data>
  <data key="d3">Perindopril also improves arterial structure and reduces left ventricular hypertrophy in hypertensive patients.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-2924540186561608243">
  <data key="d0">Result</data>
  <data key="d1">Beneficial acute haemodynamic effects comprising a reduction in preload and afterload with only a slight reduction in heart rate, and increased renal blood flow are seen after oral administration of perindopril 2 to 4mg in patients with congestive heart failure.</data>
  <data key="d3">Beneficial acute haemodynamic effects comprising a reduction in preload and afterload with only a slight reduction in heart rate, and increased renal blood flow are seen after oral administration of perindopril 2 to 4mg in patients with congestive heart failure.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Method_9097609785825967202">
  <data key="d0">Method</data>
  <data key="d1">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
  <data key="d3">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="Protein_ACE">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">ACE</data>
  <data key="d7">ACE</data>
</node>
<node id="Protein_ANGIOTENSIN II">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">ANGIOTENSIN II</data>
  <data key="d7">Angiotensin II</data>
</node>
<node id="PDF_11_Result_-325928441815492701">
  <data key="d0">Result</data>
  <data key="d1">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals, healthy human subjects, hypertensive patients and patients with congestive heart failure.</data>
  <data key="d3">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals, healthy human subjects, hypertensive patients and patients with congestive heart failure.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_1958124885911685315">
  <data key="d0">Result</data>
  <data key="d1">As a consequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as increases in plasma renin activity and plasma angiotensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
  <data key="d3">As a consequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as increases in plasma renin activity and plasma angiotensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="Protein_RENIN">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">RENIN</data>
  <data key="d7">Renin</data>
</node>
<node id="Protein_ANGIOTENSIN I">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">ANGIOTENSIN I</data>
  <data key="d7">Angiotensin I</data>
</node>
<node id="Compound_ALDOSTERONE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">ALDOSTERONE</data>
  <data key="d7">Aldosterone</data>
</node>
<node id="PDF_11_Result_4164066221322032311">
  <data key="d0">Result</data>
  <data key="d1">Animal studies have indicated that perindopril produces significant ACE inhibition in most tissues, including lung parenchyma, pulmonary vessels, heart, aortic wall, adrenal glands, proximal renal tubules, glomerular mesangium, renal vessels, brain cortex and pituitary glands</data>
  <data key="d3">Animal studies have indicated that perindopril produces significant ACE inhibition in most tissues, including lung parenchyma, pulmonary vessels, heart, aortic wall, adrenal glands, proximal renal tubules, glomerular mesangium, renal vessels, brain cortex and pituitary glands</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-3278554037397404708">
  <data key="d0">Result</data>
  <data key="d1">Circulating levels of adrenaline (epinephrine) and noradrenaline (norepinephrine) are not significantly changed following oral administration of normal dosages of perindopril to healthy volunteers and patients with hypertension or congestive heart failure</data>
  <data key="d3">Circulating levels of adrenaline (epinephrine) and noradrenaline (norepinephrine) are not significantly changed following oral administration of normal dosages of perindopril to healthy volunteers and patients with hypertension or congestive heart failure</data>
  <data key="d4">PDF_11</data>
</node>
<node id="Compound_ADRENALINE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">ADRENALINE</data>
  <data key="d7">Adrenaline</data>
</node>
<node id="PDF_11_Result_5718932015073294189">
  <data key="d0">Result</data>
  <data key="d1">Perindopril has been reported to normalise the increased plasma atrial natriuretic factor levels in rats with myocardial infarction experimentally induced by coronary artery ligation</data>
  <data key="d3">Perindopril has been reported to normalise the increased plasma atrial natriuretic factor levels in rats with myocardial infarction experimentally induced by coronary artery ligation</data>
  <data key="d4">PDF_11</data>
</node>
<node id="Protein_ATRIAL NATRIURETIC FACTOR">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">ATRIAL NATRIURETIC FACTOR</data>
  <data key="d7">Atrial natriuretic factor</data>
</node>
<node id="PDF_11_Result_-3615334711993736401">
  <data key="d0">Result</data>
  <data key="d1">The reduction in blood pressure produced by perindopril in animals with spontaneous or renovascular hypertension was associated with a decrease in peripheral vascular resistance with no significant change in heart rate or cardiac output</data>
  <data key="d3">The reduction in blood pressure produced by perindopril in animals with spontaneous or renovascular hypertension was associated with a decrease in peripheral vascular resistance with no significant change in heart rate or cardiac output</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-2607616780817729797">
  <data key="d0">Result</data>
  <data key="d1">Perindopril inhibited and even prevented development of cardiac hypertrophy in the rat; this was also associated with reversal of the isoenzyme shift of myocardial myosin and improvement in coronary blood flow and papillary muscle mechanical performance</data>
  <data key="d3">Perindopril inhibited and even prevented development of cardiac hypertrophy in the rat; this was also associated with reversal of the isoenzyme shift of myocardial myosin and improvement in coronary blood flow and papillary muscle mechanical performance</data>
  <data key="d4">PDF_11</data>
</node>
<node id="Protein_CARDIAC MYOSIN">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">CARDIAC MYOSIN</data>
  <data key="d7">cardiac myosin</data>
</node>
<node id="PDF_11_Result_4793552220060895356">
  <data key="d0">Result</data>
  <data key="d1">Perindopril improved large artery (carotid and aorta) and small resistance artery (mesenteric) structure, tending to normalise arterial wall thickness as well as collagen and elastin content, and thereby enhance arterial compliance.</data>
  <data key="d3">Perindopril improved large artery (carotid and aorta) and small resistance artery (mesenteric) structure, tending to normalise arterial wall thickness as well as collagen and elastin content, and thereby enhance arterial compliance.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="Protein_COLLAGEN">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">COLLAGEN</data>
  <data key="d7">collagen</data>
</node>
<node id="Protein_ELASTIN">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">ELASTIN</data>
  <data key="d7">elastin</data>
</node>
<node id="PDF_11_Result_52978127278251961">
  <data key="d0">Result</data>
  <data key="d1">Long term perindopril administration either prevented or inhibited development of experimental cardiac hypertrophy</data>
  <data key="d3">Long term perindopril administration either prevented or inhibited development of experimental cardiac hypertrophy</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_2441972062334837159">
  <data key="d0">Result</data>
  <data key="d1">Perindopril inhibited the shift in the cardiac myosin isoenzyme profile and attenuated the elevated levels of cardiac sympathetic activity normally associated with coronary artery ligation</data>
  <data key="d3">Perindopril inhibited the shift in the cardiac myosin isoenzyme profile and attenuated the elevated levels of cardiac sympathetic activity normally associated with coronary artery ligation</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-8176057543638146958">
  <data key="d0">Result</data>
  <data key="d1">Furthermore, perindopril normalised experimentally induced prolongation of the action potential</data>
  <data key="d3">Furthermore, perindopril normalised experimentally induced prolongation of the action potential</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-7168754858484395335">
  <data key="d0">Result</data>
  <data key="d1">Appropriate acute reductions in systolic and diastolic blood pressure have been demonstrated with single oral doses of perindopril 4 to 16mg in patients with essential hypertension</data>
  <data key="d3">Appropriate acute reductions in systolic and diastolic blood pressure have been demonstrated with single oral doses of perindopril 4 to 16mg in patients with essential hypertension</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_671829205114393818">
  <data key="d0">Result</data>
  <data key="d1">Regression of left ventricular hypertrophy on long term therapy (3 to 12 months) with perindopril 4 to 8mg daily has been confirmed in other studies in patients with essential hypertension</data>
  <data key="d3">Regression of left ventricular hypertrophy on long term therapy (3 to 12 months) with perindopril 4 to 8mg daily has been confirmed in other studies in patients with essential hypertension</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-4934740466665465018">
  <data key="d0">Result</data>
  <data key="d1">Investigation of the effect of perindopril 2 to 8mg daily on the elastic properties of the brachial artery in 15 patients with essential hypertension revealed that it increased arterial compliance (assessed by a pulsed Doppler technique) by 42%, decreased pulsed wave velocity (an indicator of arterial stiffness) by 13% and reduced arterial impedance by 29% after 3 months' treatment</data>
  <data key="d3">Investigation of the effect of perindopril 2 to 8mg daily on the elastic properties of the brachial artery in 15 patients with essential hypertension revealed that it increased arterial compliance (assessed by a pulsed Doppler technique) by 42%, decreased pulsed wave velocity (an indicator of arterial stiffness) by 13% and reduced arterial impedance by 29% after 3 months' treatment</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-2065021580055796562">
  <data key="d0">Result</data>
  <data key="d1">Overall, there was a reduction in preload and afterload, with a slight reduction in heart rate. The peak haemodynamic effect occurred about 4 hours after perindopril administration and was maintained for at least 24 hours after a single dose.</data>
  <data key="d3">Overall, there was a reduction in preload and afterload, with a slight reduction in heart rate. The peak haemodynamic effect occurred about 4 hours after perindopril administration and was maintained for at least 24 hours after a single dose.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_1895219285029411287">
  <data key="d0">Result</data>
  <data key="d1">The renal histological changes in rats with experimentally induced renovascular hypertension were prevented by administration of perindopril for 5 weeks</data>
  <data key="d3">The renal histological changes in rats with experimentally induced renovascular hypertension were prevented by administration of perindopril for 5 weeks</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_1317638041999125774">
  <data key="d0">Result</data>
  <data key="d1">Renal blood flow and glomerular filtration rate were increased in normotensive and spontaneously hypertensive rats during 1 to 12 weeks' administration of perindopril</data>
  <data key="d3">Renal blood flow and glomerular filtration rate were increased in normotensive and spontaneously hypertensive rats during 1 to 12 weeks' administration of perindopril</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_10">
  <data key="d0">Paper</data>
  <data key="d1">Here is the full text extracted from the scientific PDF, as requested:

The Journal of Clinical Investigation
RESEARCH ARTICLE
The arcuate nucleus mediates GLP-1 receptor agonist
liraglutide-dependent weight loss
Anna Secher,¹ Jacob Jelsing,¹ Arian F. Baquero,³ Jacob Hecksher-Sørensen,¹ Michael A. Cowley, Louise S. Dalbøge,2
Gitte Hansen,² Kevin L. Grove, Charles Pyke,¹ Kirsten Raun,¹ Lauge Schäffer,¹ Mads Tang-Christensen,¹ Saurabh Verma,³
Brent M. Witgen,¹ Niels Vrang, 2 and Lotte Bjerre Knuds</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_10_Hypothesis_-1108694323970151223">
  <data key="d0">Hypothesis</data>
  <data key="d1">GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
  <data key="d3">GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="Process_ARC">
  <data key="d0">Entity</data>
  <data key="d5">Process</data>
  <data key="d6">ARC</data>
  <data key="d7">ARC</data>
</node>
<node id="PDF_10_Method_-2190073069729990293">
  <data key="d0">Method</data>
  <data key="d1">We used fluorescently labeled liraglutide injected peripherally to describe access to specific brain areas using a highly sensitive scanning technique.</data>
  <data key="d3">We used fluorescently labeled liraglutide injected peripherally to describe access to specific brain areas using a highly sensitive scanning technique.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Method_8637960767432038323">
  <data key="d0">Method</data>
  <data key="d1">Different surgical lesioning techniques were used to assign the body weight-lowering effect to specific brain areas, and immunohistochemistry, in situ hybridization, and electrophysiology were used to suggest specific cellular and neuronal actions.</data>
  <data key="d3">Different surgical lesioning techniques were used to assign the body weight-lowering effect to specific brain areas, and immunohistochemistry, in situ hybridization, and electrophysiology were used to suggest specific cellular and neuronal actions.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_-8571693380956232666">
  <data key="d0">Result</data>
  <data key="d1">Liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus.</data>
  <data key="d3">Liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_2691464121370026756">
  <data key="d0">Result</data>
  <data key="d1">Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus.</data>
  <data key="d3">Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_2635403832457689701">
  <data key="d0">Result</data>
  <data key="d1">GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r-/- mice.</data>
  <data key="d3">GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r-/- mice.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_6944104196469185986">
  <data key="d0">Result</data>
  <data key="d1">In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART).</data>
  <data key="d3">In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART).</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_6402641960452747127">
  <data key="d0">Result</data>
  <data key="d1">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
  <data key="d3">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="Gene_AGRP">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">AGRP</data>
  <data key="d7">AgRP</data>
</node>
<node id="PDF_10_Conclusion_-5191606018148845715">
  <data key="d0">Conclusion</data>
  <data key="d1">Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
  <data key="d3">Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_7389730533980749714">
  <data key="d0">Result</data>
  <data key="d1">Liraglutide treatment significantly increased the mean Cart mRNA levels in the ARC compared with both vehicle-treated, ad libitum–fed rats and weight-matched rats, whereas Pomc expression was unaffected.</data>
  <data key="d3">Liraglutide treatment significantly increased the mean Cart mRNA levels in the ARC compared with both vehicle-treated, ad libitum–fed rats and weight-matched rats, whereas Pomc expression was unaffected.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_8159948098383069522">
  <data key="d0">Result</data>
  <data key="d1">A 1.4-fold increase in Npy mRNA levels and a 1.7-fold increase in Agrp mRNA levels were observed in weight-matched rats, while levels were unaltered following treatment with liraglutide, suggesting an ability of liraglutide to suppress the food-deprived hunger signals observed in the weight-matched control group.</data>
  <data key="d3">A 1.4-fold increase in Npy mRNA levels and a 1.7-fold increase in Agrp mRNA levels were observed in weight-matched rats, while levels were unaltered following treatment with liraglutide, suggesting an ability of liraglutide to suppress the food-deprived hunger signals observed in the weight-matched control group.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_6472271266940705396">
  <data key="d0">Result</data>
  <data key="d1">Although the ARC NPY/AgRP neurons did not express GLP-1R, the marked suppression of NPY/AgRP expression that followed chronic liraglutide treatment prompted us to examine the effect of GLP-1R stimulation on NPY neurons.</data>
  <data key="d3">Although the ARC NPY/AgRP neurons did not express GLP-1R, the marked suppression of NPY/AgRP expression that followed chronic liraglutide treatment prompted us to examine the effect of GLP-1R stimulation on NPY neurons.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_-8108579247609607560">
  <data key="d0">Result</data>
  <data key="d1">In 5 of 9 NPY cells (from 3 mice), GLP 1(7-36)amide (10 nM) caused a substantial outward current, with average current change of 20.8 ± 1.7 pA.</data>
  <data key="d3">In 5 of 9 NPY cells (from 3 mice), GLP 1(7-36)amide (10 nM) caused a substantial outward current, with average current change of 20.8 ± 1.7 pA.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_1443318649360939712">
  <data key="d0">Result</data>
  <data key="d1">GLP-1(7-36)amide failed to change the current in the presence of bicuculline, demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.</data>
  <data key="d3">GLP-1(7-36)amide failed to change the current in the presence of bicuculline, demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_-8615896456070211746">
  <data key="d0">Result</data>
  <data key="d1">ghrelin and leptin receptor mRNA levels were significantly increased in weight-matched animals, and this was prevented by liraglutide treatment.</data>
  <data key="d3">ghrelin and leptin receptor mRNA levels were significantly increased in weight-matched animals, and this was prevented by liraglutide treatment.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="Protein_GHRELIN">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">GHRELIN</data>
  <data key="d7">ghrelin</data>
</node>
<node id="Protein_LEPTIN RECEPTOR">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">LEPTIN RECEPTOR</data>
  <data key="d7">leptin receptor</data>
</node>
<node id="PDF_10_Result_3272732411012992129">
  <data key="d0">Result</data>
  <data key="d1">Preproglucagon (Ppg) mRNA in the NTS was decreased in both weight-matched and liraglutide-treated rats compared with ad libitum–fed vehicle animals.</data>
  <data key="d3">Preproglucagon (Ppg) mRNA in the NTS was decreased in both weight-matched and liraglutide-treated rats compared with ad libitum–fed vehicle animals.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_8469503454768034537">
  <data key="d0">Result</data>
  <data key="d1">peripheral liraglutide does not directly engage GLP-1R in this region</data>
  <data key="d3">peripheral liraglutide does not directly engage GLP-1R in this region</data>
  <data key="d4">PDF_10</data>
</node>
<edge source="PDF_15" target="PDF_15_Method_-578211472894560442">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_15" target="PDF_15_Result_5014316397909361333">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_15" target="PDF_15_Result_3256342382947594458">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_15" target="PDF_15_Result_-973644626587201168">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_15" target="PDF_15_Conclusion_-6193526426296019953">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_15_Result_5014316397909361333" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril was significantly more effective than placebo in decreasing supine BP, both diastolic and systolic at all visits on double-blind treatment.</data>
</edge>
<edge source="PDF_15_Result_3256342382947594458" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Successful treatment, defined as supine diastolic BP &lt;90 mm Hg or &gt;10 mm Hg decrease from baseline at end of treatment was significantly (P = 0.014) higher on perindopril (58/96 = 60%) compared to placebo (42/95 = 44%).</data>
</edge>
<edge source="PDF_15_Result_-973644626587201168" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Relative to baseline, perindopril as monotherapy lowered diastolic BP by about 6 mm Hg, and systolic BP by about 10–11 mm Hg</data>
</edge>
<edge source="PDF_15_Conclusion_-6193526426296019953" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">In summary, the present double-blind, placebo-controlled study shows a significant antihypertensive effect of placebo, and additional effect of perindopril in an elderly population.</data>
</edge>
<edge source="PDF_13" target="PDF_13_Result_-2118415563075348230">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_13" target="PDF_13_Result_-9132323818105741274">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_13" target="PDF_13_Result_6225785780675340033">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_13" target="PDF_13_Result_-6788833057832102103">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_13" target="PDF_13_Conclusion_-42029183976039292">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_13" target="PDF_13_Conclusion_-1048253378150093435">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_13_Result_-2118415563075348230" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril was effective as monotherapy in the great majority of the study patients, achieving a significant reduction in both systolic and diastolic blood pressure.</data>
</edge>
<edge source="PDF_13_Result_-9132323818105741274" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">In three-quarters of the study patients, perindopril normalized both systolic and diastolic blood pressure.</data>
</edge>
<edge source="PDF_13_Result_6225785780675340033" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The effectiveness of perindopril was shown in both patients with previously and newly diagnosed hypertension.</data>
</edge>
<edge source="PDF_13_Result_6225785780675340033" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">The effectiveness of perindopril was shown in both patients with previously and newly diagnosed hypertension.</data>
</edge>
<edge source="PDF_13_Result_-6788833057832102103" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Adverse events were mild and rare, even hyperkalemia was encountered less often than before the onset of the therapy with perindopril.</data>
</edge>
<edge source="PDF_13_Conclusion_-42029183976039292" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Our study confirmed excellent effectiveness of perindopril in the treatment of essential hypertension and its remarkable safety.</data>
</edge>
<edge source="PDF_13_Conclusion_-42029183976039292" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Our study confirmed excellent effectiveness of perindopril in the treatment of essential hypertension and its remarkable safety.</data>
</edge>
<edge source="PDF_13_Conclusion_-1048253378150093435" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">When used as monotherapy of hypertension, perindopril's doses should be carefully titrated until the achievement of full effect, which in some patients should be awaited for at least 6 months from onset of the therapy.</data>
</edge>
<edge source="PDF_13_Conclusion_-1048253378150093435" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">When used as monotherapy of hypertension, perindopril's doses should be carefully titrated until the achievement of full effect, which in some patients should be awaited for at least 6 months from onset of the therapy.</data>
</edge>
<edge source="PDF_1" target="PDF_1_Result_-5167562052163967682">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_1" target="PDF_1_Result_7495475486352378264">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_1" target="PDF_1_Result_2527217168376533811">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_1" target="PDF_1_Conclusion_-889991433722731225">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_1_Result_-5167562052163967682" target="Protein_HBA1C">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
</edge>
<edge source="PDF_1_Result_-5167562052163967682" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
</edge>
<edge source="PDF_1_Result_-5167562052163967682" target="Compound_DAPAGLIFLOZIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
</edge>
<edge source="PDF_1_Result_-5167562052163967682" target="Disease_SIDD">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
</edge>
<edge source="PDF_1_Result_7495475486352378264" target="Disease_SIDD">
  <data key="d8">MENTIONS</data>
  <data key="d9">No significant interaction was found between drug assignment and the SIDD or SIRD subgroup.</data>
</edge>
<edge source="PDF_1_Result_7495475486352378264" target="Disease_SIRD">
  <data key="d8">MENTIONS</data>
  <data key="d9">No significant interaction was found between drug assignment and the SIDD or SIRD subgroup.</data>
</edge>
<edge source="PDF_1_Result_7495475486352378264" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">No significant interaction was found between drug assignment and the SIDD or SIRD subgroup.</data>
</edge>
<edge source="PDF_1_Result_7495475486352378264" target="Compound_DAPAGLIFLOZIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">No significant interaction was found between drug assignment and the SIDD or SIRD subgroup.</data>
</edge>
<edge source="PDF_1_Result_2527217168376533811" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">continuous measures of body mass index, blood pressure, insulin secretion and insulin resistance were useful in identifying those likely to have the largest improvements in glycaemic control and cardiovascular risk factors by adding semaglutide or dapagliflozin.</data>
</edge>
<edge source="PDF_1_Result_2527217168376533811" target="Compound_DAPAGLIFLOZIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">continuous measures of body mass index, blood pressure, insulin secretion and insulin resistance were useful in identifying those likely to have the largest improvements in glycaemic control and cardiovascular risk factors by adding semaglutide or dapagliflozin.</data>
</edge>
<edge source="PDF_1_Result_2527217168376533811" target="Protein_INSULIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">continuous measures of body mass index, blood pressure, insulin secretion and insulin resistance were useful in identifying those likely to have the largest improvements in glycaemic control and cardiovascular risk factors by adding semaglutide or dapagliflozin.</data>
</edge>
<edge source="PDF_1_Conclusion_-889991433722731225" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">systematic evaluation of continuous pathophysiological variables can guide the prediction of the treatment response to these drugs and provide more information than stratified subgroups</data>
</edge>
<edge source="PDF_1_Conclusion_-889991433722731225" target="Compound_DAPAGLIFLOZIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">systematic evaluation of continuous pathophysiological variables can guide the prediction of the treatment response to these drugs and provide more information than stratified subgroups</data>
</edge>
<edge source="PDF_16" target="PDF_16_Method_234051311002480332">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_16" target="PDF_16_Method_3080411910226675941">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_16" target="PDF_16_Method_-7430451657682466480">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_16" target="PDF_16_Method_-6242020639914613255">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_16" target="PDF_16_Result_-8253323808069576894">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_16" target="PDF_16_Result_3574267891343578640">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_16" target="PDF_16_Conclusion_6335179029935553904">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_16_Method_3080411910226675941" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Participants were randomly assigned to receive either perindopril or placebo for 20 weeks.</data>
</edge>
<edge source="PDF_16_Result_-8253323808069576894" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">At 20 weeks, the mean 6-minute walking distance was significantly improved in the perindopril group relative to the placebo group</data>
</edge>
<edge source="PDF_16_Result_3574267891343578640" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">There was a significant impact on health-related quality of life: although the mean score for part 1 of the EQ-5D questionnaire deteriorated over time in the placebo group, quality of life was maintained in the perindopril group</data>
</edge>
<edge source="PDF_16_Conclusion_6335179029935553904" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Use of the ACE inhibitor perindopril improved exercise capacity in functionally impaired elderly people who had no heart failure and maintained health-related quality of life.</data>
</edge>
<edge source="PDF_18" target="PDF_18_Hypothesis_-6782162243753243341">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18" target="PDF_18_Method_-5430719080444498488">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18" target="PDF_18_Result_6797652856178707722">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18" target="PDF_18_Result_-4624684354295206998">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18" target="PDF_18_Result_-5494509411713272209">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18" target="PDF_18_Conclusion_-8075648162043344478">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18_Hypothesis_-6782162243753243341" target="Gene_MICROCEBUS MURINUS">
  <data key="d8">MENTIONS</data>
  <data key="d9">We hypothesize that long-term supplementation with intermediate dose of RSV (i.e. 200 mg/kg.day¯¹) affects the health and lifespan of the grey mouse lemur (Microcebus murinus).</data>
</edge>
<edge source="PDF_18_Hypothesis_-6782162243753243341" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">We hypothesize that long-term supplementation with intermediate dose of RSV (i.e. 200 mg/kg.day¯¹) affects the health and lifespan of the grey mouse lemur (Microcebus murinus).</data>
</edge>
<edge source="PDF_18_Method_-5430719080444498488" target="Gene_MICROCEBUS MURINUS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Longitudinal monitoring of cognitive and motor performances, occurrence of age-related pathologies, age-related brain atrophy and mortality was performed from adulthood to death in a cohort of male grey mouse lemurs (Microcebus murinus, N = 33), all receiving 105 kJ/day of food but with a subset of 18 animals receiving RSV (200 mg.kg¯¹ body weight.day¯¹).</data>
</edge>
<edge source="PDF_18_Method_-5430719080444498488" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Longitudinal monitoring of cognitive and motor performances, occurrence of age-related pathologies, age-related brain atrophy and mortality was performed from adulthood to death in a cohort of male grey mouse lemurs (Microcebus murinus, N = 33), all receiving 105 kJ/day of food but with a subset of 18 animals receiving RSV (200 mg.kg¯¹ body weight.day¯¹).</data>
</edge>
<edge source="PDF_18_Result_6797652856178707722" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RSV supplementation improved cognitive and motor performance at middle age as compared to control (CTL) animals.</data>
</edge>
<edge source="PDF_18_Result_-4624684354295206998" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Median-lifespan was greater in RSV-fed animals (7.9 years compared to 6.4 years for CTL) but long-term RSV supplementation did not significantly affect all-cause nor age-related mortality.</data>
</edge>
<edge source="PDF_18_Result_-5494509411713272209" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Brain grey matter atrophy accelerated in the RSV group at old age as compared to the CTL group.</data>
</edge>
<edge source="PDF_18_Conclusion_-8075648162043344478" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Long-term RSV supplementation procures health benefits at middle-age in male mouse lemurs but has limited long-term effects on health and longevity and might even impair brain integrity at older ages.</data>
</edge>
<edge source="PDF_17" target="PDF_17_Result_9194818847878280887">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_17" target="PDF_17_Result_-8106803482728420531">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_17" target="PDF_17_Method_3672532031162465124">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_17" target="PDF_17_Result_-2199568380892004508">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_17" target="PDF_17_Result_-2134582742111352736">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_17" target="PDF_17_Conclusion_-6127952188890531347">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_17" target="PDF_17_Conclusion_4444072132154960485">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_17_Result_-8106803482728420531" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Six minute walking distance is improved considerably by treatment with perindopril in older patients with heart failure caused by left ventricular systolic dysfunction.</data>
</edge>
<edge source="PDF_17_Method_3672532031162465124" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Prospective, double blind placebo controlled trial to determine the effects of perindopril on exercise capacity, quality of life, and cognitive function in elderly patients with congestive heart failure caused by left ventricular systolic dysfunction.</data>
</edge>
<edge source="PDF_17_Result_-2199568380892004508" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Patients randomly assigned to perindopril significantly improved their mean walking distance compared with those in the placebo group (p &lt; 0.001) with a mean increase of 37 m in the mean walking distance at 10 weeks.</data>
</edge>
<edge source="PDF_17_Result_-2134582742111352736" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Patients who were in NYHA functional class I or II (n = 29) improved significantly with perindopril (36.1 m v 2.0 m, p &lt; 0.05) as did those who were in NYHA III or IV (n = 37) (38.2 m v -1.7 m, p = 0.003).</data>
</edge>
<edge source="PDF_17_Conclusion_-6127952188890531347" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril significantly improved the six minute walking distance compared with placebo but had no effect on quality of life measures.</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_3611453984888046248">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_-5317477738240816202">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_-9131761359181572749">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Hypothesis_-5185562836786652076">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_-1578089971508452148">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_-4157133644117106142">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_7590995980995773769">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_-4774825531143330166">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7_Result_3611453984888046248" target="Protein_MTORC1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment downregulates proteins involved in xenobiotic metabolism, fatty acid metabolism, and MTORC1 signaling.</data>
</edge>
<edge source="PDF_7_Result_3611453984888046248" target="Process_FATTY ACID METABOLISM">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment downregulates proteins involved in xenobiotic metabolism, fatty acid metabolism, and MTORC1 signaling.</data>
</edge>
<edge source="PDF_7_Result_-5317477738240816202" target="Disease_CVD">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment reduces a 27-protein CVD risk score compared to placebo.</data>
</edge>
<edge source="PDF_7_Result_-9131761359181572749" target="Disease_CVD">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment favorably reduces the cardiovascular disease 2 (CVD2) risk score.</data>
</edge>
<edge source="PDF_7_Hypothesis_-5185562836786652076" target="Protein_TNC">
  <data key="d8">MENTIONS</data>
  <data key="d9">TNC may act as a mediator, with downregulation contributing to the cardiovascular-protective effects of GLP-1RAs. This hypothesis will be tested using proteomic data from the SELECT trial for the six cardiovascular proteins listed above that were downregulated by semaglutide in STEP 1.</data>
</edge>
<edge source="PDF_7_Hypothesis_-5185562836786652076" target="Compound_GLP-1RAS">
  <data key="d8">MENTIONS</data>
  <data key="d9">TNC may act as a mediator, with downregulation contributing to the cardiovascular-protective effects of GLP-1RAs. This hypothesis will be tested using proteomic data from the SELECT trial for the six cardiovascular proteins listed above that were downregulated by semaglutide in STEP 1.</data>
</edge>
<edge source="PDF_7_Hypothesis_-5185562836786652076" target="Disease_CVD">
  <data key="d8">MENTIONS</data>
  <data key="d9">TNC may act as a mediator, with downregulation contributing to the cardiovascular-protective effects of GLP-1RAs. This hypothesis will be tested using proteomic data from the SELECT trial for the six cardiovascular proteins listed above that were downregulated by semaglutide in STEP 1.</data>
</edge>
<edge source="PDF_7_Result_-1578089971508452148" target="Disease_CVD">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment reduced this CVD risk score compared with placebo.</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-9187083338672855303">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-5733080962139891931">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_4120594458912425293">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_674491331230390053">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_1905569409571579676">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-8756349941327744436">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_7292076278537665474">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_4012132410910561633">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-7520773854883127398">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12_Result_-9187083338672855303" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol is effective in acute and chronic pain states due to its dual action: binding to opioid receptors and weakly inhibiting reuptake of biogenic amines.</data>
</edge>
<edge source="PDF_12_Result_-5733080962139891931" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol does not aggravate hypertension or congestive heart failure, nor does it cause peptic ulcer disease, unlike NSAIDs.</data>
</edge>
<edge source="PDF_12_Result_-5733080962139891931" target="Compound_NSAIDS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol does not aggravate hypertension or congestive heart failure, nor does it cause peptic ulcer disease, unlike NSAIDs.</data>
</edge>
<edge source="PDF_12_Result_4120594458912425293" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol binds to the u opioid receptor site in the central nervous system, with a binding affinity 6000 times less than that of morphine.</data>
</edge>
<edge source="PDF_12_Result_4120594458912425293" target="Compound_MORPHINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol binds to the u opioid receptor site in the central nervous system, with a binding affinity 6000 times less than that of morphine.</data>
</edge>
<edge source="PDF_12_Result_674491331230390053" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol-mediated analgesia is only partially reduced by naloxone, suggesting a nonopioid mechanism of action.</data>
</edge>
<edge source="PDF_12_Result_674491331230390053" target="Compound_NALOXONE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol-mediated analgesia is only partially reduced by naloxone, suggesting a nonopioid mechanism of action.</data>
</edge>
<edge source="PDF_12_Result_1905569409571579676" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Reuptake inhibitory effects on noradrenaline and serotonin contribute to the analgesic effects of tramadol by inhibiting pain transmission in the spinal cord.</data>
</edge>
<edge source="PDF_12_Result_1905569409571579676" target="Compound_NOREPINEPHRINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Reuptake inhibitory effects on noradrenaline and serotonin contribute to the analgesic effects of tramadol by inhibiting pain transmission in the spinal cord.</data>
</edge>
<edge source="PDF_12_Result_1905569409571579676" target="Compound_SEROTONIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Reuptake inhibitory effects on noradrenaline and serotonin contribute to the analgesic effects of tramadol by inhibiting pain transmission in the spinal cord.</data>
</edge>
<edge source="PDF_12_Result_-8756349941327744436" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The (+) enantiomer of tramadol inhibits the reuptake of serotonin, whereas the (-) enantiomer preferentially inhibits the reuptake of noradrenaline.</data>
</edge>
<edge source="PDF_12_Result_-8756349941327744436" target="Compound_SEROTONIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">The (+) enantiomer of tramadol inhibits the reuptake of serotonin, whereas the (-) enantiomer preferentially inhibits the reuptake of noradrenaline.</data>
</edge>
<edge source="PDF_12_Result_-8756349941327744436" target="Compound_NOREPINEPHRINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">The (+) enantiomer of tramadol inhibits the reuptake of serotonin, whereas the (-) enantiomer preferentially inhibits the reuptake of noradrenaline.</data>
</edge>
<edge source="PDF_12_Result_7292076278537665474" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol showed comparable efficacy to diclofenac after 4 weeks in patients with osteoarthritis of the hip and/or knee.</data>
</edge>
<edge source="PDF_12_Result_7292076278537665474" target="Compound_DICLOFENAC">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol showed comparable efficacy to diclofenac after 4 weeks in patients with osteoarthritis of the hip and/or knee.</data>
</edge>
<edge source="PDF_12_Result_7292076278537665474" target="Disease_OSTEOARTHRITIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol showed comparable efficacy to diclofenac after 4 weeks in patients with osteoarthritis of the hip and/or knee.</data>
</edge>
<edge source="PDF_12_Result_4012132410910561633" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol can be effectively substituted for NSAIDs in some patients with osteoarthritis.</data>
</edge>
<edge source="PDF_12_Result_4012132410910561633" target="Compound_NSAIDS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol can be effectively substituted for NSAIDs in some patients with osteoarthritis.</data>
</edge>
<edge source="PDF_12_Result_4012132410910561633" target="Disease_OSTEOARTHRITIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol can be effectively substituted for NSAIDs in some patients with osteoarthritis.</data>
</edge>
<edge source="PDF_12_Result_-7520773854883127398" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol was significantly more effective than placebo in reducing the severity of pain at rest in patients with osteoarthritis.</data>
</edge>
<edge source="PDF_12_Result_-7520773854883127398" target="Disease_OSTEOARTHRITIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol was significantly more effective than placebo in reducing the severity of pain at rest in patients with osteoarthritis.</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_8306978191084530718">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_2173756238646118882">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_2090660425365293038">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_-8070704830058289503">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_8851808403034214315">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_-8257117801097698704">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Conclusion_4473825811740049547">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Conclusion_2000144748216711248">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Conclusion_3344410280758824495">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Method_-1812287868508375680">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Method_5467834125242263946">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_-7969519358875206180">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6_Result_8306978191084530718" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide increased time in the target range by a mean 4.8 (s.d. = 7.6) percentage points (P = 0.006), without increasing the time spent below 3.9 mmol 1¯¹ (P = 0.19) or below 3.0 mmol l¯¹ (P = 0.65).</data>
</edge>
<edge source="PDF_6_Result_2173756238646118882" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide improves glycemic control with automated insulin delivery compared to placebo.</data>
</edge>
<edge source="PDF_6_Result_2090660425365293038" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide led to a higher time in range by 4.3 percentage points (5.5, P = 0.02), lower insulin usage by 12.2 U [-16.2, -5.4] (P = 0.008) and lower carbohydrate intake by 50 g (35; P = 0.0004) compared to placebo, without increasing time spent in hypoglycemia</data>
</edge>
<edge source="PDF_6_Result_2090660425365293038" target="Compound_INSULIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide led to a higher time in range by 4.3 percentage points (5.5, P = 0.02), lower insulin usage by 12.2 U [-16.2, -5.4] (P = 0.008) and lower carbohydrate intake by 50 g (35; P = 0.0004) compared to placebo, without increasing time spent in hypoglycemia</data>
</edge>
<edge source="PDF_6_Result_2090660425365293038" target="Disease_HYPOGLYCEMIA">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide led to a higher time in range by 4.3 percentage points (5.5, P = 0.02), lower insulin usage by 12.2 U [-16.2, -5.4] (P = 0.008) and lower carbohydrate intake by 50 g (35; P = 0.0004) compared to placebo, without increasing time spent in hypoglycemia</data>
</edge>
<edge source="PDF_6_Result_-8070704830058289503" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Weight was reduced by 5.3 (2.9) kg with semaglutide compared to placebo (P&lt;0.001; Table 3), constituting a -5.1% (3.0) relative change from baseline.</data>
</edge>
<edge source="PDF_6_Result_8851808403034214315" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Daily insulin use was reduced by 11.3 units [-23.6, -4.9] with semaglutide compared to placebo (P&lt;0.001; Table 2).</data>
</edge>
<edge source="PDF_6_Result_8851808403034214315" target="Compound_INSULIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Daily insulin use was reduced by 11.3 units [-23.6, -4.9] with semaglutide compared to placebo (P&lt;0.001; Table 2).</data>
</edge>
<edge source="PDF_6_Result_-8257117801097698704" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Daily carbohydrate intake (as entered into the participants' bolus calculator) was also reduced by 36 g [-55, -15] with semaglutide compared to placebo (P&lt;0.001).</data>
</edge>
<edge source="PDF_6_Conclusion_4473825811740049547" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide improved glycemic control, with lower insulin requirements, in adults with T1D when used with AID.</data>
</edge>
<edge source="PDF_6_Conclusion_4473825811740049547" target="Compound_INSULIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide improved glycemic control, with lower insulin requirements, in adults with T1D when used with AID.</data>
</edge>
<edge source="PDF_6_Conclusion_4473825811740049547" target="Disease_TYPE 1 DIABETES">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide improved glycemic control, with lower insulin requirements, in adults with T1D when used with AID.</data>
</edge>
<edge source="PDF_6_Conclusion_2000144748216711248" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide also reduced carbohydrate intake, body weight, BMI and waist and hip circumferences compared to placebo.</data>
</edge>
<edge source="PDF_6_Method_-1812287868508375680" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">We performed a randomized, double-blind, crossover trial to assess semaglutide as adjunct to automated insulin delivery therapy in adults with type 1 diabetes.</data>
</edge>
<edge source="PDF_6_Method_-1812287868508375680" target="Disease_TYPE 1 DIABETES">
  <data key="d8">MENTIONS</data>
  <data key="d9">We performed a randomized, double-blind, crossover trial to assess semaglutide as adjunct to automated insulin delivery therapy in adults with type 1 diabetes.</data>
</edge>
<edge source="PDF_6_Method_5467834125242263946" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">participants were titrated up to 1 mg or the maximum tolerated dose of semaglutide or placebo over 11 weeks, followed by the use of an automated insulin delivery system for 4 weeks.</data>
</edge>
<edge source="PDF_20" target="PDF_20_Hypothesis_7815950929145965661">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Method_-3192592762685504414">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_7880338680616154425">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_-2454235102931694743">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Conclusion_332732362293398497">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Method_-2759039647837489812">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_-1958938736660902508">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_8971111134504406777">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_8833305366754644014">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_-7934427894631955237">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_-3313445731501826354">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20_Hypothesis_7815950929145965661" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Resveratrol is efficacious for counteracting age-related memory and mood impairments and the associated detrimental changes in the hippocampus.</data>
</edge>
<edge source="PDF_20_Method_-3192592762685504414" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Two groups of male F344 rats in late middle-age having similar learning and memory abilities were chosen and treated with resveratrol or vehicle for four weeks.</data>
</edge>
<edge source="PDF_20_Result_7880338680616154425" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Analyses at ~25 months of age uncovered improved learning, memory and mood function in resveratrol-treated animals but impairments in vehicle-treated animals.</data>
</edge>
<edge source="PDF_20_Result_-2454235102931694743" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Resveratrol-treated animals also displayed increased net neurogenesis and microvasculature, and diminished astrocyte hypertrophy and microglial activation in the hippocampus.</data>
</edge>
<edge source="PDF_20_Conclusion_332732362293398497" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Resveratrol treatment in late middle age is efficacious for improving memory and mood function in old age. Modulation of the hippocampus plasticity and suppression of chronic low-level inflammation appear to underlie the functional benefits mediated by resveratrol.</data>
</edge>
<edge source="PDF_20_Method_-2759039647837489812" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Administration of resveratrol (RESV), a naturally occurring polyphenol found in high concentrations in the skin of red grapes, appears suitable for counteracting age-related detrimental changes in the hippocampus because of its pro-angiogenic and antiinflammatory properties with no adverse side effects</data>
</edge>
<edge source="PDF_20_Result_-1958938736660902508" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RESV treatment enhanced net neurogenesis in the hippocampus of aged rats.</data>
</edge>
<edge source="PDF_20_Result_8971111134504406777" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RESV treatment promoted increased neurogenesis in aged rats for prolonged periods.</data>
</edge>
<edge source="PDF_20_Result_8833305366754644014" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RESV treatment enhanced microvasculature in the hippocampus of aged rats.</data>
</edge>
<edge source="PDF_20_Result_-7934427894631955237" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RESV treatment reduced the hypertrophy of astrocytes in aged rats.</data>
</edge>
<edge source="PDF_20_Result_-3313445731501826354" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RESV treatment reduced activation of microglia in aged rats.</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_7755476335848891001">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_-334082166859481260">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_1284800464766322825">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_-5160257447693917409">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_6540219734818116931">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_-4969595479476564550">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_-5592462067182580329">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_3558410145889663672">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_-3112029605417809537">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_8672654303686994003">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_-1203627661883813793">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_7122110065846937519">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_-5164405377201281036">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Method_-8999913684500077984">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5_Result_7755476335848891001" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Systemically administered high-dose semaglutide delivered weekly to juvenile INAD mice improved locomotor function and extended the lifespan.</data>
</edge>
<edge source="PDF_5_Result_7755476335848891001" target="Disease_INAD">
  <data key="d8">MENTIONS</data>
  <data key="d9">Systemically administered high-dose semaglutide delivered weekly to juvenile INAD mice improved locomotor function and extended the lifespan.</data>
</edge>
<edge source="PDF_5_Result_-334082166859481260" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">semaglutide significantly increased levels of key neuroprotective molecules while decreasing those involved in pro-neurodegenerative pathways.</data>
</edge>
<edge source="PDF_5_Result_1284800464766322825" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">The expression of mediators in both the apoptotic and necroptotic pathways were also significantly reduced in semaglutide treated mice.</data>
</edge>
<edge source="PDF_5_Result_6540219734818116931" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">There was no obvious inflammatory response in wild-type mice associated with the repeated high doses of semaglutide used in this study.</data>
</edge>
<edge source="PDF_5_Result_-4969595479476564550" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">A significant increase in survival was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide, with median survival at 129 days vs 99 days for untreated Pla2g6¯¹- mice</data>
</edge>
<edge source="PDF_5_Result_-4969595479476564550" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">A significant increase in survival was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide, with median survival at 129 days vs 99 days for untreated Pla2g6¯¹- mice</data>
</edge>
<edge source="PDF_5_Result_-5592462067182580329" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">Pla2g6-/- mice treated with 0.5 µg/g semaglutide did not show a significant deficit in rotarod performance compared to wild-type controls at any time point measured.</data>
</edge>
<edge source="PDF_5_Result_-5592462067182580329" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Pla2g6-/- mice treated with 0.5 µg/g semaglutide did not show a significant deficit in rotarod performance compared to wild-type controls at any time point measured.</data>
</edge>
<edge source="PDF_5_Result_3558410145889663672" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">Treatment of Pla2g6-¹- mice with 0.5 µg/g semaglutide resulted in a significant improvement in performance of the vertical pole test compared to untreated mice from week 9 to week 13</data>
</edge>
<edge source="PDF_5_Result_3558410145889663672" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Treatment of Pla2g6-¹- mice with 0.5 µg/g semaglutide resulted in a significant improvement in performance of the vertical pole test compared to untreated mice from week 9 to week 13</data>
</edge>
<edge source="PDF_5_Result_-3112029605417809537" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">Data analyses showed a significant reduction in the total distance travelled, average speed, total mobility time, total immobility time and freezing time measurements in 12-week-old Pla2g6- mice when compared to wild-type counterparts.</data>
</edge>
<edge source="PDF_5_Result_8672654303686994003" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">Data analyses didn't reveal a significant difference when comparing the untreated Pla2g6¯/¯ mice to the Pla2g6-¹- group treated with high-dose semaglutide, except for a significant decrease in the freezing time at 12 weeks.</data>
</edge>
<edge source="PDF_5_Result_8672654303686994003" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Data analyses didn't reveal a significant difference when comparing the untreated Pla2g6¯/¯ mice to the Pla2g6-¹- group treated with high-dose semaglutide, except for a significant decrease in the freezing time at 12 weeks.</data>
</edge>
<edge source="PDF_5_Result_-1203627661883813793" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">The Pla2g6-/- group treated with high-dose semaglutide were comparable to age-matched wild type controls for all measured parameters, excluding the total mobility and immobility time.</data>
</edge>
<edge source="PDF_5_Result_-1203627661883813793" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">The Pla2g6-/- group treated with high-dose semaglutide were comparable to age-matched wild type controls for all measured parameters, excluding the total mobility and immobility time.</data>
</edge>
<edge source="PDF_5_Result_7122110065846937519" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">A significant increase in GLP-1R expression was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide at 14 weeks when compared to age-matched wild-type and untreated Pla2g6¯¹- controls</data>
</edge>
<edge source="PDF_5_Result_7122110065846937519" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">A significant increase in GLP-1R expression was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide at 14 weeks when compared to age-matched wild-type and untreated Pla2g6¯¹- controls</data>
</edge>
<edge source="PDF_5_Result_7122110065846937519" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">A significant increase in GLP-1R expression was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide at 14 weeks when compared to age-matched wild-type and untreated Pla2g6¯¹- controls</data>
</edge>
<edge source="PDF_5_Result_-5164405377201281036" target="Protein_ATF-3">
  <data key="d8">MENTIONS</data>
  <data key="d9">A significant increase of ATF-3 was detected by qPCR at 14 weeks in untreated Pla2g6-- mice compared to age-matched wild-type controls.</data>
</edge>
<edge source="PDF_5_Result_-5164405377201281036" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">A significant increase of ATF-3 was detected by qPCR at 14 weeks in untreated Pla2g6-- mice compared to age-matched wild-type controls.</data>
</edge>
<edge source="PDF_5_Method_-8999913684500077984" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">The Pla2g6-inad knock-in mouse model (Pla2g6-/-) was administered with semaglutide at three doses; 0.5 µg/g, 0.25 µg/g or 0.15 µg/g, via intraperitoneal injection once a week.</data>
</edge>
<edge source="PDF_5_Method_-8999913684500077984" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">The Pla2g6-inad knock-in mouse model (Pla2g6-/-) was administered with semaglutide at three doses; 0.5 µg/g, 0.25 µg/g or 0.15 µg/g, via intraperitoneal injection once a week.</data>
</edge>
<edge source="PDF_3" target="PDF_3_Hypothesis_5937887320383361804">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Method_4983325178299917240">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_-8926515749602198478">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_-8889060088529917024">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_7738172035843986321">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_-6606204955788834190">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_-2337145280325494230">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_5019986530835264392">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_-6432978783889930376">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_3176674364245536181">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_-6444487890488775633">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_6663617786060617154">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_3284929924712106620">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_1069820669888993396">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Conclusion_8825786606699857213">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Conclusion_8475083258189845961">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Conclusion_-8971442004466911014">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3_Hypothesis_5937887320383361804" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">peripheral GLP-1 signals to the brain to suppress eating via vagal and/or endocrine activation of central GLP-1-producing preproglucagon (PPG) neurons, i.e. that peripheral and central GLP-1 systems comprise a unified, directly connected gut-brain satiation circuit.</data>
</edge>
<edge source="PDF_3_Hypothesis_5937887320383361804" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">peripheral GLP-1 signals to the brain to suppress eating via vagal and/or endocrine activation of central GLP-1-producing preproglucagon (PPG) neurons, i.e. that peripheral and central GLP-1 systems comprise a unified, directly connected gut-brain satiation circuit.</data>
</edge>
<edge source="PDF_3_Method_4983325178299917240" target="Gene_PPGNTS">
  <data key="d8">MENTIONS</data>
  <data key="d9">viral ablation of PPGNTS neurons, using AAV-mediated selective expression of diptheria toxin subunit A (DTA)</data>
</edge>
<edge source="PDF_3_Result_-8889060088529917024" target="Gene_PPGNTS">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neuron inhibition increased fasting-induced pellet refeeding during hour 1 in a sex-independent manner, and this effect was driven by increased meal size, rather than frequency</data>
</edge>
<edge source="PDF_3_Result_7738172035843986321" target="Gene_PPGNTS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Ensure intake was increased by PPGNTS neuron inhibition, and, consistent with effects on pellet intake in the FED system, this increase was driven by increased duration of Ensure eating</data>
</edge>
<edge source="PDF_3_Result_-6606204955788834190" target="Gene_PPGNTS">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS activation reduced intake by ~40% in the first 24 hours</data>
</edge>
<edge source="PDF_3_Result_-2337145280325494230" target="Gene_PPGNTS">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neuron activation advanced the point of satiation by ~15 minutes</data>
</edge>
<edge source="PDF_3_Result_5019986530835264392" target="Gene_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">chemogenetic activation of Glp1rVANs using the excitatory hM3Dq DREADD in ad libitum eating mice suppressed eating during the dark but not subsequent light phase</data>
</edge>
<edge source="PDF_3_Result_-6432978783889930376" target="Gene_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">Optogenetic activation of Glp1r terminals within the NTS conditioned avoidance of the paired flavour</data>
</edge>
<edge source="PDF_3_Result_3176674364245536181" target="Compound_OXYTOCIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">superfusion of oxytocin activated 84% of glutamate-responsive PPGNTS neurons</data>
</edge>
<edge source="PDF_3_Result_3176674364245536181" target="Gene_PPGNTS">
  <data key="d8">MENTIONS</data>
  <data key="d9">superfusion of oxytocin activated 84% of glutamate-responsive PPGNTS neurons</data>
</edge>
<edge source="PDF_3_Result_-6444487890488775633" target="Compound_OXYTOCIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">oxytocin acutely suppressed eating in ad libitum eating control mice, this effect was completely abolished in mice in which PPGNTS neurons had been virally ablated by DTA expression</data>
</edge>
<edge source="PDF_3_Result_-6444487890488775633" target="Gene_PPGNTS">
  <data key="d8">MENTIONS</data>
  <data key="d9">oxytocin acutely suppressed eating in ad libitum eating control mice, this effect was completely abolished in mice in which PPGNTS neurons had been virally ablated by DTA expression</data>
</edge>
<edge source="PDF_3_Result_6663617786060617154" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Liraglutide robustly suppressed intake and bodyweight over 24 hours in ad libitum eating eGFP-transduced control mice, however DTA ablation of PPGNTS neurons had no effect on the magnitude of eating suppression at any timepoint</data>
</edge>
<edge source="PDF_3_Result_6663617786060617154" target="Gene_PPGNTS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Liraglutide robustly suppressed intake and bodyweight over 24 hours in ad libitum eating eGFP-transduced control mice, however DTA ablation of PPGNTS neurons had no effect on the magnitude of eating suppression at any timepoint</data>
</edge>
<edge source="PDF_3_Result_3284929924712106620" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide induced robust cFos expression within the AP and throughout the rostro-caudal extent of the NTS</data>
</edge>
<edge source="PDF_3_Result_1069820669888993396" target="Gene_PPGNTS">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neuron activation augments semaglutide-induced eating suppression</data>
</edge>
<edge source="PDF_3_Result_1069820669888993396" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neuron activation augments semaglutide-induced eating suppression</data>
</edge>
<edge source="PDF_3_Conclusion_8825786606699857213" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">central and peripheral GLP-1 systems suppress eating via independent gut-brain circuits, providing a rationale for pharmacological activation of PPGNTS neurons in combination with GLP-1 receptor agonists as an obesity treatment strategy.</data>
</edge>
<edge source="PDF_3_Conclusion_8825786606699857213" target="Gene_PPGNTS">
  <data key="d8">MENTIONS</data>
  <data key="d9">central and peripheral GLP-1 systems suppress eating via independent gut-brain circuits, providing a rationale for pharmacological activation of PPGNTS neurons in combination with GLP-1 receptor agonists as an obesity treatment strategy.</data>
</edge>
<edge source="PDF_3_Conclusion_8475083258189845961" target="Gene_PPGNTS">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neurons are not necessary for GLP-1RA-induced suppression of eating.</data>
</edge>
<edge source="PDF_3_Conclusion_-8971442004466911014" target="Gene_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">Oxtr- rather than Glp1r-expressing VANs are the primary source of gastrointestinal distension signals driving PPGNTS neuron-mediated satiation.</data>
</edge>
<edge source="PDF_3_Conclusion_-8971442004466911014" target="Gene_PPGNTS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Oxtr- rather than Glp1r-expressing VANs are the primary source of gastrointestinal distension signals driving PPGNTS neuron-mediated satiation.</data>
</edge>
<edge source="PDF_2" target="PDF_2_Hypothesis_1815441347359116181">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_4611493572516884927">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_-2273015844379847364">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_-6346404022377378758">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_-6241028819256066407">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_9092086921935191153">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_-5072708663807857775">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_8364534849777428125">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_-4903554970747745773">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_-5696175074845712873">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_3465555475323324561">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2_Hypothesis_1815441347359116181" target="Compound_GLP-1RAS">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1RAs may reduce food intake and BW through distributed effects in the CNS, rather than through a specific localized population of GLP-1Rs.</data>
</edge>
<edge source="PDF_2_Hypothesis_1815441347359116181" target="Process_BW">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1RAs may reduce food intake and BW through distributed effects in the CNS, rather than through a specific localized population of GLP-1Rs.</data>
</edge>
<edge source="PDF_2_Result_4611493572516884927" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide dose-dependently reduced BW and suppressed food intake in DIO mice.</data>
</edge>
<edge source="PDF_2_Result_4611493572516884927" target="Process_BW">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide dose-dependently reduced BW and suppressed food intake in DIO mice.</data>
</edge>
<edge source="PDF_2_Result_-2273015844379847364" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide suppressed food intake and induced a 17%-18% reduction in BW.</data>
</edge>
<edge source="PDF_2_Result_-2273015844379847364" target="Process_BW">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide suppressed food intake and induced a 17%-18% reduction in BW.</data>
</edge>
<edge source="PDF_2_Result_-6346404022377378758" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide transiently reduced dark phase EE until day 6 of treatment, after which levels were not significantly lower than those of the vehicle-treated controls.</data>
</edge>
<edge source="PDF_2_Result_-6346404022377378758" target="Process_EE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide transiently reduced dark phase EE until day 6 of treatment, after which levels were not significantly lower than those of the vehicle-treated controls.</data>
</edge>
<edge source="PDF_2_Result_-6241028819256066407" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide VT750 was observed in the choroid plexus.</data>
</edge>
<edge source="PDF_2_Result_9092086921935191153" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide increased prolactin-releasing peptide (PrRP) and tyrosine hydroxylase (TH) in the hindbrain.</data>
</edge>
<edge source="PDF_2_Result_9092086921935191153" target="Protein_PRRP">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide increased prolactin-releasing peptide (PrRP) and tyrosine hydroxylase (TH) in the hindbrain.</data>
</edge>
<edge source="PDF_2_Result_9092086921935191153" target="Protein_TH">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide increased prolactin-releasing peptide (PrRP) and tyrosine hydroxylase (TH) in the hindbrain.</data>
</edge>
<edge source="PDF_2_Result_-5072708663807857775" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
</edge>
<edge source="PDF_2_Result_-5072708663807857775" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
</edge>
<edge source="PDF_2_Result_-5072708663807857775" target="Protein_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
</edge>
<edge source="PDF_2_Result_-5072708663807857775" target="Protein_SST">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
</edge>
<edge source="PDF_2_Result_-5072708663807857775" target="Protein_TH">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
</edge>
<edge source="PDF_2_Result_-5072708663807857775" target="Process_ARH">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
</edge>
<edge source="PDF_2_Result_8364534849777428125" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide stimulates neuronal activity in brain areas involved in appetite regulation.</data>
</edge>
<edge source="PDF_2_Result_-4903554970747745773" target="Gene_POMC">
  <data key="d8">MENTIONS</data>
  <data key="d9">POMC/CART neurons were depolarized in response to semaglutide, whereas NPY/AgRP neurons elicited membrane hyperpolarization and became inactivated</data>
</edge>
<edge source="PDF_2_Result_-4903554970747745773" target="Protein_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">POMC/CART neurons were depolarized in response to semaglutide, whereas NPY/AgRP neurons elicited membrane hyperpolarization and became inactivated</data>
</edge>
<edge source="PDF_2_Result_-4903554970747745773" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">POMC/CART neurons were depolarized in response to semaglutide, whereas NPY/AgRP neurons elicited membrane hyperpolarization and became inactivated</data>
</edge>
<edge source="PDF_2_Result_-4903554970747745773" target="Gene_NPY">
  <data key="d8">MENTIONS</data>
  <data key="d9">POMC/CART neurons were depolarized in response to semaglutide, whereas NPY/AgRP neurons elicited membrane hyperpolarization and became inactivated</data>
</edge>
<edge source="PDF_2_Result_-4903554970747745773" target="Protein_AGRP">
  <data key="d8">MENTIONS</data>
  <data key="d9">POMC/CART neurons were depolarized in response to semaglutide, whereas NPY/AgRP neurons elicited membrane hyperpolarization and became inactivated</data>
</edge>
<edge source="PDF_2_Result_-5696175074845712873" target="Gene_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">CART mRNA levels were increased in semaglutide-treated mice compared with the vehicle-fed mice and weight-matched mice, whereas POMC expression was unaffected</data>
</edge>
<edge source="PDF_2_Result_-5696175074845712873" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">CART mRNA levels were increased in semaglutide-treated mice compared with the vehicle-fed mice and weight-matched mice, whereas POMC expression was unaffected</data>
</edge>
<edge source="PDF_2_Result_-5696175074845712873" target="Gene_POMC">
  <data key="d8">MENTIONS</data>
  <data key="d9">CART mRNA levels were increased in semaglutide-treated mice compared with the vehicle-fed mice and weight-matched mice, whereas POMC expression was unaffected</data>
</edge>
<edge source="PDF_2_Result_3465555475323324561" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Increased c-Fos activity was observed in the bed nuclei of the stria terminalis (BST), central amygdala nucleus (CeA), OV, parasubthalamic nucleus (PSTN), SFO, midline group of the dorsal thalamus (MTN), PB, AP, DMX, and NTS after acute s.c. semaglutide (4 hours)</data>
</edge>
<edge source="PDF_2_Result_3465555475323324561" target="Protein_C-FOS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Increased c-Fos activity was observed in the bed nuclei of the stria terminalis (BST), central amygdala nucleus (CeA), OV, parasubthalamic nucleus (PSTN), SFO, midline group of the dorsal thalamus (MTN), PB, AP, DMX, and NTS after acute s.c. semaglutide (4 hours)</data>
</edge>
<edge source="PDF_14" target="PDF_14_Result_3338617942436835057">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_14" target="PDF_14_Conclusion_-950585630135367454">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_14" target="PDF_14_Method_1698245611462071840">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_14" target="PDF_14_Result_-2440080024292915146">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_14" target="PDF_14_Result_-3056562445746325210">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_14" target="PDF_14_Result_4601801854187065423">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_14" target="PDF_14_Result_2377162177953663172">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_14" target="PDF_14_Result_617687932927020519">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_14" target="PDF_14_Result_5930299763765613412">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_14" target="PDF_14_Result_-7620526291293552557">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_14" target="PDF_14_Result_-5779278007953804647">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_14_Result_3338617942436835057" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality.</data>
</edge>
<edge source="PDF_14_Result_3338617942436835057" target="Compound_ACEIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality.</data>
</edge>
<edge source="PDF_14_Result_3338617942436835057" target="Disease_MYOCARDIAL INFARCTION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality.</data>
</edge>
<edge source="PDF_14_Result_3338617942436835057" target="Disease_STROKE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality.</data>
</edge>
<edge source="PDF_14_Result_3338617942436835057" target="Process_MORTALITY">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality.</data>
</edge>
<edge source="PDF_14_Conclusion_-950585630135367454" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">In the presence of positive outcomes from robust randomised, controlled trials for perindopril, one cannot assume a class effect for all ACEIs.</data>
</edge>
<edge source="PDF_14_Conclusion_-950585630135367454" target="Compound_ACEIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">In the presence of positive outcomes from robust randomised, controlled trials for perindopril, one cannot assume a class effect for all ACEIs.</data>
</edge>
<edge source="PDF_14_Method_1698245611462071840" target="Compound_ACEIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Published randomised, controlled trials were selected using an applicable literature search for all ACEIs, irrespective of drug combination, for any cardiovascular outcome (both composite and individual outcomes were included).</data>
</edge>
<edge source="PDF_14_Result_-2440080024292915146" target="Compound_ACEIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">The ACEIs as a class had a lower likelihood of an event occurring, compared to any of the comparator drugs or placebo.</data>
</edge>
<edge source="PDF_14_Result_-3056562445746325210" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril showed a significant risk reduction of 18% (OR 0.82; 95% CI: 0.77-0.88; p &lt; 0.0001) when compared to the overall ACEI effect.</data>
</edge>
<edge source="PDF_14_Result_-3056562445746325210" target="Compound_ACEIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril showed a significant risk reduction of 18% (OR 0.82; 95% CI: 0.77-0.88; p &lt; 0.0001) when compared to the overall ACEI effect.</data>
</edge>
<edge source="PDF_14_Result_4601801854187065423" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">When this analysis was repeated, excluding the perindopril studies, the ACEI effect was reduced to 5% (OR 0.95; 95% CI: 0.91-0.98; p = 0.0039).</data>
</edge>
<edge source="PDF_14_Result_4601801854187065423" target="Compound_ACEIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">When this analysis was repeated, excluding the perindopril studies, the ACEI effect was reduced to 5% (OR 0.95; 95% CI: 0.91-0.98; p = 0.0039).</data>
</edge>
<edge source="PDF_14_Result_2377162177953663172" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The perindopril trials demonstrated a highly significant event reduction (OR 0.78; 95% CI: 0.72-0.85; p &lt; 0.0001). This was better than the event reduction with all other ACEIs combined (OR 0.86; 95% CI: 0.80-0.91; p &lt; 0.0001).</data>
</edge>
<edge source="PDF_14_Result_2377162177953663172" target="Compound_ACEIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">The perindopril trials demonstrated a highly significant event reduction (OR 0.78; 95% CI: 0.72-0.85; p &lt; 0.0001). This was better than the event reduction with all other ACEIs combined (OR 0.86; 95% CI: 0.80-0.91; p &lt; 0.0001).</data>
</edge>
<edge source="PDF_14_Result_617687932927020519" target="Compound_ACEIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">The only other ACEI that has demonstrated a benefit in reduction of MI is ramipril, as used in the HOPE trial.</data>
</edge>
<edge source="PDF_14_Result_617687932927020519" target="Compound_RAMIPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The only other ACEI that has demonstrated a benefit in reduction of MI is ramipril, as used in the HOPE trial.</data>
</edge>
<edge source="PDF_14_Result_617687932927020519" target="Disease_MYOCARDIAL INFARCTION">
  <data key="d8">MENTIONS</data>
  <data key="d9">The only other ACEI that has demonstrated a benefit in reduction of MI is ramipril, as used in the HOPE trial.</data>
</edge>
<edge source="PDF_14_Result_5930299763765613412" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">However, the exclusion of perindopril trials from the other ACEI trials reproduced a non-significant reduction in stroke events (OR 1.05; p = 0.1287).</data>
</edge>
<edge source="PDF_14_Result_5930299763765613412" target="Compound_ACEIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">However, the exclusion of perindopril trials from the other ACEI trials reproduced a non-significant reduction in stroke events (OR 1.05; p = 0.1287).</data>
</edge>
<edge source="PDF_14_Result_5930299763765613412" target="Disease_STROKE">
  <data key="d8">MENTIONS</data>
  <data key="d9">However, the exclusion of perindopril trials from the other ACEI trials reproduced a non-significant reduction in stroke events (OR 1.05; p = 0.1287).</data>
</edge>
<edge source="PDF_14_Result_-7620526291293552557" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril, in the six outcome trials, showed a reduction in death compared to other drugs and or placebo (OR = 0.89; 95% CI: 0.84-0.95; p = 0.0008). This represents a significant 11% reduction in mortality, which is both a clinically and statistically significant benefit for all cardiovascular patients.</data>
</edge>
<edge source="PDF_14_Result_-7620526291293552557" target="Process_MORTALITY">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril, in the six outcome trials, showed a reduction in death compared to other drugs and or placebo (OR = 0.89; 95% CI: 0.84-0.95; p = 0.0008). This represents a significant 11% reduction in mortality, which is both a clinically and statistically significant benefit for all cardiovascular patients.</data>
</edge>
<edge source="PDF_14_Result_-5779278007953804647" target="Compound_ACEIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">The ACEI benefit, demonstrated in 23 different ACEI trials, excluding perindopril, was only 5% (OR 0.95; 95% CI: 0.92- 0.98; p = 0.0033).</data>
</edge>
<edge source="PDF_14_Result_-5779278007953804647" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The ACEI benefit, demonstrated in 23 different ACEI trials, excluding perindopril, was only 5% (OR 0.95; 95% CI: 0.92- 0.98; p = 0.0033).</data>
</edge>
<edge source="PDF_8" target="PDF_8_Hypothesis_-3933246017705166058">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Method_6226713440386006436">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Method_6125393978213197111">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Method_-5646899149902963081">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Method_-7183003868579564070">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Method_548604743354006323">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Method_971662152183731818">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Method_6440631248198029520">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Result_-7071181622369019283">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Result_7769921366646390716">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Result_-4779896913638441684">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Result_310004542361536949">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Result_6003812801984434083">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Result_-9097538114006369516">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Conclusion_8913866471670379834">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Conclusion_8328011558311435958">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8_Hypothesis_-3933246017705166058" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Peptides known as GLP-1 protectors are predicted to increase the half-life of GLP-1 in vivo.</data>
</edge>
<edge source="PDF_8_Method_6226713440386006436" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1 and protecting peptides (peptide 1 or peptide 2) were mixed at various ratios and then incubated at 25 °C for 5 min.</data>
</edge>
<edge source="PDF_8_Method_6125393978213197111" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1/peptide complexes were prepared at the proportions of 1:10 for peptide 1 or peptide 2 and then incubated with human serum (final sample volume of 1 ml; final GLP-1 mass of 750 µg) for 5 min to 250 h.</data>
</edge>
<edge source="PDF_8_Method_-5646899149902963081" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Sprague Dawley rats (n = 5 per group, male) were subcutaneously injected with GLP-1/peptide 1 (1:10, containing of 750 µg GLP-1/kg body weight) and GLP-1/peptide 2 (1:10, containing of 750 µg GLP-1/kg body weight), respectively.</data>
</edge>
<edge source="PDF_8_Method_-7183003868579564070" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Two complexes of GLP-1/peptide 1 and GLP-1/peptide 2 were subcutaneously injected into the rats so that each animal received 100 µg f GLP-1.</data>
</edge>
<edge source="PDF_8_Method_548604743354006323" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Sprague Dawley rats (n = 5 per group) were subcutaneously injected with GLP-1/peptide 1 (1:10, containing of 100 µg GLP-1) or GLP-1/peptide 2 (1:10, containing of 100 µg GLP-1).</data>
</edge>
<edge source="PDF_8_Method_971662152183731818" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Fasting Sprague Dawley rats (n = 6 per group) were given a single dose of GLP-1/peptide complexes (GLP-1 ~300 µg/kg body weight) intraperitoneally 30 min prior to glucose administration.</data>
</edge>
<edge source="PDF_8_Method_6440631248198029520" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Male Zucker Diabetic Fatty (ZDF) rats (n = 6 per group) were treated with GLP-1/peptide 1 complex (GLP-1 ~300 µg/kg/4 days), exenatide (100 µg/kg/12 h) and liraglutide (300 µg/kg/ daily) for 28 days.</data>
</edge>
<edge source="PDF_8_Result_-7071181622369019283" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">The HPLC results predicted that the visible peak with a retention time of 18.8 min might be the GLP-1/ peptide 1 complex.</data>
</edge>
<edge source="PDF_8_Result_7769921366646390716" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">HPLC results demonstrated that either peptide 1 or peptide 2 were able to form a complex with GLP-1.</data>
</edge>
<edge source="PDF_8_Result_-4779896913638441684" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">The half-life of GLP-1 inside the GLP-1/peptide 1 complex was 90 h and inside the GLP-1/peptide 2 complex was 75 h in human serum.</data>
</edge>
<edge source="PDF_8_Result_310004542361536949" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">The concentration of GLP-1 reached a plateau at 10 h and gradually decreased but remained detectable until 150 h.</data>
</edge>
<edge source="PDF_8_Result_6003812801984434083" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">The secreted insulin level was dramatically raised to 956.7 ± 37.84 pmol/l (GLP-1/peptide 1) and 827.9 ± 31.40 pmol/l (GLP-1/peptide 2).</data>
</edge>
<edge source="PDF_8_Result_6003812801984434083" target="Protein_INSULIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">The secreted insulin level was dramatically raised to 956.7 ± 37.84 pmol/l (GLP-1/peptide 1) and 827.9 ± 31.40 pmol/l (GLP-1/peptide 2).</data>
</edge>
<edge source="PDF_8_Result_-9097538114006369516" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Blood glucose reached the maximum level 1 min after the administration of glucose and then declined to 6.66 ± 0.51 mmol/l (GLP-1/peptide 1) and 6.55 ± 0.61 mmol/l (GLP-1/peptide 2) after 10 min, P &lt; 0.01.</data>
</edge>
<edge source="PDF_8_Conclusion_8913866471670379834" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Based upon these results, it is suggested that the GLP-1/peptide 1 complex might be utilized as a possible potent anti-diabetic drug in the treatment of type 2 diabetes mellitus.</data>
</edge>
<edge source="PDF_8_Conclusion_8913866471670379834" target="Disease_TYPE 2 DIABETES MELLITUS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Based upon these results, it is suggested that the GLP-1/peptide 1 complex might be utilized as a possible potent anti-diabetic drug in the treatment of type 2 diabetes mellitus.</data>
</edge>
<edge source="PDF_8_Conclusion_8328011558311435958" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1 inside of a protecting peptide preserves the insulin secretion response and glucose regulatory effects of GLP-1.</data>
</edge>
<edge source="PDF_8_Conclusion_8328011558311435958" target="Protein_INSULIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1 inside of a protecting peptide preserves the insulin secretion response and glucose regulatory effects of GLP-1.</data>
</edge>
<edge source="PDF_19" target="PDF_19_Hypothesis_-2541411817281426873">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Method_2216283705138359622">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_6198469308610633828">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_8452349021456247325">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Conclusion_7581213139545090984">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_8488066197028720261">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_-2309636312143478063">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_3456673883778613236">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_7247821932593457490">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_-1252050076845395299">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_-7676852047247529818">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_-413335566894609786">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_-8170279167056199065">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_-7097707872932512269">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_-4897362903626893323">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_1114005357832605077">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19_Hypothesis_-2541411817281426873" target="Compound_CFCHPS">
  <data key="d8">MENTIONS</data>
  <data key="d9">lifelong assault on healthy cells by cfChPs is the underlying cause of ageing, and that ageing could be retarded by deactivating extra-cellular cfChPs</data>
</edge>
<edge source="PDF_19_Method_2216283705138359622" target="Gene_C57BL/6">
  <data key="d8">MENTIONS</data>
  <data key="d9">C57BL/6 mice were divided into 3 equal groups; one group was sacrificed at age 3 months, and which acted as young controls. The remaining mice were allowed to age, and at age 10 months the experimental ageing group was given R-Cu by oral gavage twice daily for further 12 months at a dose of 1 mg/kg of R and 0.1 µg/kg of Cu. The control ageing group was given water by oral gavage twice daily for 12 months. Animals of both groups were sacrificed at age 22 months</data>
</edge>
<edge source="PDF_19_Method_2216283705138359622" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">C57BL/6 mice were divided into 3 equal groups; one group was sacrificed at age 3 months, and which acted as young controls. The remaining mice were allowed to age, and at age 10 months the experimental ageing group was given R-Cu by oral gavage twice daily for further 12 months at a dose of 1 mg/kg of R and 0.1 µg/kg of Cu. The control ageing group was given water by oral gavage twice daily for 12 months. Animals of both groups were sacrificed at age 22 months</data>
</edge>
<edge source="PDF_19_Method_2216283705138359622" target="Compound_R">
  <data key="d8">MENTIONS</data>
  <data key="d9">C57BL/6 mice were divided into 3 equal groups; one group was sacrificed at age 3 months, and which acted as young controls. The remaining mice were allowed to age, and at age 10 months the experimental ageing group was given R-Cu by oral gavage twice daily for further 12 months at a dose of 1 mg/kg of R and 0.1 µg/kg of Cu. The control ageing group was given water by oral gavage twice daily for 12 months. Animals of both groups were sacrificed at age 22 months</data>
</edge>
<edge source="PDF_19_Method_2216283705138359622" target="Compound_CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">C57BL/6 mice were divided into 3 equal groups; one group was sacrificed at age 3 months, and which acted as young controls. The remaining mice were allowed to age, and at age 10 months the experimental ageing group was given R-Cu by oral gavage twice daily for further 12 months at a dose of 1 mg/kg of R and 0.1 µg/kg of Cu. The control ageing group was given water by oral gavage twice daily for 12 months. Animals of both groups were sacrificed at age 22 months</data>
</edge>
<edge source="PDF_19_Result_6198469308610633828" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction</data>
</edge>
<edge source="PDF_19_Result_6198469308610633828" target="Gene_TELOMERE">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction</data>
</edge>
<edge source="PDF_19_Result_6198469308610633828" target="Protein_AMYLOID">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction</data>
</edge>
<edge source="PDF_19_Result_6198469308610633828" target="Gene_DNA">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction</data>
</edge>
<edge source="PDF_19_Result_6198469308610633828" target="Process_APOPTOSIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction</data>
</edge>
<edge source="PDF_19_Result_6198469308610633828" target="Process_INFLAMMATION">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction</data>
</edge>
<edge source="PDF_19_Result_6198469308610633828" target="Process_SENESCENCE">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction</data>
</edge>
<edge source="PDF_19_Result_6198469308610633828" target="Process_ANEUPLOIDY">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction</data>
</edge>
<edge source="PDF_19_Result_6198469308610633828" target="Disease_MITOCHONDRIAL DYSFUNCTION">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction</data>
</edge>
<edge source="PDF_19_Result_8452349021456247325" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment also led to significant reduction in blood levels of glucose, cholesterol and C-reactive protein</data>
</edge>
<edge source="PDF_19_Result_8452349021456247325" target="Compound_GLUCOSE">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment also led to significant reduction in blood levels of glucose, cholesterol and C-reactive protein</data>
</edge>
<edge source="PDF_19_Result_8452349021456247325" target="Compound_CHOLESTEROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment also led to significant reduction in blood levels of glucose, cholesterol and C-reactive protein</data>
</edge>
<edge source="PDF_19_Result_8452349021456247325" target="Protein_C-REACTIVE PROTEIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment also led to significant reduction in blood levels of glucose, cholesterol and C-reactive protein</data>
</edge>
<edge source="PDF_19_Conclusion_7581213139545090984" target="Compound_CFCHPS">
  <data key="d8">MENTIONS</data>
  <data key="d9">cfChPs may act as global instigators of ageing and neurodegeneration, and that therapeutic use of R-Cu may help to make healthy ageing an attainable goal</data>
</edge>
<edge source="PDF_19_Conclusion_7581213139545090984" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">cfChPs may act as global instigators of ageing and neurodegeneration, and that therapeutic use of R-Cu may help to make healthy ageing an attainable goal</data>
</edge>
<edge source="PDF_19_Result_8488066197028720261" target="Protein_SOD">
  <data key="d8">MENTIONS</data>
  <data key="d9">ageing mice showed significant reduction in SOD levels in brain cells</data>
</edge>
<edge source="PDF_19_Result_-2309636312143478063" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment led to marked increase in SOD levels that were similar to that detected in young control mice</data>
</edge>
<edge source="PDF_19_Result_-2309636312143478063" target="Protein_SOD">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment led to marked increase in SOD levels that were similar to that detected in young control mice</data>
</edge>
<edge source="PDF_19_Result_3456673883778613236" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment did lead to an increase in SOD activity in serum of ageing mice, restoring them to levels similar to those seen in young control mice</data>
</edge>
<edge source="PDF_19_Result_3456673883778613236" target="Protein_SOD">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment did lead to an increase in SOD activity in serum of ageing mice, restoring them to levels similar to those seen in young control mice</data>
</edge>
<edge source="PDF_19_Result_7247821932593457490" target="Compound_CFCHPS">
  <data key="d8">MENTIONS</data>
  <data key="d9">cfChPs were virtually eliminated following R-Cu treatment for one-year</data>
</edge>
<edge source="PDF_19_Result_7247821932593457490" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">cfChPs were virtually eliminated following R-Cu treatment for one-year</data>
</edge>
<edge source="PDF_19_Result_-1252050076845395299" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment restored telomere length to a significant degree in female mice</data>
</edge>
<edge source="PDF_19_Result_-1252050076845395299" target="Gene_TELOMERE">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment restored telomere length to a significant degree in female mice</data>
</edge>
<edge source="PDF_19_Result_-7676852047247529818" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment resulted in significant reduction in extra-cellular amyloid in mice of both sexes</data>
</edge>
<edge source="PDF_19_Result_-7676852047247529818" target="Protein_AMYLOID">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment resulted in significant reduction in extra-cellular amyloid in mice of both sexes</data>
</edge>
<edge source="PDF_19_Result_-413335566894609786" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment for one year resorted serum BDNF levels nearly to those seen in young mice in both sexes</data>
</edge>
<edge source="PDF_19_Result_-413335566894609786" target="Protein_BDNF">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment for one year resorted serum BDNF levels nearly to those seen in young mice in both sexes</data>
</edge>
<edge source="PDF_19_Result_-8170279167056199065" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment reduced y-H2AX levels</data>
</edge>
<edge source="PDF_19_Result_-8170279167056199065" target="Protein_H2AX">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment reduced y-H2AX levels</data>
</edge>
<edge source="PDF_19_Result_-7097707872932512269" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment significantly reduced the degree of apoptosis in mice of both sexes</data>
</edge>
<edge source="PDF_19_Result_-7097707872932512269" target="Process_APOPTOSIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment significantly reduced the degree of apoptosis in mice of both sexes</data>
</edge>
<edge source="PDF_19_Result_-4897362903626893323" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment significantly reduced NF-kB levels in both sexes</data>
</edge>
<edge source="PDF_19_Result_-4897362903626893323" target="Protein_NF-KB">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment significantly reduced NF-kB levels in both sexes</data>
</edge>
<edge source="PDF_19_Result_1114005357832605077" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">Quantification of co-localising signals revealed a marked reduction following R-Cu treatment</data>
</edge>
<edge source="PDF_9" target="PDF_9_Hypothesis_-885440017935968242">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_-8127754855858081363">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_7635724024809655906">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_2338569799055427341">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_-234233171614585128">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_-5141226431183046693">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_-5258731870650769391">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_410832292106273441">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_7104102420254390310">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_-3164336535847763056">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_-1188211078373338751">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_7785137958524726452">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_2640077629412363245">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_-7511363274713565443">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_-2017196263807489895">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_4096444738177291706">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Conclusion_-8591738306725305241">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Conclusion_5764108499565985668">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Conclusion_-7020933065676688447">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9_Hypothesis_-885440017935968242" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">IDO1 inhibitors can be used in combination with other therapies to overcome tumor-induced immunosuppression.</data>
</edge>
<edge source="PDF_9_Method_-8127754855858081363" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">IDO1 inhibitory activity of small organic molecules was determined using an enzymatic assay with a specific incubation medium.</data>
</edge>
<edge source="PDF_9_Method_7635724024809655906" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">The 2,2-diphenyl-1-picrylhydrazyl (DPPH) antioxidant assay was used to investigate redox-cycling properties of IDO1 inhibitors.</data>
</edge>
<edge source="PDF_9_Method_-234233171614585128" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">UV absorption spectra of the characteristic heme peaks were used to argue for a direct binding of compounds to the iron ion in the IDO1 active site.</data>
</edge>
<edge source="PDF_9_Method_-5141226431183046693" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Cellular assays were used to assess IDO1 inhibition, considering off-target effects, cell viability, and quantification of enzymatic reaction products.</data>
</edge>
<edge source="PDF_9_Method_-5258731870650769391" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Structure-based drug design, including docking studies, was used to identify and optimize IDO1 inhibitors.</data>
</edge>
<edge source="PDF_9_Method_410832292106273441" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">High throughput screening (HTS) was used to discover new IDO1 inhibitor scaffolds.</data>
</edge>
<edge source="PDF_9_Result_7104102420254390310" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Selenic compound ebselen inhibits IDO1 by binding to several of its cysteine residues.</data>
</edge>
<edge source="PDF_9_Result_7104102420254390310" target="Compound_EBSELEN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Selenic compound ebselen inhibits IDO1 by binding to several of its cysteine residues.</data>
</edge>
<edge source="PDF_9_Result_-3164336535847763056" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Isothiazolinone derivatives probably inhibit IDO1 through covalent modification of nucleophilic amino acid side chains.</data>
</edge>
<edge source="PDF_9_Result_-1188211078373338751" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Menadione does not inhibit IDO1 when cytochrome P450 reductase/NADPH and cytochrome b5 are used as reductants.</data>
</edge>
<edge source="PDF_9_Result_-1188211078373338751" target="Protein_CYTOCHROME P450">
  <data key="d8">MENTIONS</data>
  <data key="d9">Menadione does not inhibit IDO1 when cytochrome P450 reductase/NADPH and cytochrome b5 are used as reductants.</data>
</edge>
<edge source="PDF_9_Result_-1188211078373338751" target="Protein_CYTOCHROME B5">
  <data key="d8">MENTIONS</data>
  <data key="d9">Menadione does not inhibit IDO1 when cytochrome P450 reductase/NADPH and cytochrome b5 are used as reductants.</data>
</edge>
<edge source="PDF_9_Result_-1188211078373338751" target="Compound_MENADIONE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Menadione does not inhibit IDO1 when cytochrome P450 reductase/NADPH and cytochrome b5 are used as reductants.</data>
</edge>
<edge source="PDF_9_Result_7785137958524726452" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Substrate inhibition of IDO1 by L-Trp has been described and attributed to sequential ordered binding.</data>
</edge>
<edge source="PDF_9_Result_2640077629412363245" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">4-phenylimidazole (4PI) has a higher affinity for ferric rabbit small intestine IDO1 than for its ferrous form.</data>
</edge>
<edge source="PDF_9_Result_2640077629412363245" target="Compound_4-PHENYLIMIDAZOLE">
  <data key="d8">MENTIONS</data>
  <data key="d9">4-phenylimidazole (4PI) has a higher affinity for ferric rabbit small intestine IDO1 than for its ferrous form.</data>
</edge>
<edge source="PDF_9_Result_-7511363274713565443" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Binding of ebselen to cysteine residues of IDO1 shifts the Soret band of ferric IDO1 from 404 to 411 nm.</data>
</edge>
<edge source="PDF_9_Result_-7511363274713565443" target="Compound_EBSELEN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Binding of ebselen to cysteine residues of IDO1 shifts the Soret band of ferric IDO1 from 404 to 411 nm.</data>
</edge>
<edge source="PDF_9_Result_-2017196263807489895" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Miconazole and econazole are active against IDO1, while fluconazole is completely inactive.</data>
</edge>
<edge source="PDF_9_Result_-2017196263807489895" target="Compound_MICONAZOLE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Miconazole and econazole are active against IDO1, while fluconazole is completely inactive.</data>
</edge>
<edge source="PDF_9_Result_-2017196263807489895" target="Compound_ECONAZOLE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Miconazole and econazole are active against IDO1, while fluconazole is completely inactive.</data>
</edge>
<edge source="PDF_9_Result_-2017196263807489895" target="Compound_FLUCONAZOLE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Miconazole and econazole are active against IDO1, while fluconazole is completely inactive.</data>
</edge>
<edge source="PDF_9_Result_4096444738177291706" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">The rationally designed triazole 3 (MMG-0358) showed nanomolar activities in both enzymatic and cellular assays, low cellular toxicity, and high selectivity for IDO1 over TDO.</data>
</edge>
<edge source="PDF_9_Result_4096444738177291706" target="Gene_TDO">
  <data key="d8">MENTIONS</data>
  <data key="d9">The rationally designed triazole 3 (MMG-0358) showed nanomolar activities in both enzymatic and cellular assays, low cellular toxicity, and high selectivity for IDO1 over TDO.</data>
</edge>
<edge source="PDF_9_Conclusion_-8591738306725305241" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Redox-cycling compounds will not only affect the kynurenine pathway of Trp degradation but also interfere with many other cellular pathways, so their use for IDO1 inhibition should be avoided.</data>
</edge>
<edge source="PDF_9_Conclusion_5764108499565985668" target="Gene_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Kinetic measurements with variable L-Trp concentrations do not yield direct information if a compound binds to the IDO1 active site or not.</data>
</edge>
<edge source="PDF_4" target="PDF_4_Result_-2683875459945412904">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Result_-7469028941740501493">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Result_3068870194127367817">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Result_3883041000718020292">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Result_7260200767491106545">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Result_-5668495360853338388">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Result_5041084921487977895">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Result_-4924147953508963545">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Result_3170910469353222436">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Result_-274728614665499438">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Result_-3067587265170287859">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Result_2835513584163089734">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Result_-6654836911274506089">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Result_3844259810186391888">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Conclusion_-7705113909564477352">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Conclusion_-9037046781256448444">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Conclusion_-4318393518980955366">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4" target="PDF_4_Conclusion_-4078007186907932872">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_4_Result_-2683875459945412904" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide was associated with mean reduction in weight (-10.2%), waist circumference (-7.7 cm) and waist-to-height ratio (-6.9%) versus placebo (-1.5%, -1.3 cm and -1.0%, respectively; P &lt; 0.0001 for all comparisons versus placebo) at 208 weeks.</data>
</edge>
<edge source="PDF_4_Result_-7469028941740501493" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Weight loss continued over 65 weeks and was sustained for up to 4 years in patients treated with semaglutide.</data>
</edge>
<edge source="PDF_4_Result_3068870194127367817" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide was associated with fewer serious adverse events.</data>
</edge>
<edge source="PDF_4_Result_3883041000718020292" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">At week 208, mean weight loss in the semaglutide group analyzed as first on-treatment was -11.7% compared with -1.5% for the placebo group (P&lt;0.0001).</data>
</edge>
<edge source="PDF_4_Result_7260200767491106545" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Weight loss of ≥5%, ≥10%, ≥15%, ≥20% and ≥25% was achieved by 67.8%, 44.2%, 22.9%, 11.0% and 4.9%, respectively, of those treated with semaglutide compared with 21.3%, 6.9%, 1.7%, 0.6% and 0.1% of those receiving placebo at week 104.</data>
</edge>
<edge source="PDF_4_Result_-5668495360853338388" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">At week 208, average reduction in WC was -7.7 cm with semaglutide versus -1.3 cm with placebo (P&lt;0.0001).</data>
</edge>
<edge source="PDF_4_Result_5041084921487977895" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">At week 208, in the group randomized to semaglutide, there was a relative reduction of 6.9% in WHtR compared with 1.0% in placebo (P&lt;0.0001).</data>
</edge>
<edge source="PDF_4_Result_-4924147953508963545" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">At week 104, 52.4% of patients treated with semaglutide achieved improvement in BMI category compared with 15.7% of those receiving placebo.</data>
</edge>
<edge source="PDF_4_Result_3170910469353222436" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">In the semaglutide group, 12.0% of patients achieved a BMI&lt;25 kg m², compared with 1.2% for placebo.</data>
</edge>
<edge source="PDF_4_Result_-274728614665499438" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">The proportion of patients with obesity (BMI ≥30 kg m²) fell from 71.0% to 43.3% in the semaglutide group versus 71.9% to 67.9% in the placebo group.</data>
</edge>
<edge source="PDF_4_Result_-3067587265170287859" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Women had a greater difference in mean weight loss with semaglutide versus placebo (-11.1% versus -7.5% in men; P &lt; 0.0001).</data>
</edge>
<edge source="PDF_4_Result_2835513584163089734" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Asian patients experienced slightly lower mean weight loss (estimated treatment difference with semaglutide for Asian race -7.27% (P = 0.0147) and for Asia -7.30 (P = 0.0016)).</data>
</edge>
<edge source="PDF_4_Result_-6654836911274506089" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Lower BMI classes, discontinuation rates are higher in the semaglutide group but not the placebo group.</data>
</edge>
<edge source="PDF_4_Result_3844259810186391888" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide was associated with lower SAEs, primarily driven by CV event and infections.</data>
</edge>
<edge source="PDF_4_Conclusion_-7705113909564477352" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">The weight-loss trajectory with semaglutide occurred over 65 weeks and was sustained up to 4 years.</data>
</edge>
<edge source="PDF_4_Conclusion_-9037046781256448444" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">The weight loss was associated with a greater proportion of patients receiving semaglutide achieving improvement in BMI category, healthy BMI (&lt;25 kg m²) and falling below the WC cutoff point above which increased cardiometabolic risk for the sex and race is greater.</data>
</edge>
<edge source="PDF_4_Conclusion_-4078007186907932872" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">These data, representing the longest clinical trial of the effects of semaglutide versus placebo on weight, establish the safety and durability of semaglutide effects on weight loss and maintenance in a geographically and racially diverse population of adult men and women with overweight and obesity but not diabetes.</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-5252757803203019223">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-8330347455423032070">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-2924540186561608243">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Method_9097609785825967202">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-325928441815492701">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_1958124885911685315">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_4164066221322032311">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-3278554037397404708">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_5718932015073294189">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-3615334711993736401">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-2607616780817729797">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_4793552220060895356">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_52978127278251961">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_2441972062334837159">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-8176057543638146958">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-7168754858484395335">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_671829205114393818">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-4934740466665465018">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-2065021580055796562">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_1895219285029411287">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_1317638041999125774">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11_Result_-5252757803203019223" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril 4 to 8mg once daily significantly reduces supine and standing blood pressure in patients with essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_-8330347455423032070" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril also improves arterial structure and reduces left ventricular hypertrophy in hypertensive patients.</data>
</edge>
<edge source="PDF_11_Result_-2924540186561608243" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Beneficial acute haemodynamic effects comprising a reduction in preload and afterload with only a slight reduction in heart rate, and increased renal blood flow are seen after oral administration of perindopril 2 to 4mg in patients with congestive heart failure.</data>
</edge>
<edge source="PDF_11_Method_9097609785825967202" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
</edge>
<edge source="PDF_11_Method_9097609785825967202" target="Protein_ACE">
  <data key="d8">MENTIONS</data>
  <data key="d9">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
</edge>
<edge source="PDF_11_Method_9097609785825967202" target="Protein_ANGIOTENSIN II">
  <data key="d8">MENTIONS</data>
  <data key="d9">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
</edge>
<edge source="PDF_11_Result_-325928441815492701" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals, healthy human subjects, hypertensive patients and patients with congestive heart failure.</data>
</edge>
<edge source="PDF_11_Result_-325928441815492701" target="Protein_ACE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals, healthy human subjects, hypertensive patients and patients with congestive heart failure.</data>
</edge>
<edge source="PDF_11_Result_1958124885911685315" target="Protein_ACE">
  <data key="d8">MENTIONS</data>
  <data key="d9">As a consequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as increases in plasma renin activity and plasma angiotensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
</edge>
<edge source="PDF_11_Result_1958124885911685315" target="Protein_ANGIOTENSIN II">
  <data key="d8">MENTIONS</data>
  <data key="d9">As a consequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as increases in plasma renin activity and plasma angiotensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
</edge>
<edge source="PDF_11_Result_1958124885911685315" target="Protein_RENIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">As a consequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as increases in plasma renin activity and plasma angiotensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
</edge>
<edge source="PDF_11_Result_1958124885911685315" target="Protein_ANGIOTENSIN I">
  <data key="d8">MENTIONS</data>
  <data key="d9">As a consequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as increases in plasma renin activity and plasma angiotensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
</edge>
<edge source="PDF_11_Result_1958124885911685315" target="Compound_ALDOSTERONE">
  <data key="d8">MENTIONS</data>
  <data key="d9">As a consequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as increases in plasma renin activity and plasma angiotensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
</edge>
<edge source="PDF_11_Result_4164066221322032311" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Animal studies have indicated that perindopril produces significant ACE inhibition in most tissues, including lung parenchyma, pulmonary vessels, heart, aortic wall, adrenal glands, proximal renal tubules, glomerular mesangium, renal vessels, brain cortex and pituitary glands</data>
</edge>
<edge source="PDF_11_Result_4164066221322032311" target="Protein_ACE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Animal studies have indicated that perindopril produces significant ACE inhibition in most tissues, including lung parenchyma, pulmonary vessels, heart, aortic wall, adrenal glands, proximal renal tubules, glomerular mesangium, renal vessels, brain cortex and pituitary glands</data>
</edge>
<edge source="PDF_11_Result_-3278554037397404708" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Circulating levels of adrenaline (epinephrine) and noradrenaline (norepinephrine) are not significantly changed following oral administration of normal dosages of perindopril to healthy volunteers and patients with hypertension or congestive heart failure</data>
</edge>
<edge source="PDF_11_Result_-3278554037397404708" target="Compound_ADRENALINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Circulating levels of adrenaline (epinephrine) and noradrenaline (norepinephrine) are not significantly changed following oral administration of normal dosages of perindopril to healthy volunteers and patients with hypertension or congestive heart failure</data>
</edge>
<edge source="PDF_11_Result_-3278554037397404708" target="Compound_NOREPINEPHRINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Circulating levels of adrenaline (epinephrine) and noradrenaline (norepinephrine) are not significantly changed following oral administration of normal dosages of perindopril to healthy volunteers and patients with hypertension or congestive heart failure</data>
</edge>
<edge source="PDF_11_Result_5718932015073294189" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril has been reported to normalise the increased plasma atrial natriuretic factor levels in rats with myocardial infarction experimentally induced by coronary artery ligation</data>
</edge>
<edge source="PDF_11_Result_5718932015073294189" target="Protein_ATRIAL NATRIURETIC FACTOR">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril has been reported to normalise the increased plasma atrial natriuretic factor levels in rats with myocardial infarction experimentally induced by coronary artery ligation</data>
</edge>
<edge source="PDF_11_Result_-3615334711993736401" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The reduction in blood pressure produced by perindopril in animals with spontaneous or renovascular hypertension was associated with a decrease in peripheral vascular resistance with no significant change in heart rate or cardiac output</data>
</edge>
<edge source="PDF_11_Result_-2607616780817729797" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril inhibited and even prevented development of cardiac hypertrophy in the rat; this was also associated with reversal of the isoenzyme shift of myocardial myosin and improvement in coronary blood flow and papillary muscle mechanical performance</data>
</edge>
<edge source="PDF_11_Result_-2607616780817729797" target="Protein_CARDIAC MYOSIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril inhibited and even prevented development of cardiac hypertrophy in the rat; this was also associated with reversal of the isoenzyme shift of myocardial myosin and improvement in coronary blood flow and papillary muscle mechanical performance</data>
</edge>
<edge source="PDF_11_Result_4793552220060895356" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril improved large artery (carotid and aorta) and small resistance artery (mesenteric) structure, tending to normalise arterial wall thickness as well as collagen and elastin content, and thereby enhance arterial compliance.</data>
</edge>
<edge source="PDF_11_Result_4793552220060895356" target="Protein_COLLAGEN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril improved large artery (carotid and aorta) and small resistance artery (mesenteric) structure, tending to normalise arterial wall thickness as well as collagen and elastin content, and thereby enhance arterial compliance.</data>
</edge>
<edge source="PDF_11_Result_4793552220060895356" target="Protein_ELASTIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril improved large artery (carotid and aorta) and small resistance artery (mesenteric) structure, tending to normalise arterial wall thickness as well as collagen and elastin content, and thereby enhance arterial compliance.</data>
</edge>
<edge source="PDF_11_Result_52978127278251961" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Long term perindopril administration either prevented or inhibited development of experimental cardiac hypertrophy</data>
</edge>
<edge source="PDF_11_Result_2441972062334837159" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril inhibited the shift in the cardiac myosin isoenzyme profile and attenuated the elevated levels of cardiac sympathetic activity normally associated with coronary artery ligation</data>
</edge>
<edge source="PDF_11_Result_2441972062334837159" target="Protein_CARDIAC MYOSIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril inhibited the shift in the cardiac myosin isoenzyme profile and attenuated the elevated levels of cardiac sympathetic activity normally associated with coronary artery ligation</data>
</edge>
<edge source="PDF_11_Result_-8176057543638146958" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Furthermore, perindopril normalised experimentally induced prolongation of the action potential</data>
</edge>
<edge source="PDF_11_Result_-7168754858484395335" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Appropriate acute reductions in systolic and diastolic blood pressure have been demonstrated with single oral doses of perindopril 4 to 16mg in patients with essential hypertension</data>
</edge>
<edge source="PDF_11_Result_671829205114393818" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Regression of left ventricular hypertrophy on long term therapy (3 to 12 months) with perindopril 4 to 8mg daily has been confirmed in other studies in patients with essential hypertension</data>
</edge>
<edge source="PDF_11_Result_-4934740466665465018" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Investigation of the effect of perindopril 2 to 8mg daily on the elastic properties of the brachial artery in 15 patients with essential hypertension revealed that it increased arterial compliance (assessed by a pulsed Doppler technique) by 42%, decreased pulsed wave velocity (an indicator of arterial stiffness) by 13% and reduced arterial impedance by 29% after 3 months' treatment</data>
</edge>
<edge source="PDF_11_Result_-2065021580055796562" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Overall, there was a reduction in preload and afterload, with a slight reduction in heart rate. The peak haemodynamic effect occurred about 4 hours after perindopril administration and was maintained for at least 24 hours after a single dose.</data>
</edge>
<edge source="PDF_11_Result_1895219285029411287" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The renal histological changes in rats with experimentally induced renovascular hypertension were prevented by administration of perindopril for 5 weeks</data>
</edge>
<edge source="PDF_11_Result_1317638041999125774" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Renal blood flow and glomerular filtration rate were increased in normotensive and spontaneously hypertensive rats during 1 to 12 weeks' administration of perindopril</data>
</edge>
<edge source="PDF_10" target="PDF_10_Hypothesis_-1108694323970151223">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Method_-2190073069729990293">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Method_8637960767432038323">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_-8571693380956232666">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_2691464121370026756">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_2635403832457689701">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_6944104196469185986">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_6402641960452747127">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Conclusion_-5191606018148845715">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_7389730533980749714">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_8159948098383069522">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_6472271266940705396">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_-8108579247609607560">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_1443318649360939712">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_-8615896456070211746">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_3272732411012992129">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_8469503454768034537">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10_Hypothesis_-1108694323970151223" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
</edge>
<edge source="PDF_10_Hypothesis_-1108694323970151223" target="Gene_POMC">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
</edge>
<edge source="PDF_10_Hypothesis_-1108694323970151223" target="Gene_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
</edge>
<edge source="PDF_10_Hypothesis_-1108694323970151223" target="Process_ARC">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
</edge>
<edge source="PDF_10_Hypothesis_-1108694323970151223" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
</edge>
<edge source="PDF_10_Method_-2190073069729990293" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">We used fluorescently labeled liraglutide injected peripherally to describe access to specific brain areas using a highly sensitive scanning technique.</data>
</edge>
<edge source="PDF_10_Result_-8571693380956232666" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus.</data>
</edge>
<edge source="PDF_10_Result_-8571693380956232666" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus.</data>
</edge>
<edge source="PDF_10_Result_-8571693380956232666" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">Liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus.</data>
</edge>
<edge source="PDF_10_Result_2691464121370026756" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus.</data>
</edge>
<edge source="PDF_10_Result_2691464121370026756" target="Process_ARC">
  <data key="d8">MENTIONS</data>
  <data key="d9">Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus.</data>
</edge>
<edge source="PDF_10_Result_2635403832457689701" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r-/- mice.</data>
</edge>
<edge source="PDF_10_Result_2635403832457689701" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r-/- mice.</data>
</edge>
<edge source="PDF_10_Result_6944104196469185986" target="Process_ARC">
  <data key="d8">MENTIONS</data>
  <data key="d9">In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART).</data>
</edge>
<edge source="PDF_10_Result_6944104196469185986" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART).</data>
</edge>
<edge source="PDF_10_Result_6944104196469185986" target="Gene_POMC">
  <data key="d8">MENTIONS</data>
  <data key="d9">In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART).</data>
</edge>
<edge source="PDF_10_Result_6944104196469185986" target="Gene_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART).</data>
</edge>
<edge source="PDF_10_Result_6402641960452747127" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
</edge>
<edge source="PDF_10_Result_6402641960452747127" target="Gene_POMC">
  <data key="d8">MENTIONS</data>
  <data key="d9">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
</edge>
<edge source="PDF_10_Result_6402641960452747127" target="Gene_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
</edge>
<edge source="PDF_10_Result_6402641960452747127" target="Gene_NPY">
  <data key="d8">MENTIONS</data>
  <data key="d9">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
</edge>
<edge source="PDF_10_Result_6402641960452747127" target="Gene_AGRP">
  <data key="d8">MENTIONS</data>
  <data key="d9">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
</edge>
<edge source="PDF_10_Conclusion_-5191606018148845715" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
</edge>
<edge source="PDF_10_Conclusion_-5191606018148845715" target="Gene_POMC">
  <data key="d8">MENTIONS</data>
  <data key="d9">Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
</edge>
<edge source="PDF_10_Conclusion_-5191606018148845715" target="Gene_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
</edge>
<edge source="PDF_10_Conclusion_-5191606018148845715" target="Process_ARC">
  <data key="d8">MENTIONS</data>
  <data key="d9">Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
</edge>
<edge source="PDF_10_Conclusion_-5191606018148845715" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
</edge>
<edge source="PDF_10_Result_7389730533980749714" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Liraglutide treatment significantly increased the mean Cart mRNA levels in the ARC compared with both vehicle-treated, ad libitum–fed rats and weight-matched rats, whereas Pomc expression was unaffected.</data>
</edge>
<edge source="PDF_10_Result_7389730533980749714" target="Gene_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">Liraglutide treatment significantly increased the mean Cart mRNA levels in the ARC compared with both vehicle-treated, ad libitum–fed rats and weight-matched rats, whereas Pomc expression was unaffected.</data>
</edge>
<edge source="PDF_10_Result_7389730533980749714" target="Process_ARC">
  <data key="d8">MENTIONS</data>
  <data key="d9">Liraglutide treatment significantly increased the mean Cart mRNA levels in the ARC compared with both vehicle-treated, ad libitum–fed rats and weight-matched rats, whereas Pomc expression was unaffected.</data>
</edge>
<edge source="PDF_10_Result_7389730533980749714" target="Gene_POMC">
  <data key="d8">MENTIONS</data>
  <data key="d9">Liraglutide treatment significantly increased the mean Cart mRNA levels in the ARC compared with both vehicle-treated, ad libitum–fed rats and weight-matched rats, whereas Pomc expression was unaffected.</data>
</edge>
<edge source="PDF_10_Result_8159948098383069522" target="Gene_NPY">
  <data key="d8">MENTIONS</data>
  <data key="d9">A 1.4-fold increase in Npy mRNA levels and a 1.7-fold increase in Agrp mRNA levels were observed in weight-matched rats, while levels were unaltered following treatment with liraglutide, suggesting an ability of liraglutide to suppress the food-deprived hunger signals observed in the weight-matched control group.</data>
</edge>
<edge source="PDF_10_Result_8159948098383069522" target="Gene_AGRP">
  <data key="d8">MENTIONS</data>
  <data key="d9">A 1.4-fold increase in Npy mRNA levels and a 1.7-fold increase in Agrp mRNA levels were observed in weight-matched rats, while levels were unaltered following treatment with liraglutide, suggesting an ability of liraglutide to suppress the food-deprived hunger signals observed in the weight-matched control group.</data>
</edge>
<edge source="PDF_10_Result_8159948098383069522" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">A 1.4-fold increase in Npy mRNA levels and a 1.7-fold increase in Agrp mRNA levels were observed in weight-matched rats, while levels were unaltered following treatment with liraglutide, suggesting an ability of liraglutide to suppress the food-deprived hunger signals observed in the weight-matched control group.</data>
</edge>
<edge source="PDF_10_Result_6472271266940705396" target="Process_ARC">
  <data key="d8">MENTIONS</data>
  <data key="d9">Although the ARC NPY/AgRP neurons did not express GLP-1R, the marked suppression of NPY/AgRP expression that followed chronic liraglutide treatment prompted us to examine the effect of GLP-1R stimulation on NPY neurons.</data>
</edge>
<edge source="PDF_10_Result_6472271266940705396" target="Gene_NPY">
  <data key="d8">MENTIONS</data>
  <data key="d9">Although the ARC NPY/AgRP neurons did not express GLP-1R, the marked suppression of NPY/AgRP expression that followed chronic liraglutide treatment prompted us to examine the effect of GLP-1R stimulation on NPY neurons.</data>
</edge>
<edge source="PDF_10_Result_6472271266940705396" target="Gene_AGRP">
  <data key="d8">MENTIONS</data>
  <data key="d9">Although the ARC NPY/AgRP neurons did not express GLP-1R, the marked suppression of NPY/AgRP expression that followed chronic liraglutide treatment prompted us to examine the effect of GLP-1R stimulation on NPY neurons.</data>
</edge>
<edge source="PDF_10_Result_6472271266940705396" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">Although the ARC NPY/AgRP neurons did not express GLP-1R, the marked suppression of NPY/AgRP expression that followed chronic liraglutide treatment prompted us to examine the effect of GLP-1R stimulation on NPY neurons.</data>
</edge>
<edge source="PDF_10_Result_6472271266940705396" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Although the ARC NPY/AgRP neurons did not express GLP-1R, the marked suppression of NPY/AgRP expression that followed chronic liraglutide treatment prompted us to examine the effect of GLP-1R stimulation on NPY neurons.</data>
</edge>
<edge source="PDF_10_Result_-8108579247609607560" target="Gene_NPY">
  <data key="d8">MENTIONS</data>
  <data key="d9">In 5 of 9 NPY cells (from 3 mice), GLP 1(7-36)amide (10 nM) caused a substantial outward current, with average current change of 20.8 ± 1.7 pA.</data>
</edge>
<edge source="PDF_10_Result_-8108579247609607560" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">In 5 of 9 NPY cells (from 3 mice), GLP 1(7-36)amide (10 nM) caused a substantial outward current, with average current change of 20.8 ± 1.7 pA.</data>
</edge>
<edge source="PDF_10_Result_1443318649360939712" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1(7-36)amide failed to change the current in the presence of bicuculline, demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.</data>
</edge>
<edge source="PDF_10_Result_1443318649360939712" target="Gene_NPY">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1(7-36)amide failed to change the current in the presence of bicuculline, demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.</data>
</edge>
<edge source="PDF_10_Result_-8615896456070211746" target="Protein_GHRELIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">ghrelin and leptin receptor mRNA levels were significantly increased in weight-matched animals, and this was prevented by liraglutide treatment.</data>
</edge>
<edge source="PDF_10_Result_-8615896456070211746" target="Protein_LEPTIN RECEPTOR">
  <data key="d8">MENTIONS</data>
  <data key="d9">ghrelin and leptin receptor mRNA levels were significantly increased in weight-matched animals, and this was prevented by liraglutide treatment.</data>
</edge>
<edge source="PDF_10_Result_-8615896456070211746" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">ghrelin and leptin receptor mRNA levels were significantly increased in weight-matched animals, and this was prevented by liraglutide treatment.</data>
</edge>
<edge source="PDF_10_Result_3272732411012992129" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Preproglucagon (Ppg) mRNA in the NTS was decreased in both weight-matched and liraglutide-treated rats compared with ad libitum–fed vehicle animals.</data>
</edge>
<edge source="PDF_10_Result_3272732411012992129" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">Preproglucagon (Ppg) mRNA in the NTS was decreased in both weight-matched and liraglutide-treated rats compared with ad libitum–fed vehicle animals.</data>
</edge>
<edge source="PDF_10_Result_8469503454768034537" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">peripheral liraglutide does not directly engage GLP-1R in this region</data>
</edge>
<edge source="PDF_10_Result_8469503454768034537" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">peripheral liraglutide does not directly engage GLP-1R in this region</data>
</edge>
</graph></graphml>